| 1 |
Jiang S, Cai M, Zhang Z, Qian C, Wang J, Li Z, Guo Q, Zhou H, Xin H, Cai W, Wang H, Guo S, Huang Y, Xie Q. The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance. Hum Vaccin Immunother 2023;19:2161254. [PMID: 36683193 DOI: 10.1080/21645515.2022.2161254] [Reference Citation Analysis]
|
| 2 |
Tian Y, Fan Z, Xu L, Cao Y, Chen S, Pan Z, Gao Y, Li H, Zheng S, Ma Y, Duan Z, Zhang X, Ren F. CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients. Emerg Microbes Infect 2023;12:e2177088. [PMID: 36735916 DOI: 10.1080/22221751.2023.2177088] [Reference Citation Analysis]
|
| 3 |
Zhang L, Yang L, Gao Y, Bi X, Lin Y, Deng W, Jiang T, Lu Y, Hao H, Wan G, Yi W, Xie Y, Li M. Nomogram for evaluating obvious liver inflammation in treatment-naïve HBeAg positive chronic hepatitis B virus infection patients with normal ALT. Virulence 2023;14:2158710. [PMID: 36600180 DOI: 10.1080/21505594.2022.2158710] [Reference Citation Analysis]
|
| 4 |
Liu R, Yang L, Jiang T, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hao H, Hu L, Gao Y, Xu M, Chen X, Yi W, Li M, Xie Y. Hepatitis B core-related antigen serum levels may be a predictor of acute flare of chronic hepatitis B among pregnant women in the immune-tolerant phase of chronic HBV infection after short-course antiviral therapy. Virulence 2023;14:2186335. [PMID: 36864005 DOI: 10.1080/21505594.2023.2186335] [Reference Citation Analysis]
|
| 5 |
Liu YQ, Zhang C, Li JW, Cao LH, Zhang ZQ, Zhao WF, Shang QH, Zhang DZ, Ma AL, Xie Q, Gui HL, Zhang G, Liu YX, Shang J, Xie SB, Li J, Zhang XQ, Zou ZQ, Chen YP, Zhang Z, Zhang MX, Cheng J, Zhang FC, Huang LH, Li JB, Meng QH, Yu HB, Mi YQ, Peng YZ, Wang ZJ, Chen LM, Meng FP, Ren WH, Bai L, Zeng YL, Fan R, Lou XZ, Liang WF, Liu H, Zhuang H, Zhao H, Wang GQ. An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir. J Clin Transl Hepatol 2023;11:304-13. [PMID: 36643032 DOI: 10.14218/JCTH.2022.00091] [Reference Citation Analysis]
|
| 6 |
Kardashian A, Serper M, Terrault N, Nephew LD. Health disparities in chronic liver disease. Hepatology 2023;77:1382-403. [PMID: 35993341 DOI: 10.1002/hep.32743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Barlas T, Yalcin MM, Ozger HS, Altinova AE, Akturk M, Toruner FB, Karakoc A, Yetkin I. Overlooked complication of Cushing's syndrome: Reactivation of hepatitis B. Clin Endocrinol (Oxf) 2023;98:481-6. [PMID: 36443641 DOI: 10.1111/cen.14855] [Reference Citation Analysis]
|
| 8 |
Cao X, Hu Q, Xu W, Li Q, Zhang J, Chen L, Huang Y, Qi X. Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon-alfa. J Viral Hepat 2023;30:310-8. [PMID: 36529685 DOI: 10.1111/jvh.13787] [Reference Citation Analysis]
|
| 9 |
Wang J, Huang R, Liu J, Lai R, Liu Y, Zhu C, Qiu Y, He Z, Yin S, Chen Y, Yan X, Ding W, Zheng Q, Li J, Wu C. A novel non-invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD. J Viral Hepat 2023;30:287-96. [PMID: 36696366 DOI: 10.1111/jvh.13808] [Reference Citation Analysis]
|
| 10 |
Loureiro D, Tout I, Narguet S, Bed CM, Roinard M, Sleiman A, Boyer N, Pons-Kerjean N, Castelnau C, Giuly N, Tonui D, Soumelis V, El Benna J, Soussan P, Moreau R, Paradis V, Mansouri A, Asselah T. Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis. Hepatology 2023;77:1348-65. [PMID: 35971873 DOI: 10.1002/hep.32731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Tseng TC, Chiang C, Liu CJ, Hong CM, Su TH, Yang HC, Yang WT, Liu CH, Chen PJ, Kao JH. Low Hepatitis B Core-Related Antigen Levels Correlate Higher Spontaneous Seroclearance of Hepatitis B Surface Antigen in Chronic Hepatitis B Patients With High Hepatitis B Surface Antigen Levels. Gastroenterology 2023;164:669-679.e6. [PMID: 36642151 DOI: 10.1053/j.gastro.2023.01.005] [Reference Citation Analysis]
|
| 12 |
Hsu YC, Nguyen MH. Curing chronic hepatitis B virus infection. Lancet Infect Dis 2023;23:392-3. [PMID: 36509099 DOI: 10.1016/S1473-3099(22)00743-5] [Reference Citation Analysis]
|
| 13 |
Pham TTH, Toy M, Hutton D, Thompson W, Conners EE, Nelson NP, Salomon JA, So S. Gaps and Disparities in Chronic Hepatitis B Monitoring and Treatment in the United States, 2016-2019. Med Care 2023;61:247-53. [PMID: 36893410 DOI: 10.1097/MLR.0000000000001825] [Reference Citation Analysis]
|
| 14 |
Jiang H, Ye X, Chen C, Zhou G, Han G. Efficacy and Long-term Safety of Telbivudine Usage During Second or Third Trimester in Hepatitis B Surface Antigen Positive Mothers With High Viral Load: A 10-year Prospective Study. J Clin Gastroenterol 2023;57:423-8. [PMID: 36227027 DOI: 10.1097/MCG.0000000000001779] [Reference Citation Analysis]
|
| 15 |
Adraneda C, Tan YC, Yeo EJ, Kew GS, Khakpoor A, Lim SG. A critique and systematic review of the clinical utility of hepatitis B core-related antigen. J Hepatol 2023;78:731-41. [PMID: 36586590 DOI: 10.1016/j.jhep.2022.12.017] [Reference Citation Analysis]
|
| 16 |
Okonko IO, Chindah JO. Serological Evidence of Hbc Igm Virus Among Febrile Patients in Rumueme, Port Harcourt, Rivers State, Nigeria.. [DOI: 10.21203/rs.3.rs-2730410/v1] [Reference Citation Analysis]
|
| 17 |
Jachs M, Sauberer R, Stiegler A, Dechêne A, Tazreiter R, Hartl L, Bauer D, Balcar L, Strassl R, Mandorfer M, Trauner M, Munda P, Ferenci P, Reiberger T. Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center. United European Gastroenterol J 2023. [PMID: 36965148 DOI: 10.1002/ueg2.12376] [Reference Citation Analysis]
|
| 18 |
Giráldez-Gallego Á, Rodríguez-Seguel EDP, Valencia-Martín R, Morillo-García Á, Salamanca-Rivera C, Ruiz-Pérez R, Cuaresma-Duque M, Rosso-Fernández C, Ferrer-Ríos MT, Sousa-Martín JM, Praena-Fernández JM, Desongles-Corrales T, Rodríguez-Pérez A, Camino-Durán F, Gasch-Illescas A, Ampuero-Herrojo J, Pascasio-Acevedo JM. Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial. Gut 2023:gutjnl-2022-328222. [PMID: 36963815 DOI: 10.1136/gutjnl-2022-328222] [Reference Citation Analysis]
|
| 19 |
Takamatsu Y, Hayashi S, Kumamoto H, Imoto S, Tanaka Y, Mitsuya H, Higashi-Kuwata N. A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes. Virus Res 2023;329:199094. [PMID: 36933835 DOI: 10.1016/j.virusres.2023.199094] [Reference Citation Analysis]
|
| 20 |
Mak LY, Hui RW, Cheung KS, Fung J, Seto WK, Yuen MF. Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers. Expert Opin Drug Discov 2023;:1-16. [PMID: 36943183 DOI: 10.1080/17460441.2023.2192920] [Reference Citation Analysis]
|
| 21 |
Ghany MG, Saraswat VA. Patients With Compensated Hepatitis B Virus-Related Cirrhosis and Low-Level Viremia: Treat or Not to Treat? Am J Gastroenterol 2023. [PMID: 36940387 DOI: 10.14309/ajg.0000000000002224] [Reference Citation Analysis]
|
| 22 |
Ren J, Lin Q, Chen Q, Xu J, Chen D, Chen R, Lin K, Zhu H, Ye C, Luo X, Chen S, Kong H, Lin Q, Li N, Lin X, Chen Z, Hu J, Yang T. Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT. iScience 2023;26:106290. [PMID: 36936790 DOI: 10.1016/j.isci.2023.106290] [Reference Citation Analysis]
|
| 23 |
Moussa D, Wallace J, Manski-Nankervis JA, Doyle JS, Nguyen L, Boyle D, Stoové MA, Asselin J, Valaydon Z, Ahad M, Glasgow S, New K, Hocking JS, Sanci L, Thompson A, Hellard M, Howell J. Assessment of a primary care e-support package of automated case finding, simplified treatment algorithm and decision support to increase hepatitis B treatment uptake in primary care clinics in Australia (SIMPLY-B Study): protocol for a pilot evaluation. BMJ Open 2023;13:e070663. [PMID: 36927591 DOI: 10.1136/bmjopen-2022-070663] [Reference Citation Analysis]
|
| 24 |
Yendewa GA, James PB, Mohareb AM, Barrie U, Massaquoi SP, Yendewa SA, Ghazzawi M, Bockarie T, Cumming PE, Diallo IS, Johnson A, Vohnm B, Babawo LS, Deen GF, Kabba M, Sahr F, Lakoh S, Salata RA. Childhood Hepatitis B Immunization Coverage and Barriers in Sierra Leone, Liberia, and Guinea: Analysis of National Surveys (2018-2020).. [DOI: 10.1101/2023.03.16.23287374] [Reference Citation Analysis]
|
| 25 |
He M, Liu S, Lai Z, Du Z, Li Q, Xu L, Kan A, Shen J, Shi M. Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. Curr Opin Pharmacol 2023;70:102362. [PMID: 36931163 DOI: 10.1016/j.coph.2023.102362] [Reference Citation Analysis]
|
| 26 |
Cerveny L, Karbanova S, Karahoda R, Horackova H, Jiraskova L, Ali MNH, Staud F. Assessment of the role of nucleoside transporters, P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in the placental transport of entecavir using in vitro, ex vivo, and in situ methods. Toxicol Appl Pharmacol 2023;463:116427. [PMID: 36801311 DOI: 10.1016/j.taap.2023.116427] [Reference Citation Analysis]
|
| 27 |
Lan TY, Lin YC, Tseng TC, Yang HC, Kao JH, Cheng CF, Lee TJ, Huang SC, Lu CH, Li KJ, Hsieh SC. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas. Gut Liver 2023;17:288-98. [PMID: 36268584 DOI: 10.5009/gnl210551] [Reference Citation Analysis]
|
| 28 |
Ding Y, Feng M, Ma D, Zhao G, Wang X, An B, Xu Y, Lou S, Lin L, Xie Q, Liu K, Bao S, Wang H. The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1109980] [Reference Citation Analysis]
|
| 29 |
Kao WY, Tan EC, Lee HL, Huang YH, Huo TI, Chang CC, Chiou JF, Hou MC, Wu JC, Su CW. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. Aliment Pharmacol Ther 2023. [PMID: 36914943 DOI: 10.1111/apt.17438] [Reference Citation Analysis]
|
| 30 |
Chang ML, Liaw YF. Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure. Drugs 2023. [PMID: 36906663 DOI: 10.1007/s40265-023-01843-2] [Reference Citation Analysis]
|
| 31 |
Conners EE, Panagiotakopoulos L, Hofmeister MG, Spradling PR, Hagan LM, Harris AM, Rogers-Brown JS, Wester C, Nelson NP; Contributors. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023. MMWR Recomm Rep 2023;72:1-25. [PMID: 36893044 DOI: 10.15585/mmwr.rr7201a1] [Reference Citation Analysis]
|
| 32 |
Lemoh C, Xiao Y, Tran L, Yussf N, Moro P, Dutertre S, Wallace J. An Intersectional Approach to Hepatitis B. IJERPH 2023;20:4879. [DOI: 10.3390/ijerph20064879] [Reference Citation Analysis]
|
| 33 |
So S, Terrault N, Conners EE. Universal Adult Hepatitis B Screening and Vaccination as the Path to Elimination. JAMA 2023. [PMID: 36897598 DOI: 10.1001/jama.2023.2806] [Reference Citation Analysis]
|
| 34 |
Pham TTH, Maria N, Cheng V, Nguyen B, Toy M, Hutton D, Conners EE, Nelson NP, Salomon JA, So S. Gaps in Prenatal Hepatitis B Screening and Management of HBsAg Positive Pregnant Persons in the U.S., 2015-2020. Am J Prev Med 2023:S0749-3797(23)00056-9. [PMID: 36906494 DOI: 10.1016/j.amepre.2023.01.041] [Reference Citation Analysis]
|
| 35 |
Ornos ED, Murillo KJ, Ong JP. Liver diseases: Perspective from the Philippines. Ann Hepatol 2023;:101085. [PMID: 36889673 DOI: 10.1016/j.aohep.2023.101085] [Reference Citation Analysis]
|
| 36 |
Lin MJ, Su TH, Liu CJ, Yang HC, Chen CL, Liou JM, Tseng TC, Liu CH, Hong CM, Chen PJ, Kao JH. Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy. J Formos Med Assoc 2023:S0929-6646(23)00038-4. [PMID: 36872131 DOI: 10.1016/j.jfma.2023.02.002] [Reference Citation Analysis]
|
| 37 |
Fang HW, Hu TH, Wang JH, Hung CH, Lu SN, Chen CH. Post-treatment HBsAg decline predicts high rate of HBsAg loss after stopping entecavir or tenofovir in HBeAg-negative patients without retreatment. Dig Liver Dis 2023:S1590-8658(23)00220-7. [PMID: 36870864 DOI: 10.1016/j.dld.2023.02.006] [Reference Citation Analysis]
|
| 38 |
Nathani R, Leibowitz R, Giri D, Villarroel C, Salman S, Sehmbhi M, Yoon BH, Dinani A, Weisberg I. The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection. J Viral Hepat 2023;30:195-200. [PMID: 36458863 DOI: 10.1111/jvh.13779] [Reference Citation Analysis]
|
| 39 |
Jeng WJ, Wong GL. The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? Hepatol Commun 2023;7:e0060. [PMID: 36790353 DOI: 10.1097/HC9.0000000000000060] [Reference Citation Analysis]
|
| 40 |
Sun X, Fu H, Wang C, Zhang Y, Han W, Chen H, Wang Y, Chen Q, He Y, Huang Q, Yan C, Chen Y, Han T, Lv M, Mo X, Wang J, Wang F, Chen Y, Zhu X, Xu L, Liu K, Huang X, Zhang X. Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection. Bone Marrow Transplant 2023;58:265-72. [PMID: 36456810 DOI: 10.1038/s41409-022-01880-7] [Reference Citation Analysis]
|
| 41 |
Huang C, Yang C, Su P, Chen Y, Huang S, Yen H. Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy. Biomedicines 2023;11:752. [DOI: 10.3390/biomedicines11030752] [Reference Citation Analysis]
|
| 42 |
Wu JF, Tai CS, Chang KC, Chen HL, Ni YH, Hsu HY, Chang MH. Baseline Hepatitis B Virus Surface Antigen Titers in Childhood Predict the Risk of Advanced Liver Fibrosis in Adulthood. Clin Gastroenterol Hepatol 2023;21:663-669.e1. [PMID: 35240329 DOI: 10.1016/j.cgh.2022.02.046] [Reference Citation Analysis]
|
| 43 |
Li S, Jin J, Jiang Y, Shi J, Jiang X, Lin N, Ma Z. Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate. Int J Antimicrob Agents 2023;61:106726. [PMID: 36646229 DOI: 10.1016/j.ijantimicag.2023.106726] [Reference Citation Analysis]
|
| 44 |
Wong DK, Inoue T, Mak LY, Hui RW, Fung J, Cheung KS, Seto WK, Tanaka Y, Yuen MF. A longitudinal study to detect hepatitis B surface and core-related antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays. J Clin Virol 2023;160:105375. [PMID: 36623378 DOI: 10.1016/j.jcv.2022.105375] [Reference Citation Analysis]
|
| 45 |
Wang J, Yan X, Zhu L, Liu J, Qiu Y, Li Y, Liu Y, Xue R, Zhan J, Jiang S, Geng Y, Wan Y, Li M, Mao M, Gao D, Yin S, Tong X, Xia J, Ding W, Chen Y, Li J, Zhu C, Huang R, Wu C. Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone. Aliment Pharmacol Ther 2023;57:464-74. [PMID: 36324235 DOI: 10.1111/apt.17272] [Reference Citation Analysis]
|
| 46 |
Huang R, Wang J, Yan X, Zhu C, Wu C. Letter: improved alanine aminotransferase level in non-cirrhotic and low-viral load chronic hepatitis B patients treated with nucleotide/nucleoside analogues -authors' reply. Aliment Pharmacol Ther 2023;57:589-90. [PMID: 36786453 DOI: 10.1111/apt.17367] [Reference Citation Analysis]
|
| 47 |
Ho JCL, Mak JWY, Yip TCF, Lam HM, Cheng TY, Lam TO, Tam LS, Law MF, Cheung CKM, Ng SC, Wong VWS, Wong GLH. Risk of alanine aminotransferase flare in patients with previous hepatitis B virus exposure on biological modifier therapies-A population-based study. Liver Int 2023;43:588-98. [PMID: 36516362 DOI: 10.1111/liv.15499] [Reference Citation Analysis]
|
| 48 |
Crespo J, Cabezas J, Aguilera A, Berenguer M, Buti M, Forns X, García F, García-samaniego J, Hernández-guerra M, Jorquera F, Lazarus JV, Lens S, Martró E, Antonio Pineda J, Prieto M, Rodríguez-frías F, Rodríguez M, Ángel Serra M, Turnes J, Domínguez-hernández R, Ángel Casado M, Calleja JL. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction. Gastroenterología y Hepatología (English Edition) 2023. [DOI: 10.1016/j.gastre.2022.09.001] [Reference Citation Analysis]
|
| 49 |
Huang R, Wang J, Yan X, Zhu C, Wu C. Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients-authors' reply. Aliment Pharmacol Ther 2023;57:579-80. [PMID: 36786454 DOI: 10.1111/apt.17369] [Reference Citation Analysis]
|
| 50 |
Yoshida O, Akbar SMF, Imai Y, Sanada T, Tsukiyama-Kohara K, Miyazaki T, Kamishita T, Miyake T, Tokumoto Y, Hikita H, Tsuge M, Shimizu M, Al Mahtab M, Aguilar JC, Guillen G, Kohara M, Hiasa Y. Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study. Hepatol Res 2023;53:196-207. [PMID: 36399406 DOI: 10.1111/hepr.13851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 51 |
Huang SW, Li XT, Chen C, Ning Q, Huang JQ. Effect of Anti-HBs on Mortality Among Resolved HBV Infection: a Population-Based Prospective Cohort Study. Infect Dis Ther 2023;12:871-90. [PMID: 36754951 DOI: 10.1007/s40121-023-00766-5] [Reference Citation Analysis]
|
| 52 |
Ludwig H, Kumar S. Prevention of infections including vaccination strategies in multiple myeloma. Am J Hematol 2023;98 Suppl 2:S46-62. [PMID: 36251367 DOI: 10.1002/ajh.26766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 53 |
Choi WM, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Cant H, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Lim YS. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol 2023;78:534-42. [PMID: 36572349 DOI: 10.1016/j.jhep.2022.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 54 |
Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, Corral O, Soriano V. Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain. Aliment Pharmacol Ther 2023;57:540-8. [PMID: 36320189 DOI: 10.1111/apt.17280] [Reference Citation Analysis]
|
| 55 |
Yip TC, Wong VW, Lai MS, Lai JC, Hui VW, Liang LY, Tse YK, Chan HL, Wong GL. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss. J Hepatol 2023;78:524-33. [PMID: 36463985 DOI: 10.1016/j.jhep.2022.11.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Durham SH, Milam A, Waer D, Chahine EB. Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis. Ann Pharmacother 2023;57:306-16. [PMID: 35778802 DOI: 10.1177/10600280221102532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 57 |
Zhang S, Wang C, Liu B, Lu Q, Shang J, Zhou Y, Jia J, Xu X, Rao H, Han B, Zhao T, Chen L, Xie M, Cui J, Du J, zeng J, huang N, Liu Y, Zhang L, Zhuang H, Cui F. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation. The Lancet Regional Health - Western Pacific 2023. [DOI: 10.1016/j.lanwpc.2023.100738] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 58 |
Chen C, Yuan Z, Li W, Fei L, Ji L, Huang Q, Zhang S, Chen L. Complement C3 Facilitates Stratification of Stages of Chronic Hepatitis B and Signifies Development of Acute-on-Chronic Liver Failure in Acute Decompensated Cirrhosis. Adv Ther 2023;40:1171-86. [PMID: 36652176 DOI: 10.1007/s12325-022-02416-7] [Reference Citation Analysis]
|
| 59 |
Jocius D, Vajauskas D, Samuilis A, Mikelis K, Jokubauskiene S, Strupas K, Tamosiunas AE. Assessing Liver Fibrosis Using 2D-SWE Liver Ultrasound Elastography and Dynamic Liver Scintigraphy with 99mTc-mebrofenin: A Comparative Prospective Single-Center Study. Medicina 2023;59:479. [DOI: 10.3390/medicina59030479] [Reference Citation Analysis]
|
| 60 |
Wang H, Xi R, Song J, Wen B, Zhang Y, Zhou L, Zhang X, Li Y, Zhou F, Zhu Y, Ji Y, Lai Q, He Q, Luo W, Qi T, Liu M, Lan X, Dai L, Chen J. Combined model with acoustic radiation force impulse to rule out high-risk varices in HBV-related cirrhosis with viral suppression. Dig Liver Dis 2023:S1590-8658(23)00223-2. [PMID: 36863930 DOI: 10.1016/j.dld.2023.02.007] [Reference Citation Analysis]
|
| 61 |
Cochrane Hepato-Biliary Group, Jing Wu, Shitong Xie, Yanfang Ma, Xiaoning He, Xinyue Dong, Qianling Shi, Qiangqiang Guo, Qi Wang, Meixuan Li, Naijuan Yao, Liang Yao. Entecavir for children and adults with chronic hepatitis B. Cochrane Database Syst Rev 2023;2023:CD015536. [ DOI: 10.1002/14651858.CD015536] [Reference Citation Analysis]
|
| 62 |
Wang WQ, Xu GY, Li J, Liang BY, Li J, Lin ML, Chen XP, Zhang EL, Huang ZY. HBcAb positivity increases the risk of postoperative complications after extended hemihepatectomy for hilar cholangiocarcinoma. Cancer Med 2023. [PMID: 36847156 DOI: 10.1002/cam4.5740] [Reference Citation Analysis]
|
| 63 |
Miao LL, Wang JW, Liu HH, Gao S, Fan YC, Wang K. Hypomethylation of glycine dehydrogenase promoter in peripheral blood mononuclear cells is a new diagnostic marker of hepatitis B virus-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2023:S1499-3872(23)00034-6. [PMID: 36878837 DOI: 10.1016/j.hbpd.2023.02.011] [Reference Citation Analysis]
|
| 64 |
Yip TC, Wai-Sun Wong V, Sze-Man Lai M, Che-To Lai J, Tse YK, Liang LY, Wing-Ki Hui V, Lik-Yuen Chan H, Lai-Hung Wong G. Diabetes Mellitus Impacts on the Performance of Hepatocellular Carcinoma Risk Scores in Chronic Hepatitis B Patients. Clin Gastroenterol Hepatol 2023:S1542-3565(23)00112-X. [PMID: 36828301 DOI: 10.1016/j.cgh.2023.02.004] [Reference Citation Analysis]
|
| 65 |
Zeng Y, Huang J, Pang J, Wu Y, Li B, Jie Y, Li X, Chong Y. PD-1 Inhibitor-based Therapies Could Lead to A Diversity of Viral Kinetics in Cancer Patients with Concomitant HBV Infection.. [DOI: 10.21203/rs.3.rs-2573373/v1] [Reference Citation Analysis]
|
| 66 |
Liu Y, Nuersulitan R, Zhang C, Na H, Li J, Song Y, Zhu J, Wang G, Liu W, Zhao H. Steadily decline of HBV DNA load under NAs in lymphoma patients and higher level of qAnti-HBc predict HBV reactivation.. [DOI: 10.21203/rs.3.rs-2596830/v1] [Reference Citation Analysis]
|
| 67 |
Jansson-Knodell CL, Rubio-Tapia A. The Liver in Celiac Disease: A Strong 2-Way Talk! Am J Gastroenterol 2023. [PMID: 36799893 DOI: 10.14309/ajg.0000000000002144] [Reference Citation Analysis]
|
| 68 |
Altaf F, Qureshi ZA, Kandhi S, Khaja M. Clinical Conundrum of Acute Hepatitis B With Concurrent Hepatitis E Infection Leading to Severe Acute Liver Injury. Cureus 2023. [DOI: 10.7759/cureus.35216] [Reference Citation Analysis]
|
| 69 |
Pan C, Cao M, Yan C, Ou X, Zhang X, Xu W, Xu Y, Cui X. Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature. Expert Opin Drug Saf 2023. [PMID: 36794347 DOI: 10.1080/14740338.2023.2181339] [Reference Citation Analysis]
|
| 70 |
Kim D, Choi Y, Rhu J, Hwang S, You YK, Kim D, Nah YW, Kim B, Cho JY, Kang KJ, Yang JD, Choi D, Joo DJ, Kim MS, Ryu JH, Lee JG. Entecavir versus tenofovir on recurrence of hepatitis B virus–related hepatocellular carcinoma in liver transplantation.. [DOI: 10.21203/rs.3.rs-2568480/v1] [Reference Citation Analysis]
|
| 71 |
Liu J, Kam LY, Huang DQ, Henry L, Cheung R, Nguyen MH. Racial and Ethnic Disparities in Characteristics and Care Patterns of Chronic Hepatitis B Patients in the United States. Clin Gastroenterol Hepatol 2023:S1542-3565(23)00102-7. [PMID: 36781005 DOI: 10.1016/j.cgh.2023.01.035] [Reference Citation Analysis]
|
| 72 |
Li WF, Liu YW, Wang CC, Yong CC, Lin CC, Yen YH. Microscopic vascular invasion may not be associated with survival of patients undergoing resection for solitary hepatoma of ≤ 2 cm. PLoS One 2023;18:e0281154. [PMID: 36758025 DOI: 10.1371/journal.pone.0281154] [Reference Citation Analysis]
|
| 73 |
Hong X, Xiao Y, Xu L, Liu L, Mo H, Mo H. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. Immun Inflamm Dis 2023;11:e780. [PMID: 36840482 DOI: 10.1002/iid3.780] [Reference Citation Analysis]
|
| 74 |
Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet 2023:S0140-6736(22)01468-4. [PMID: 36774930 DOI: 10.1016/S0140-6736(22)01468-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 75 |
Wong RJ, Kaufman HW, Niles JK, Kapoor H, Gish RG. Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination. Clin Infect Dis 2023;76:e791-800. [PMID: 35594550 DOI: 10.1093/cid/ciac385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 76 |
Xu X, Wu C, Lou Z, Peng C, Jiang L, Wu T, Zeng T, Dong Y, Ruan B. Changing incidence of hepatitis B and persistent infection risk in adults: a population-based follow-up study from 2011 in China. BMC Public Health 2023;23:256. [PMID: 36747172 DOI: 10.1186/s12889-023-15130-y] [Reference Citation Analysis]
|
| 77 |
Cheng TW, Yang JF, Chen YY, Wu KT, Lee MS, Kuo HJ, Lin TC, Wang CL, Hsieh MH, Lin CY, Batsaikhan B, Ho CK, Dai CY. Epidemiology of Chronic Hepatitis B Infection in the Cohort of College Students with Vaccination in Taiwan. Vaccines (Basel) 2023;11. [PMID: 36851225 DOI: 10.3390/vaccines11020348] [Reference Citation Analysis]
|
| 78 |
Liu Z, Li W, Zhu Z, Wen H, Li MD, Hou C, Shen H, Huang B, Luo Y, Wang W, Chen X. A deep learning model with data integration of ultrasound contrast-enhanced micro-flow cines, B-mode images, and clinical parameters for diagnosing significant liver fibrosis in patients with chronic hepatitis B. Eur Radiol 2023. [PMID: 36735040 DOI: 10.1007/s00330-023-09436-z] [Reference Citation Analysis]
|
| 79 |
Freeland C, Cohen C. The impact of a hepatitis B diagnosis. Gastrointestinal Nursing 2023;21:S8-S10. [DOI: 10.12968/gasn.2023.21.sup1.s8] [Reference Citation Analysis]
|
| 80 |
Li M, Sun F, Bi X, Lin Y, Yang L, Jiang T, Deng W, Lu Y, Zhang L, Yi W, Xie Y. Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection. Hepatol Int 2023;17:42-51. [PMID: 36109430 DOI: 10.1007/s12072-022-10412-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 81 |
Hasan I, Loho IM, Setiawan PB, Djumhana A, Purnomo HD, Siregar L, Gani RA, Sulaiman AS, Lesmana CRA. Indonesian consensus on systemic therapies for hepatocellular carcinoma. Asia Pac J Clin Oncol 2023;19:263-74. [PMID: 35599455 DOI: 10.1111/ajco.13768] [Reference Citation Analysis]
|
| 82 |
Blaney H, Khalid M, Heller T, Koh C. Epidemiology, presentation, and therapeutic approaches for hepatitis D infections. Expert Rev Anti Infect Ther 2023;21:127-42. [PMID: 36519386 DOI: 10.1080/14787210.2023.2159379] [Reference Citation Analysis]
|
| 83 |
Hsu C, Ducreux M, Zhu AX, Qin S, Ikeda M, Kim TY, Galle PR, Finn RS, Chen E, Ma N, Hu Y, Li L, Cheng AL. Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab. Liver Cancer 2023;12:44-56. [PMID: 36872921 DOI: 10.1159/000525499] [Reference Citation Analysis]
|
| 84 |
Lee HA, Kim SU, Seo YS, Ahn SH, Rim CH. Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis. Hepatol Commun 2023;7:e0011. [PMID: 36691962 DOI: 10.1097/HC9.0000000000000011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 85 |
Shui LP, Zhu Y, Duan XQ, Chen YT, Yang L, Tang XQ, Zhang HB, Xiao Q, Wang L, Liu L, Luo XH. HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy. J Med Virol 2023;95:e28549. [PMID: 36734081 DOI: 10.1002/jmv.28549] [Reference Citation Analysis]
|
| 86 |
Pawlotsky JM. New hepatitis B drug development disillusions: time to reset? Lancet Gastroenterol Hepatol 2023;8:192-7. [PMID: 36343654 DOI: 10.1016/S2468-1253(22)00341-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 87 |
An M, Wang W, Zhang J, Till BG, Zhao L, Huang H, Yang Y, Li T, Han L, Zhang X, Qin P, Wang Y, Zhang M, Cui H, Gao Q, Wang Z. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy. Cancer Immunol Immunother 2023;72:385-95. [PMID: 35907016 DOI: 10.1007/s00262-022-03254-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 88 |
Cheng T, Li G, Ning H, Hao L. Antiviral Therapy for Chronic Hepatitis B Infection Improves Outcomes After Total Hip Arthroplasty: A Multicenter Retrospective Study. J Arthroplasty 2023;38:300-6. [PMID: 35963280 DOI: 10.1016/j.arth.2022.08.005] [Reference Citation Analysis]
|
| 89 |
Pokorska-Śpiewak M, Marczyńska M. HBV and HCV Infection in Children and Adolescents. Vaccines (Basel) 2023;11. [PMID: 36851208 DOI: 10.3390/vaccines11020330] [Reference Citation Analysis]
|
| 90 |
Jabeen K, Javed A, Waris A, Shahzad S. Restoration of IL-11 and IL-15 cytokine production post calcium modulators and ROS treatment can assist viral clearance both in vitro and in vivo. Iran J Basic Med Sci 2023;26:176-82. [PMID: 36742132 DOI: 10.22038/IJBMS.2022.65983.14536] [Reference Citation Analysis]
|
| 91 |
Brakenhoff SM, de Knegt RJ, van Campenhout MJH, van der Eijk AA, Brouwer WP, van Bömmel F, Boonstra A, Hansen BE, Berg T, Janssen HLA, de Man RA, Sonneveld MJ. End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients. J Microbiol Immunol Infect 2023;56:31-9. [PMID: 35941076 DOI: 10.1016/j.jmii.2022.06.002] [Reference Citation Analysis]
|
| 92 |
Dezan MGF, Cavalcante LN, Cotrim HP, Lyra AC. Hepatobiliary disease after bone marrow transplant. Expert Rev Gastroenterol Hepatol 2023;17:129-43. [PMID: 36655915 DOI: 10.1080/17474124.2023.2169671] [Reference Citation Analysis]
|
| 93 |
Luo H, Hu X, Li Y, Lei D, Tan G, Zeng Y, Qin B. The antiviral activity of tripartite motif protein 38 in hepatitis B virus replication and gene expression and its association with treatment responses during PEG-IFN-α antiviral therapy. Virology 2023;579:84-93. [PMID: 36623352 DOI: 10.1016/j.virol.2022.12.014] [Reference Citation Analysis]
|
| 94 |
Sefa Sayar M, Bulut D, Acar A. Evaluation of hepatosteatosis in patients with chronic hepatitis B virus infection. Arab J Gastroenterol 2023;24:11-5. [PMID: 35688683 DOI: 10.1016/j.ajg.2022.05.002] [Reference Citation Analysis]
|
| 95 |
Brakenhoff SM, Hoekstra R, Honkoop P, Roomer R, den Hollander JG, Bezemer G, de Knegt RJ, Sonneveld MJ, de Man RA. Patients treated with rituximab are poorly screened for hepatitis B infection: Data from a low-incidence country. Eur J Intern Med 2023;108:68-73. [PMID: 36462966 DOI: 10.1016/j.ejim.2022.11.024] [Reference Citation Analysis]
|
| 96 |
Zhu L, Park J, Deng Y, Pan CQ. The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B. J Clin Gastroenterol 2023;57:127-38. [PMID: 36598804 DOI: 10.1097/MCG.0000000000001785] [Reference Citation Analysis]
|
| 97 |
Etienne S, Vosbeck J, Bernsmeier C, Osthoff M. Prevention of Hepatitis B Reactivation in Patients Receiving Immunosuppressive Therapy: a Case Series and Appraisal of Society Guidelines. J Gen Intern Med 2023;38:490-501. [PMID: 36138278 DOI: 10.1007/s11606-022-07806-9] [Reference Citation Analysis]
|
| 98 |
Robinson A, Wong R, Gish RG. Chronic Hepatitis B Virus and Hepatitis D Virus: New Developments. Clin Liver Dis 2023;27:17-25. [PMID: 36400464 DOI: 10.1016/j.cld.2022.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 99 |
Crespo J, Cabezas J, Aguilera A, Berenguer M, Buti M, Forns X, García F, García-Samaniego J, Hernández-Guerra M, Jorquera F, Lazarus JV, Lens S, Martró E, Pineda JA, Prieto M, Rodríguez-Frías F, Rodríguez M, Serra MÁ, Turnes J, Domínguez-Hernández R, Casado MÁ, Calleja JL. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction. Gastroenterol Hepatol 2023;46:150-62. [PMID: 36257502 DOI: 10.1016/j.gastrohep.2022.09.009] [Reference Citation Analysis]
|
| 100 |
Ünver Ulusoy T, Bilek HC, Demirköse H, Keleş A. Evaluation of TyG index and TG/HDL-C ratio in HBeAg negative chronic hepatitis B infected patients. Biomol Biomed 2023;23:137-44. [PMID: 35765946 DOI: 10.17305/bjbms.2022.7320] [Reference Citation Analysis]
|
| 101 |
Li H, Niu X, Zhang Y, Zhang D, Zhang Y, Wang L, Miao Y, Jiang Y, Ji J, Chen Q, Wu X, Ediage EN, Kakuda TN, Biermer M. Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants. Clin Pharmacol Drug Dev 2023;12:175-80. [PMID: 36415122 DOI: 10.1002/cpdd.1197] [Reference Citation Analysis]
|
| 102 |
Howell J, Van H, Pham MD, Sawhney R, Li F, Bhat P, Lubel J, Kemp W, Bloom S, Majumdar A, McCaughan GW, Hall S, Spelman T, Doyle JS, Hellard M, Visvanathan K, Thompson A, Drummer HE, Anderson D. Validation of a novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study. Liver Int 2023. [PMID: 36719055 DOI: 10.1111/liv.15531] [Reference Citation Analysis]
|
| 103 |
Sun LL, Wang M, Zhang NN, Chen MX, Li YY, Zhang S, Qin CY. Establishment and validation of a diagnostic nomogram for significant histopathologic changes of hepatic injury in HBV-infected patients. Ann Transl Med 2023;11:40. [PMID: 36819502 DOI: 10.21037/atm-22-5840] [Reference Citation Analysis]
|
| 104 |
Ouyang S, Chen Z, Peng T, Geng Y, Qiu J, Xiao Z, Pan CQ. Incidence and predictors of elevated postpartum alanine aminotransferase in chronic hepatitis B mothers.. [DOI: 10.21203/rs.3.rs-2501080/v1] [Reference Citation Analysis]
|
| 105 |
Harabor V, Mogos R, Nechita A, Adam AM, Adam G, Melinte-Popescu AS, Melinte-Popescu M, Stuparu-Cretu M, Vasilache IA, Mihalceanu E, Carauleanu A, Bivoleanu A, Harabor A. Machine Learning Approaches for the Prediction of Hepatitis B and C Seropositivity. Int J Environ Res Public Health 2023;20. [PMID: 36767747 DOI: 10.3390/ijerph20032380] [Reference Citation Analysis]
|
| 106 |
Lazarevic I, Banko A, Miljanovic D, Cupic M. Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas. Viruses 2023;15. [PMID: 36851587 DOI: 10.3390/v15020373] [Reference Citation Analysis]
|
| 107 |
Karaoglu DA, Uner M, Simsek C, Gure AO, Demirkol-Canli S. Transcriptomic Analysis of Hepatitis B Infected Liver for Prediction of Hepatocellular Carcinoma. Biology (Basel) 2023;12. [PMID: 36829466 DOI: 10.3390/biology12020188] [Reference Citation Analysis]
|
| 108 |
Janssen HLA, Hou J, Asselah T, Chan HLY, Zoulim F, Tanaka Y, Janczewska E, Nahass RG, Bourgeois S, Buti M, Lampertico P, Lenz O, Verbinnen T, Vandenbossche J, Talloen W, Kalmeijer R, Beumont M, Biermer M, Shukla U. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut 2023:gutjnl-2022-328041. [PMID: 36697207 DOI: 10.1136/gutjnl-2022-328041] [Reference Citation Analysis]
|
| 109 |
Lasagna A, Albi G, Maserati R, Zuccarini A, Quaccini M, Baldanti F, Sacchi P, Bruno R, Pedrazzoli P. Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1044098] [Reference Citation Analysis]
|
| 110 |
Wang WX, Jia R, Jin XY, Li X, Zhou SN, Zhang XN, Zhou CB, Wang FS, Fu J. Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients. Front Immunol 2023;14:1121778. [PMID: 36756119 DOI: 10.3389/fimmu.2023.1121778] [Reference Citation Analysis]
|
| 111 |
Lee HA, Lee YS, Jung YK, Kim JH, Yim HJ, Yeon JE, Seo YS, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA. J Gastroenterol Hepatol 2023. [PMID: 36681856 DOI: 10.1111/jgh.16132] [Reference Citation Analysis]
|
| 112 |
Congly SE, Syed A, Haylock-jacobs S, Israelson H, Pinto J, Williams S, Lee SS, Coffin CS. A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B. Canadian Liver Journal 2023. [DOI: 10.3138/canlivj-2022-0043] [Reference Citation Analysis]
|
| 113 |
Shao J, Wang Y, Hu L, Zhang L, Lyu C. Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-naïve chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants. Clin Exp Med 2023. [PMID: 36648567 DOI: 10.1007/s10238-023-00990-w] [Reference Citation Analysis]
|
| 114 |
Monroe MK, Wang H, Anderson CF, Qin M, Thio CL, Flexner C, Cui H. Antiviral supramolecular polymeric hydrogels by self-assembly of tenofovir-bearing peptide amphiphiles. Biomater Sci 2023;11:489-98. [PMID: 36449365 DOI: 10.1039/d2bm01649d] [Reference Citation Analysis]
|
| 115 |
Edwards D, Lin J, Toman L, Gurakar M, Pustavoitau A, Kohli R, Wesson R, Ottmann SE, Dao D, Gurakar A, Kim A. Role of lower dose hepatitis B immune globulin prophylaxis in liver transplantation: A single center perspective. Hepatol Forum 2023;4:3-6. [PMID: 36843892 DOI: 10.14744/hf.2022.2022.0030] [Reference Citation Analysis]
|
| 116 |
Lee Y, Bae S, Kim JH, Kwak M, Jeon SY, Kim T, Yim SY, Lee YS, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS. Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study. J Clin Med 2023;12. [PMID: 36675640 DOI: 10.3390/jcm12020712] [Reference Citation Analysis]
|
| 117 |
Zhao Y, Song Y, Zhang H, Qu T, Axinbai M, Yang Y, Zhang L. Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis. Front Oncol 2022;12:1050714. [PMID: 36727050 DOI: 10.3389/fonc.2022.1050714] [Reference Citation Analysis]
|
| 118 |
Li M, Zong Z, Xiong X, Fan J, Zhong H, Liu N, Ye W, Jing J. Ascites re-compensation in HBV-related first decompensated cirrhosis after anti-viral therapy. Front Cell Infect Microbiol 2022;12:1053608. [PMID: 36710977 DOI: 10.3389/fcimb.2022.1053608] [Reference Citation Analysis]
|
| 119 |
Teng J, Du Y, Visalath P, Zhou T, Du B, Zhang Q, Cai W. A noninvasive model discriminating significant histological changes in treatment-naive chronic hepatitis B patients with normal ALT. Virol J 2023;20:7. [PMID: 36631824 DOI: 10.1186/s12985-023-01963-x] [Reference Citation Analysis]
|
| 120 |
Li Z, Yang D, Ge Y, Song S, Lv Q, Ye Y. Histologic changes in immune-tolerant patients with chronic hepatitis B: a systematic review and meta-analysis. Sci Rep 2023;13:469. [PMID: 36627364 DOI: 10.1038/s41598-023-27545-z] [Reference Citation Analysis]
|
| 121 |
Majeed NA, Hitawala AA, Heller T, Koh C. Diagnosis of HDV: From virology to non-invasive markers of fibrosis. Liver Int 2023. [PMID: 36621853 DOI: 10.1111/liv.15515] [Reference Citation Analysis]
|
| 122 |
Manso T, de Salazar A, Rodríguez-Velasco M, García F, Aguilera A. Detection and quantification of HBV and HCV in plasma samples by means of different molecular assays: Comparative study. Enferm Infecc Microbiol Clin (Engl Ed) 2023:S2529-993X(22)00298-2. [PMID: 36624027 DOI: 10.1016/j.eimce.2022.12.007] [Reference Citation Analysis]
|
| 123 |
Dusheiko G, Agarwal K, Maini MK. New Approaches to Chronic Hepatitis B. N Engl J Med 2023;388:55-69. [PMID: 36599063 DOI: 10.1056/NEJMra2211764] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 124 |
Zhang L, Jiang T, Yang Y, Deng W, Lu H, Wang S, Liu R, Chang M, Wu S, Gao Y, Hao H, Shen G, Xu M, Chen X, Hu L, Yang L, Bi X, Lin Y, Lu Y, Jiang Y, Li M, Xie Y. Postpartum hepatitis and host immunity in pregnant women with chronic HBV infection. Front Immunol 2022;13:1112234. [PMID: 36685527 DOI: 10.3389/fimmu.2022.1112234] [Reference Citation Analysis]
|
| 125 |
Johannessen A, Stockdale AJ, Henrion MYR, Okeke E, Seydi M, Wandeler G, Sonderup M, Spearman CW, Vinikoor M, Sinkala E, Desalegn H, Fall F, Riches N, Davwar P, Duguru M, Maponga T, Taljaard J, Matthews PC, Andersson M, Mboup S, Sombie R, Shimakawa Y, Lemoine M. Systematic review and individual-patient-data meta-analysis of non-invasive fibrosis markers for chronic hepatitis B in Africa. Nat Commun 2023;14:45. [PMID: 36596805 DOI: 10.1038/s41467-022-35729-w] [Reference Citation Analysis]
|
| 126 |
Hansi NK, Suddle AR. Hematology. The Liver in Systemic Disease 2023. [DOI: 10.1002/9781119802181.ch15] [Reference Citation Analysis]
|
| 127 |
Kilany M, Cunningham M. Oncology. The Liver in Systemic Disease 2023. [DOI: 10.1002/9781119802181.ch14] [Reference Citation Analysis]
|
| 128 |
Inoue T, Tanaka Y. Noninvasive assessments of liver disease severity based on biomarkers. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00009-4] [Reference Citation Analysis]
|
| 129 |
Loh K, Badalyan V. Acute Hepatitis. Principles and Practice of Pediatric Infectious Diseases 2023. [DOI: 10.1016/b978-0-323-75608-2.00059-8] [Reference Citation Analysis]
|
| 130 |
Ali SE, Vutien P, Bonham CA, Landis C, Kwo P, Esquivel C, Nguyen MH. Use and outcomes of hepatitis B virus-positive grafts in orthotopic liver transplantation in the United States from 1999 to 2021. Liver Transpl 2023;29:80-90. [PMID: 35844046 DOI: 10.1002/lt.26543] [Reference Citation Analysis]
|
| 131 |
Harris AM, Schillie S. Hepatitis B and Hepatitis D Viruses. Principles and Practice of Pediatric Infectious Diseases 2023. [DOI: 10.1016/b978-0-323-75608-2.00213-5] [Reference Citation Analysis]
|
| 132 |
Davwar PM, Okeke E, Duguru M, Nyam D, Bell K, Odeghe EA, Oyeleke G, Lesi OA, Singh R, Kim KY, Imade G, Akanmu AS, Sagay AS, Ogunsola FT, Peters MG, Roberts LR, Hou L, Murphy RL, Hawkins CA. Hepatocellular carcinoma presentation and prognosis among Nigerian adults with and without HIV. PLoS One 2023;18:e0282539. [PMID: 36877687 DOI: 10.1371/journal.pone.0282539] [Reference Citation Analysis]
|
| 133 |
Ito T, Nguyen MH. Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes. J Hepatocell Carcinoma 2023;10:413-28. [PMID: 36926055 DOI: 10.2147/JHC.S347959] [Reference Citation Analysis]
|
| 134 |
Zhang C, Li J, Cheng Y, Meng F, Song JW, Fan X, Fan H, Li J, Fu YL, Zhou MJ, Hu W, Wang SY, Fu YJ, Zhang JY, Xu RN, Shi M, Hu X, Zhang Z, Ren X, Wang FS. Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients. Gut 2023;72:153-67. [PMID: 35361683 DOI: 10.1136/gutjnl-2021-325915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 135 |
Diao Y, Tang J, Wang X, Deng W, Tang J, You C. Metabolic Syndrome, Nonalcoholic Fatty Liver Disease, and Chronic Hepatitis B: A Narrative Review. Infect Dis Ther 2023;12:53-66. [PMID: 36441483 DOI: 10.1007/s40121-022-00725-6] [Reference Citation Analysis]
|
| 136 |
Lu H, Cao W, Zhang L, Yang L, Bi X, Lin Y, Deng W, Jiang T, Sun F, Zeng Z, Lu Y, Zhang L, Liu R, Gao Y, Wu S, Hao H, Chen X, Hu L, Xu M, Xiong Q, Dong J, Song R, Li M, Xie Y. Effects of hepatitis B virus infection and strategies for preventing mother-to-child transmission on maternal and fetal T-cell immunity. Front Immunol 2023;14:1122048. [PMID: 36875136 DOI: 10.3389/fimmu.2023.1122048] [Reference Citation Analysis]
|
| 137 |
Squires KE, Ogilvie L, Jucov A, Anastasiy I, Ghicavii N, Huguet J, Melara R, Constantineau M, De La Rosa A, Mayers DL. A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection. J Viral Hepat 2023;30:19-28. [PMID: 36201354 DOI: 10.1111/jvh.13753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 138 |
Mak L, Yuen M. Hepatitis B: treatment. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00001-x] [Reference Citation Analysis]
|
| 139 |
Stockdale AJ. Hepatitis D. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00027-6] [Reference Citation Analysis]
|
| 140 |
Khalfi P, Kennedy PT, Majzoub K, Asselah T. Hepatitis D virus: Improving virological knowledge to develop new treatments. Antiviral Res 2023;209:105461. [PMID: 36396025 DOI: 10.1016/j.antiviral.2022.105461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 141 |
Seto MT, Cheung KW. Hepatitis during pregnancy. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00032-x] [Reference Citation Analysis]
|
| 142 |
Kirino S, Tamaki N, Kurosaki M, Kaneko S, Inada K, Tanaka Y, Ishido S, Yamashita K, Nobusawa T, Matsumoto H, Hayakawa Y, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B. Hepatol Res 2023;53:35-42. [PMID: 36117296 DOI: 10.1111/hepr.13839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 143 |
Mak LY, Beasley I, Kennedy PTF. Chronic viral hepatitis in athletes: an overlooked population? Br J Sports Med 2023;57:72-4. [PMID: 36167668 DOI: 10.1136/bjsports-2022-105837] [Reference Citation Analysis]
|
| 144 |
Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study. Eur J Intern Med 2023;107:66-72. [PMID: 36347739 DOI: 10.1016/j.ejim.2022.10.026] [Reference Citation Analysis]
|
| 145 |
Zhou M, Cai H, Yi W, Gao X. A Nonlinear Relationship Between ALT Levels at Delivery and the Risk of Postpartum ALT Flares in Pregnant Women with Chronic Hepatitis B. Int J Med Sci 2023;20:247-53. [PMID: 36794153 DOI: 10.7150/ijms.79663] [Reference Citation Analysis]
|
| 146 |
Huang DQ, Lee DH, Le MH, Le A, Yeo YH, Trinh HN, Chung M, Nguyen V, Johnson T, Zhang JQ, Wong C, Wong C, Li J, Cheung R, Nguyen MH. Liver Complications in Untreated Treatment-Ineligible versus Treated Treatment-Eligible Patients with Hepatitis B. Dig Dis 2023;41:115-23. [PMID: 36070707 DOI: 10.1159/000526933] [Reference Citation Analysis]
|
| 147 |
Liu Z, Li Y, Wang Y, Bai X, Zhang Y. Exosomes in HBV infection. Clin Chim Acta 2023;538:65-9. [PMID: 36375524 DOI: 10.1016/j.cca.2022.11.012] [Reference Citation Analysis]
|
| 148 |
Ramadan HK, Hassan W, Elossily NA. Hepatitis B Virus Reactivation After COVID-19 Vaccination. Infect Dis Clin Pract 2023;31. [DOI: 10.1097/ipc.0000000000001207] [Reference Citation Analysis]
|
| 149 |
Giordano C, Picardi M, Pugliese N, Vincenzi A, Abagnale DP, De Fazio L, Giannattasio ML, Fatigati C, Ciriello M, Salemme A, Muccioli Casadei G, Vigliar E, Mascolo M, Troncone G, Pane F. Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21. Front Oncol 2023;13:1130899. [PMID: 36890828 DOI: 10.3389/fonc.2023.1130899] [Reference Citation Analysis]
|
| 150 |
Choi W, Choi J, Lim Y. Hepatitis B: epidemiology, natural history, and diagnosis. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00007-0] [Reference Citation Analysis]
|
| 151 |
Mak LY, Wong D, Kuchta A, Hilfiker M, Hamilton A, Chow N, Mao X, Seto WK, Yuen MF. Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B. Clin Mol Hepatol 2023;29:146-62. [PMID: 35989092 DOI: 10.3350/cmh.2022.0172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 152 |
Tetali B, Kuperus B, Mazumder N. Identifying and Screening At-Risk Patients for Hepatitis Delta Virus: A Case Report. Cureus 2023;15:e33660. [PMID: 36788921 DOI: 10.7759/cureus.33660] [Reference Citation Analysis]
|
| 153 |
Hwang JP, Arnold KB, Unger JM, Chugh R, Tincopa MA, Loomba R, Hershman D, Ramsey SD. Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204. Support Care Cancer 2022;31:93. [PMID: 36585488 DOI: 10.1007/s00520-022-07525-1] [Reference Citation Analysis]
|
| 154 |
Kaneko S, Kurosaki M, Mashiba T, Marusawa H, Kondo M, Kojima Y, Uchida Y, Fujii H, Akahane T, Yagisawa H, Kusakabe A, Kobashi H, Abe T, Yoshida H, Ogawa C, Furuta K, Tamaki N, Tsuji K, Matsushita T, Izumi N; Japanese Red Cross Liver Study Group. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B. J Med Virol 2023;95:e28210. [PMID: 36222204 DOI: 10.1002/jmv.28210] [Reference Citation Analysis]
|
| 155 |
Yardeni D, Chang KM, Ghany MG. Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure. Gastroenterology 2023;164:42-60.e6. [PMID: 36243037 DOI: 10.1053/j.gastro.2022.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 156 |
Pawlotsky J. Antivirals against hepatitis viruses: basic mechanisms. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00008-2] [Reference Citation Analysis]
|
| 157 |
Han J, Guo Y, Zhang X, Zhang Y, Sun J, He J, Mao R, Huang Y, Zhang J. Prevalence and Associated Factors of Low-Level Viremia in Chronic Hepatitis B Patients After Long-Term Therapy with Nucleos(t)ide Analogs. Turk J Gastroenterol 2023;34:53-61. [PMID: 36620929 DOI: 10.5152/tjg.2023.21978] [Reference Citation Analysis]
|
| 158 |
Kong JH, Jang JY, Ko TH, Kang SH, Kim Y. High rate of hepatitis B reactivation during tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia in Korea. Blood Res 2022;57:290-3. [PMID: 36419239 DOI: 10.5045/br.2022.2022099] [Reference Citation Analysis]
|
| 159 |
He X, Wu J, Hou W, Li J, Xu H. Association of hydroxysteroid 11-beta dehydrogenase 1 polymorphisms with chronic liver fibrosis and the occurrence of hepatocellular carcinoma in a Han Chinese population. All Life 2022;15:951-959. [DOI: 10.1080/26895293.2021.2000893] [Reference Citation Analysis]
|
| 160 |
Li Y, Chen W, Jin C, Wang T, Yao T, Feng S, Wang B, Feng Y, Wang S. Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine. Hum Vaccin Immunother 2022;18:2029259. [PMID: 35296227 DOI: 10.1080/21645515.2022.2029259] [Reference Citation Analysis]
|
| 161 |
Lei J, Yan T, Zhang L, Chen B, Cheng J, Gao X, Liu Z, Li Y, Zuo S, Lu Y. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors. Hepatol Int 2022. [PMID: 36580258 DOI: 10.1007/s12072-022-10450-4] [Reference Citation Analysis]
|
| 162 |
Lee PH, Huang YH, Hsu YW, Chen KC, Hsu KH, Lin H, Lee TY, Tseng JS, Chang GC, Yang TY. Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment. J Clin Med 2022;12. [PMID: 36615034 DOI: 10.3390/jcm12010231] [Reference Citation Analysis]
|
| 163 |
Gridneva GI, Belov BS, Aronova ES. Chronic viral hepatitis B and rheumatic diseases: Modern view on problem. Medicinskij alfavit 2022. [DOI: 10.33667/2078-5631-2022-29-20-28] [Reference Citation Analysis]
|
| 164 |
Terrault NA, Lok AS, Wahed AS, Ghany MG, Perrillo RP, Fried MW, Wong DK, Khalili M, Lau DTY, Sterling RK, Di Bisceglie AM, Lisker-Melman M, Cooper SL, Chung RT, Patel K, Roberts LR, Belle SH, Janssen HLA. Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. Am J Gastroenterol 2022. [PMID: 36599136 DOI: 10.14309/ajg.0000000000002125] [Reference Citation Analysis]
|
| 165 |
Li H, Liang S, Liu L, Zhou D, Liu Y, Zhang Y, Chen X, Zhang J, Cao Z. Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon. Front Immunol 2022;13:1091786. [PMID: 36618361 DOI: 10.3389/fimmu.2022.1091786] [Reference Citation Analysis]
|
| 166 |
Tschäpe J, Cobernuss-Rahn A, Boyle S, Parkin N, LaBrot B, Aslam S, Young S, Gohl P. Multisite Performance Evaluation of the cobas 5800 System and Comparison to the cobas 6800/8800 Systems for Quantitative Measurement of HBV, HCV, and HIV-1 Viral Load. Microbiol Spectr 2022;10:e0312522. [PMID: 36314963 DOI: 10.1128/spectrum.03125-22] [Reference Citation Analysis]
|
| 167 |
Vélez Aguirre JD, Yepez Barreto IDJ. Factores asociados a la masa y la fuerza muscular en pacientes con cirrosis hepática: un estudio transversal. Rev colomb Gastroenterol 2022;37:410-419. [DOI: 10.22516/25007440.936] [Reference Citation Analysis]
|
| 168 |
Ozyigitoglu D, Sevgi DY, Tahtasakal CA, Oncul A, Gunduz A, Dokmetas I. Adherence to Treatment with Oral Nucleoside/Nucleotide Analogs in Patients with Chronic Hepatitis B. Sisli Etfal Hastan Tip Bul 2022;56:543-51. [PMID: 36660396 DOI: 10.14744/SEMB.2022.82608] [Reference Citation Analysis]
|
| 169 |
Asselah T. Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus. J Viral Hepat 2022. [PMID: 36529713 DOI: 10.1111/jvh.13789] [Reference Citation Analysis]
|
| 170 |
Chen JW, Cao XY, Qi X, Zhang JM. Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey. Medicine (Baltimore) 2022;101:e31980. [PMID: 36550809 DOI: 10.1097/MD.0000000000031980] [Reference Citation Analysis]
|
| 171 |
Ananchuensook P, Suksawatamnauy S, Thaimai P, Sriphoosanaphan S, Thanapirom K, Teerapakpinyo C, Pooworawan Y, Komolmit P. The association between vitamin D receptor polymorphism and phases of chronic hepatitis B infection in HBV carriers in Thailand. PLoS One 2022;17:e0277907. [PMID: 36490235 DOI: 10.1371/journal.pone.0277907] [Reference Citation Analysis]
|
| 172 |
Chiu C, Patel K, Thomas SK, Khawaja F, Dailey Garnes NJM, Lee HC, Ohanian M, Jiang Y, Wang LS, Hwang JP, Torres HA. Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodies. Hepatol Int 2022. [DOI: 10.1007/s12072-022-10462-0] [Reference Citation Analysis]
|
| 173 |
Suzuki T, Matsuura K, Urakabe K, Okumura F, Kawamura H, Sobue S, Matoya S, Miyaki T, Kimura Y, Kato D, Kusakabe A, Tanaka Y, Ozasa A, Nagura Y, Fujiwara K, Nojiri S, Hagiwara S, Kusumoto S, Inoue T, Tanaka Y, Kataoka H. Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation. Hepatol Res 2022. [PMID: 36461885 DOI: 10.1111/hepr.13864] [Reference Citation Analysis]
|
| 174 |
Koffas A, Mak LY, Kennedy PTF. Hepatitis delta virus: Disease assessment and stratification. J Viral Hepat 2022. [PMID: 36458851 DOI: 10.1111/jvh.13777] [Reference Citation Analysis]
|
| 175 |
Guo X, Ji T, Xin S, Xu J, Yu Y. A case report of hepatitis B virus reactivation 19 months after cessation of chemotherapy with rituximab. Front Immunol 2022;13:1083862. [PMID: 36532005 DOI: 10.3389/fimmu.2022.1083862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 176 |
Zeng QL, Zhang HX, Zhang JY, Huang S, Li WZ, Li GM, Pan YJ, Feng YH, Li ZQ, Zhang GF, Xu JH, Lin WB, Xu GH, Liu N, Zhang GQ, Li GT, Li W, Zeng YL, Song N, Wang M, Zhang DW, Chen ZM, Cui GL, Li J, Lv J, Liu YM, Liang HX, Sun CY, Zhou YH, Yu ZJ, Wang FS. Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study. Clin Gastroenterol Hepatol 2022;20:2826-2837.e9. [PMID: 34902570 DOI: 10.1016/j.cgh.2021.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 177 |
Qi T, Zhu C, Wang J, Li B, Huang Z, Zhu Z, Tu M, Deng G, Zheng X, Huang Y, Meng Z, Wang X, Qian Z, Li H, Gao Y, Liu F, Shang J, Shi Y, Lu X, Wang S, Li H, Chen J. MELD score < 18 rule out 28-day ACLF development among inpatients with hepatitis B-related previous compensated liver disease. J Viral Hepat 2022;29:1089-98. [PMID: 36081337 DOI: 10.1111/jvh.13747] [Reference Citation Analysis]
|
| 178 |
Yang H, Bae SH, Jang JW. Reply to: "A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations". J Hepatol 2022;77:1724-5. [PMID: 36058364 DOI: 10.1016/j.jhep.2022.08.026] [Reference Citation Analysis]
|
| 179 |
Butt SRR, Satnarine T, Ratna P, Sarker A, Ramesh AS, Munoz C, Jamil D, Tran HH, Mansoor M, Khan S. A Systematic Review on Current Trends in the Treatment of Chronic Hepatitis B to Predict Disease Remission and Relapse. Cureus 2022;14:e32247. [PMID: 36620830 DOI: 10.7759/cureus.32247] [Reference Citation Analysis]
|
| 180 |
Kam LY, Huang DQ, Tobias AF, Poon K, Henry L, Kwo P, Cheung R, Nguyen MH. Impact of advanced practice providers on characteristics and quality of care of patients with chronic hepatitis B. Aliment Pharmacol Ther 2022;56:1591-601. [PMID: 36266768 DOI: 10.1111/apt.17254] [Reference Citation Analysis]
|
| 181 |
Xu X, Jiang J, Song C, Yu C, Zhu L, Qian J, Tian T, Ding Y, Zhu F, Hu Z, Zhai X. Association of dynamic changes in serum levels of HBV DNA and risk of hepatocellular carcinoma. Curr Med 2022;1:5. [DOI: 10.1007/s44194-022-00008-9] [Reference Citation Analysis]
|
| 182 |
Chou C, Veracruz N, Chitnis AS, Wong RJ. Risk of drug-induced liver injury in chronic hepatitis B and tuberculosis co-infection: A systematic review and meta-analysis. J Viral Hepat 2022;29:1107-14. [PMID: 36138556 DOI: 10.1111/jvh.13751] [Reference Citation Analysis]
|
| 183 |
Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, Kao JH, Terrault N, Lok AS, Reddy KR. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol 2022;77:1670-89. [PMID: 35850281 DOI: 10.1016/j.jhep.2022.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 184 |
Kang CK, Brennan PN, Dillon JF. How to Effectively Monitor Aging Patients with Chronic Hepatitis B: A Review. CIA 2022;Volume 17:1811-1820. [DOI: 10.2147/cia.s366255] [Reference Citation Analysis]
|
| 185 |
Han G, Zhou G, Sun T, Luo X, Xu J, Chen C, Xu W, Jiang S, Wang C. Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: a multi-center, prospective study. J Matern Fetal Neonatal Med 2022;35:10551-8. [PMID: 36253882 DOI: 10.1080/14767058.2022.2134771] [Reference Citation Analysis]
|
| 186 |
Martin P, Awan AA, Berenguer MC, Bruchfeld A, Fabrizi F, Goldberg DS, Jia J, Kamar N, Mohamed R, Pessôa MG, Pol S, Sise ME, Balk EM, Gordon CE, Adam G, Cheung M, Earley A, Jadoul M. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int 2022;102:1228-37. [PMID: 36411019 DOI: 10.1016/j.kint.2022.07.012] [Reference Citation Analysis]
|
| 187 |
Zhang C, Liu Y, Zhao H, Wang G. Global Patterns and Trends in Total Burden of Hepatitis B from 1990 to 2019 and Predictions to 2030. CLEP 2022;Volume 14:1519-1533. [DOI: 10.2147/clep.s389853] [Reference Citation Analysis]
|
| 188 |
Feld JJ, Lawitz E, Nguyen T, Lalezari J, Hassanein T, Martin P, Han S, Dieterich D, Giard J, De La Rosa G, Ahmad A, Luo E, Conery AL, Adda N. EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B. Antiviral Therapy 2022;27:135965352211278. [DOI: 10.1177/13596535221127848] [Reference Citation Analysis]
|
| 189 |
Das S, Wang W, Ganesan M, Fonseca-Lanza F, Cobb DA, Bybee G, Sun Y, Guo L, Hanson B, Cohen SM, Gendelman HE, Osna NA, Edagwa BJ, Poluektova LY. An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression. Sci Adv 2022;8:eade9582. [PMID: 36563152 DOI: 10.1126/sciadv.ade9582] [Reference Citation Analysis]
|
| 190 |
Yang AH, Yardeni D, Hercun J, Kleiner DE, Ling A, Marko J, Heller T, Koh C. Shear wave elastography: How well does it perform in chronic hepatitis D virus infection? J Viral Hepat 2022;29:1127-33. [PMID: 36062402 DOI: 10.1111/jvh.13745] [Reference Citation Analysis]
|
| 191 |
Davidov Y, Abu Baker F, Israel A, Ben Ari Z. Real-world hepatitis B antiviral treatment trends and adherence to practice guidelines: a large cohort study. Acta Clinica Belgica 2022. [DOI: 10.1080/17843286.2022.2152566] [Reference Citation Analysis]
|
| 192 |
Aijaz R, Siddiqui H, Soomro A, Kanwal M, Hussain W, Khalique S. Prevalence of Antibodies to Hepatitis B Core Antigen in Hepatitis B Surface Antigen Negative Healthy Blood Donors. PJHS 2022. [DOI: 10.54393/pjhs.v3i06.360] [Reference Citation Analysis]
|
| 193 |
Yan Y, Sun H, Chang L, Ji H, Jiang X, Song S, Xiao Y, Feng K, Nuermaimaiti A, Lu Z, Wang L. Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection. Front Microbiol 2022;13. [DOI: 10.3389/fmicb.2022.1063616] [Reference Citation Analysis]
|
| 194 |
Oh JH, Park DA, Ko MJ, Yoo JJ, Yim SY, Ahn JH, Jun DW, Ahn SB. Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis. J Pers Med 2022;12. [PMID: 36556178 DOI: 10.3390/jpm12121957] [Reference Citation Analysis]
|
| 195 |
Lee F, Ho C. Diagnosis and management of chronic hepatitis B: A patient-friendly summary of the 2018 American Association for the Study of Liver Diseases practice guidance. Clin Liver Dis (Hoboken) 2022;20:141-5. [PMID: 36447908 DOI: 10.1002/cld.1240] [Reference Citation Analysis]
|
| 196 |
Elsebaey MA, Elbedewy TA, Elashry H, Elrefaey W, Elshweikh SA, Elhadidy AA, Shalaby NA, Elsokkary AM, Elashtokhy HEA, Abo-Amer YE, Abo-Elfetoh AR, Hassanien SEA, Fouad A, Abdellatif RS, Ismail AAM. Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation. Medicine (Baltimore) 2022;101:e31962. [PMID: 36451458 DOI: 10.1097/MD.0000000000031962] [Reference Citation Analysis]
|
| 197 |
Lai C, Lin C, Su Y, Shih Y, Wang C, Teng CJ, Chou C. Survival outcomes of patients with head and neck squamous cell cancer with hepatitis B virus infection: An analysis from an endemic tertiary center. Cancer Medicine 2022. [DOI: 10.1002/cam4.5469] [Reference Citation Analysis]
|
| 198 |
Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, Gadano A, Popescu CP, Stepanova T, Asselah T, Diaconescu G, Yim HJ, Heo J, Janczewska E, Wong A, Idriz N, Imamura M, Rizzardini G, Takaguchi K, Andreone P, Arbune M, Hou J, Park SJ, Vata A, Cremer J, Elston R, Lukić T, Quinn G, Maynard L, Kendrick S, Plein H, Campbell F, Paff M, Theodore D; B-Clear Study Group. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. N Engl J Med 2022;387:1957-68. [PMID: 36346079 DOI: 10.1056/NEJMoa2210027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 199 |
Nartey YA, Okine R, Seake-Kwawu A, Ghartey G, Asamoah YK, Senya K, Duah A, Owusu-Ofori A, Amugsi J, Suglo D, Bampoh SA, Hiebert L, Njuguna H, Ward JW, Plymoth A, Roberts LR, Bockarie AS, Awuku YA, Obiri-Yeboah D. A nationwide cross-sectional review of in-hospital hepatitis B virus testing and disease burden estimation in Ghana, 2016 - 2021. BMC Public Health 2022;22:2149. [PMID: 36419017 DOI: 10.1186/s12889-022-14618-3] [Reference Citation Analysis]
|
| 200 |
Zeng Z, Hao H, Bi X, Lin Y, Yang L, Wang S, Shen G, Chang M, Jiang T, Deng W, Lu H, Sun F, Lu Y, Gao Y, Liu R, Xu M, Chen X, Hu L, Zhang L, Li M, Xie Y. Study on liver histopathology of chronic HBV infected patients with different normal ALT values. Front Immunol 2022;13:1069752. [PMID: 36483546 DOI: 10.3389/fimmu.2022.1069752] [Reference Citation Analysis]
|
| 201 |
Thomas DL, Kiser JJ, Baum MM. Long-Acting Treatments for Hepatitis B. Clin Infect Dis 2022;75:S517-24. [PMID: 36410388 DOI: 10.1093/cid/ciac718] [Reference Citation Analysis]
|
| 202 |
Lin Y, Bi X, Yang L, Deng W, Jiang T, Li M, Xie Y. CLINICAL CURE OF A CHRONIC HEPATITIS B PATIENT WITH NORMAL SERUM ALANINE AMINOTRANSFERASE TREATED WITH PEGYLATED INTERFERON ALFA-2A: A CASE REPORT. Gastroenterology Nursing 2022;Publish Ahead of Print. [DOI: 10.1097/sga.0000000000000697] [Reference Citation Analysis]
|
| 203 |
Song Y, Zhang X, Liu M, Zhai X, Liu J, Li Y, Li L, Xiao Y, Duan Z, Jiang J, Ding F, Zhu L, Jiang J, Zou H, Zhuang H, Wang J, Li J. A booster hepatitis B vaccine for children with maternal HBsAg positivity before 2 years of age could effectively prevent vaccine breakthrough infections. BMC Infect Dis 2022;22:863. [DOI: 10.1186/s12879-022-07854-w] [Reference Citation Analysis]
|
| 204 |
Huang C, Yang H, Gao J, Yu Y, Lan C. Long-term monitoring, and hepatocellular carcinoma surveillance in patients with chronic hepatitis B infection.. [DOI: 10.21203/rs.3.rs-2257861/v1] [Reference Citation Analysis]
|
| 205 |
Chen X, Zheng X, Wu H, Zhang B, Peng L, Xie C. Virological Changes of Chronic Hepatitis B Patients with Minimally Elevated Levels of Alanine Aminotransferase: A Meta-Analysis and Systematic Review. Can J Gastroenterol Hepatol 2022;2022:7499492. [PMID: 36439633 DOI: 10.1155/2022/7499492] [Reference Citation Analysis]
|
| 206 |
Yao H, Li P, Xin J, Liang X, Jiang J, Shi D, Li J, Hassan HM, Chen X, Li J. MiRNA/mRNA network topology in hepatitis virus B-related liver cirrhosis reveals miR-20a-5p/340-5p as hubs initiating fibrosis. BMC Med Genomics 2022;15:240. [DOI: 10.1186/s12920-022-01390-x] [Reference Citation Analysis]
|
| 207 |
Kim MN, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Jang SY, Tak WY, Kweon YO, Park SY, Kim SU. ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis. Clin Gastroenterol Hepatol 2022:S1542-3565(22)01050-3. [PMID: 36375797 DOI: 10.1016/j.cgh.2022.10.035] [Reference Citation Analysis]
|
| 208 |
Wang R, Rothman RE, Mohareb AM, Laeyendecker O, Cloherty GA, Quinn TC, Hsieh YH; Johns Hopkins COVID-19 Emergency Medicine Investigators. High Burden of Undiagnosed Hepatitis B and Liver Disease in an Urban Emergency Department-Baltimore, 2020. Clin Gastroenterol Hepatol 2022:S1542-3565(22)01048-5. [PMID: 36372371 DOI: 10.1016/j.cgh.2022.10.033] [Reference Citation Analysis]
|
| 209 |
Huang X, Yan M, Deng Z, Yao L, Han D, Sun L. Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study. BMC Gastroenterol 2022;22:452. [DOI: 10.1186/s12876-022-02541-1] [Reference Citation Analysis]
|
| 210 |
Zhang W, Li YY, Shang QH, Qi L, Sun MM, Chen G, An Y, Li JX, Jia WP, Sun ZA, Xu HB, Gao QM, Tang L, Wang XW, Zhang JY, Mu YM, Wang FS. Randomised controlled trial: effect of metformin add-on therapy on functional cure in entecavir-treated patients with chronic hepatitis B. Ann Hepatol 2022;27:100745. [PMID: 35964909 DOI: 10.1016/j.aohep.2022.100745] [Reference Citation Analysis]
|
| 211 |
Papatheodoridi M, Papatheodoridis GV. State-of-the-art and emerging antivirals for chronic hepatitis B infection. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2144219] [Reference Citation Analysis]
|
| 212 |
Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, Atzeni F, Behrens GM, Bijlsma JW, Böhm P, Constantinou CA, Garcia-diaz S, Kapetanovic MC, Lauper K, Luís M, Morel J, Nagy G, Poleverino E, van Rompay J, Sebastiani M, Strangfeld A, de Thurah A, Galloway J, Hyrich KL. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2022. [DOI: 10.1136/ard-2022-223335] [Reference Citation Analysis]
|
| 213 |
Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Yuen MF. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. J Hepatol 2022;77:1265-75. [PMID: 35697332 DOI: 10.1016/j.jhep.2022.05.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 214 |
Lian J, Kuang W, Jia H, Lu Y, Zhang X, Ye C, Gu J, Lv Y, Yu J, Zhang Y, Lu X, Zhao Y, Yang D, Wang K, Zhao P, Yu Y, Bai L, Zhang J, Zhang X, Yang Y. Pegylated interferon-α-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study. J Med Virol 2022;94:5475-83. [PMID: 35836102 DOI: 10.1002/jmv.28003] [Reference Citation Analysis]
|
| 215 |
Liem KS, Chi H, Fung S, Wong DK, Yim C, Noureldin S, Chen J, de Man RA, Sarowar A, Feld JJ, Hansen BE, Hou J, Peng J, Janssen HLA. Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B. J Viral Hepat 2022;29:986-93. [PMID: 36048970 DOI: 10.1111/jvh.13742] [Reference Citation Analysis]
|
| 216 |
Pang Y, Han Y, Yu C, Kartsonaki C, Guo Y, Chen Y, Yang L, Du H, Hou W, Schmidt D, Stevens R, Chen J, Chen Z, Lv J, Li L. The role of lifestyle factors on comorbidity of chronic liver disease and cardiometabolic disease in Chinese population: A prospective cohort study. The Lancet Regional Health - Western Pacific 2022;28:100564. [DOI: 10.1016/j.lanwpc.2022.100564] [Reference Citation Analysis]
|
| 217 |
Hu Q, Qi X, Yu Y, Gao Y, Zhang X, Wang Q, Zhang X, Zhuo Y, Li J, Zhang J, Chen L, Huang Y. The efficacy and safety of adding on or switching to peginterferon α-2b in HBeAg-positive chronic hepatitis B patients with long-term entecavir treatment: a multicentre randomised controlled trial. Aliment Pharmacol Ther 2022;56:1394-407. [PMID: 36128636 DOI: 10.1111/apt.17222] [Reference Citation Analysis]
|
| 218 |
Peng CW, Jeng WJ, Yang HI, Liu YC, Chien RN, Liaw YF. A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study. J Gastroenterol Hepatol 2022;37:2164-72. [PMID: 35869752 DOI: 10.1111/jgh.15966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 219 |
Liaw YF. Perspectives on current controversial issues in the management of chronic HBV infection. J Gastroenterol 2022;57:828-37. [PMID: 36053366 DOI: 10.1007/s00535-022-01918-z] [Reference Citation Analysis]
|
| 220 |
Zhou Y, Sun S, Liu Q, Xu X, Zhang Y, Zhang Y. TED: Two-stage expert-guided interpretable diagnosis framework for microvascular invasion in hepatocellular carcinoma. Medical Image Analysis 2022;82:102575. [DOI: 10.1016/j.media.2022.102575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 221 |
Deng R, Liu S, Shen S, Guo H, Sun J. Circulating HBV RNA: From biology to clinical applications. Hepatology 2022;76:1520-30. [PMID: 35342969 DOI: 10.1002/hep.32479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 222 |
Villa G, Owusu D, Smith C, Azumah M, Abdullahi A, Phillips S, Sayeed L, Austin H, Chadwick D, Phillips RO, Geretti AM. Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection. Hepatol Commun 2022;6:3036-51. [PMID: 36103301 DOI: 10.1002/hep4.2000] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 223 |
Yuen MF, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, Thompson AJ, Given BD, Schluep T, Hamilton J, Biermer M, Kalmeijer R, Beumont M, Lenz O, De Ridder F, Cloherty G, Ka-Ho Wong D, Schwabe C, Jackson K, Lai CL, Gish RG, Gane E. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol 2022;77:1287-98. [PMID: 35870702 DOI: 10.1016/j.jhep.2022.07.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 224 |
Saab S, Pham N, Wu W, Dang L, Dang A, Yum J, Shim K, Wu S. Spontaneous Seroclearance Is Associated with Lower Liver Fibrosis in Treatment-Naïve Chronic Hepatitis B Patients. Dig Dis Sci 2022;67:5309-14. [PMID: 35244827 DOI: 10.1007/s10620-022-07402-1] [Reference Citation Analysis]
|
| 225 |
Kaewdech A, Nawalerspanya S, Assawasuwannakit S, Chamroonkul N, Jandee S, Sripongpun P. The use of Andrographis paniculata and its effects on liver biochemistry of patients with gastrointestinal problems in Thailand during the COVID-19 pandemic: a cross sectional study. Sci Rep 2022;12:18213. [PMID: 36309577 DOI: 10.1038/s41598-022-23189-7] [Reference Citation Analysis]
|
| 226 |
Wu W, Yuan X, Zhang W, Zhou H, Kong X, He Z, Fu T, Zhang W, Jia W, Liang C, Tang H, Wang F, Ye Y, Shao Z, Ji Z. Clinical significance of novel biomarkers to predict the natural course of hepatitis B infection. Front Public Health 2022;10:1037508. [PMID: 36388269 DOI: 10.3389/fpubh.2022.1037508] [Reference Citation Analysis]
|
| 227 |
Campos-valdez M, Feustel S, Monroy-ramírez HC, Barrientos-salcedo C, Ayón-pérez MF, Ramos-márquez ME, Fernández-galindo DA, Silva-gómez JA, Santos A, Armendáriz-borunda J, Sánchez-orozco LV. Influence of C107R mutation from hepatitis B virus genotype H on in vitro hepatitis B surface antigen detection and IFN-β-1a treatment. Future Virology 2022. [DOI: 10.2217/fvl-2021-0347] [Reference Citation Analysis]
|
| 228 |
Kamal H, Aleman S; D-SOLVE Consortium. Natural history of untreated HDV patients: Always a progressive disease? Liver Int 2022. [PMID: 36308026 DOI: 10.1111/liv.15467] [Reference Citation Analysis]
|
| 229 |
Ren S, Wang W, Lu J, Wang K, Ma L, Zheng Y, Zheng S, Chen X. Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1035923] [Reference Citation Analysis]
|
| 230 |
Lee IC, Lee PC, Chao Y, Chi CT, Wu CJ, Hung YP, Su CW, Hou MC, Huang YH. Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment. Viruses 2022;14. [PMID: 36366452 DOI: 10.3390/v14112355] [Reference Citation Analysis]
|
| 231 |
Durak S, Coşar AM. Evaluation of the safety and antiviral efficacy of the tenofovir alafenamide fumarate molecule in immunosuppressed patients. J Health Sci Med / JHSM 2022;5:1688-1692. [DOI: 10.32322/jhsm.1179106] [Reference Citation Analysis]
|
| 232 |
Mhlanga A, Zakh R, Churkin A, Reinharz V, Glenn JS, Etzion O, Cotler SJ, Yurdaydin C, Barash D, Dahari H. Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients. Mathematics 2022;10:3917. [DOI: 10.3390/math10203917] [Reference Citation Analysis]
|
| 233 |
Bollerup S, Engsig F, Hallager S, Mocroft A, Roege BT, Christensen PB, Laursen AL, Krarup H, Clausen MR, Thielsen P, Madsen LG, Noerregaard L, Barfod TS, Balslev U, Tarp B, Hansen JB, Mygind LH, Gerstoft J, Weis N. Incidence of Hepatocellular Carcinoma and Decompensated Liver Cirrhosis and Prognostic Accuracy of the PAGE-B HCC Risk Score in a Low Endemic Hepatitis B Virus Infected Population. J Hepatocell Carcinoma 2022;9:1093-104. [PMID: 36281336 DOI: 10.2147/JHC.S372571] [Reference Citation Analysis]
|
| 234 |
Luo H, Hu X, Li Y, Lei D, Tan G, Zeng Y, Qin B. The Antiviral Activity of Triple Motif Protein 38 In Hepatitis B Virus Replication and Gene Expression and Its Association with Treatment Responses During PEG-IFN-α Antiviral Therapy.. [DOI: 10.21203/rs.3.rs-2147174/v1] [Reference Citation Analysis]
|
| 235 |
Thanapirom K, Suksawatamnuay S, Thaimai P, Treeprasertsuk S, Komolmit P, Tangkijvanich P. Assessment and validation of the TREAT-B score to assess the treatment eligibility of patients with chronic hepatitis B virus infection. Front Med 2022;9:995857. [DOI: 10.3389/fmed.2022.995857] [Reference Citation Analysis]
|
| 236 |
Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study. Cancers (Basel) 2022;14. [PMID: 36291786 DOI: 10.3390/cancers14205002] [Reference Citation Analysis]
|
| 237 |
Xu B, Liu A, Liu Y, Han T, Guo H, Ding X, Xiang H. Correlations between serum hepatitis B core-related antigen and hepatitis B surface antigen in patients with hepatitis B cirrhosis and a hepatitis B virus-DNA-negative status: a retrospective study. J Int Med Res 2022;50:3000605221130714. [PMID: 36224762 DOI: 10.1177/03000605221130714] [Reference Citation Analysis]
|
| 238 |
Ma Y, Nakamoto S, Ao J, Qiang N, Kogure T, Ogawa K, Nakagawa M, Fujiwara K, Iwanaga T, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Ogasawara S, Muroyama R, Chiba T, Kato J, Kato N. Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus. Int J Mol Sci 2022;23:12015. [PMID: 36233317 DOI: 10.3390/ijms231912015] [Reference Citation Analysis]
|
| 239 |
Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. World J Clin Cases 2022; 10(28): 10085-10096 [DOI: 10.12998/wjcc.v10.i28.10085] [Reference Citation Analysis]
|
| 240 |
Yuen MF, Berliba E, Sukeepaisarnjaroen W, Ahn SH, Tanwandee T, Lim YS, Kim YJ, Poovorawan K, Tangkijvanich P, Schwabe C, Eley T, Brown J, Lee ACH, Thi EP, Paratala B, Mani N, Sofia MJ, Picchio G, Sims KD, Gane EJ. Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B. Hepatol Commun 2022;6:3457-72. [PMID: 36194181 DOI: 10.1002/hep4.2095] [Reference Citation Analysis]
|
| 241 |
Mak LY, Beasley I, Kennedy PTF. Chronic Viral Hepatitis in Elite Athletes: Approaches to Risk Assessment, Prevention and Management. Sports Med Open 2022;8:123. [PMID: 36192563 DOI: 10.1186/s40798-022-00517-9] [Reference Citation Analysis]
|
| 242 |
Lavolé A, Giroux Leprieur E. Infections virales chroniques (hépatites, VIH) et impact sur le choix thérapeutique. Revue des Maladies Respiratoires Actualités 2022;14:2S351-2S357. [DOI: 10.1016/s1877-1203(22)00138-0] [Reference Citation Analysis]
|
| 243 |
Tseng C, Chen T, Wu J, Lee T, Borghi JA, Lin J, Nguyen MH, Hsu Y. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100617] [Reference Citation Analysis]
|
| 244 |
Yoo S, Kim JY, Lim YS, Han S, Choi J. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. J Hepatol 2022;77:939-46. [PMID: 35643206 DOI: 10.1016/j.jhep.2022.05.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 245 |
Yuen MF, Heo J, Kumada H, Suzuki F, Suzuki Y, Xie Q, Jia J, Karino Y, Hou J, Chayama K, Imamura M, Lao-Tan JY, Lim SG, Tanaka Y, Xie W, Yoon JH, Duan Z, Kurosaki M, Park SJ, Labio ME, Kumar R, Kweon YO, Yim HJ, Tao Y, Cremer J, Elston R, Davies M, Baptiste-Brown S, Han K, Campbell FM, Paff M, Theodore D. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J Hepatol 2022;77:967-77. [PMID: 35714812 DOI: 10.1016/j.jhep.2022.05.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 246 |
El Jamaly H, Eslick GD, Weltman M. Meta-analysis: hepatitis B reactivation in patients receiving biological therapy. Aliment Pharmacol Ther 2022;56:1104-18. [PMID: 35975904 DOI: 10.1111/apt.17155] [Reference Citation Analysis]
|
| 247 |
Xu JH, Fan YN, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Zhang DZ, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. 240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C. J Viral Hepat 2022;29:862-7. [PMID: 35737855 DOI: 10.1111/jvh.13724] [Reference Citation Analysis]
|
| 248 |
Giri S, Darak H, Kasturi S. Benefit of Antiviral Therapy for HBV-Related HCC with Undetectable HBV DNA Is Still Dubious. Dig Dis Sci 2022;67:4962-4. [PMID: 35119599 DOI: 10.1007/s10620-022-07383-1] [Reference Citation Analysis]
|
| 249 |
Bae SK, Arita J, Akamatsu N, Maki H, Nishioka Y, Kawahara T, Miyata A, Kokudo T, Nagata R, Mihara Y, Ichida A, Inagaki Y, Kawaguchi Y, Ishizawa T, Kaneko J, Tamura S, Tanaka Y, Moriya K, Hasegawa K. The impact of the covalently closed circular DNA level on recurrence of hepatocellular carcinoma after initial hepatectomy: an analysis of patients with resolved hepatitis B virus infection. HPB (Oxford) 2022;24:1780-8. [PMID: 35863998 DOI: 10.1016/j.hpb.2022.06.013] [Reference Citation Analysis]
|
| 250 |
Jalal MI, Brahmbhatt M, Green K, Weinberg EM, Lammert C, Bittermann T. Autoimmune hepatitis and metabolic syndrome-associated disease development: a U.S. cohort study. Aliment Pharmacol Ther 2022;56:1183-93. [PMID: 35971856 DOI: 10.1111/apt.17191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 251 |
Tian F, Feld JJ, Feng Z, Sander B, Wong WWL. Feasibility of hepatitis B elimination in high-income countries with ongoing immigration. J Hepatol 2022;77:947-56. [PMID: 35483535 DOI: 10.1016/j.jhep.2022.04.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 252 |
Sato K, Inoue J, Akahane T, Kobayashi T, Sato S, Kisara N, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Onuki M, Masamune A. Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study. Medicine (Baltimore) 2022;101:e30630. [PMID: 36181074 DOI: 10.1097/MD.0000000000030630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 253 |
Lee S, Kwon M, Lee S, Kim J. Lactic Acidosis Adverse Drug Reaction Reporting Aspect Evaluation of Hepatitis B Treatment Using Korea Adverse Event Reporting System. Journal of Pharmacoepidemiology and Risk Management 2022;14:144-148. [DOI: 10.56142/jperm.22.0012] [Reference Citation Analysis]
|
| 254 |
Nguyen MH, Roberts LR, Engel-Nitz NM, Bancroft T, Ozbay AB, Singal AG. Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States. Hepatol Commun 2022;6:3443-56. [PMID: 36178256 DOI: 10.1002/hep4.2087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 255 |
Shang H, Hu Y, Guo H, Lai R, Fu Y, Xu S, Zeng Y, Xun Z, Liu C, Wu W, Guo J, Ou Q, Chen T. Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon-α monotherapy. J Clin Lab Anal 2022;:e24667. [PMID: 36181316 DOI: 10.1002/jcla.24667] [Reference Citation Analysis]
|
| 256 |
Lee I, Lan K, Su C, Li C, Chao Y, Lin H, Hou M, Huang Y. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. IJMS 2022;23:11335. [DOI: 10.3390/ijms231911335] [Reference Citation Analysis]
|
| 257 |
Spera AM. Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment. World J Virol 2022; 11(5): 275-282 [DOI: 10.5501/wjv.v11.i5.275] [Reference Citation Analysis]
|
| 258 |
Zhang W, Yu Q, Peng H, Zheng Z, Zhou F. Clinical observation and risk assessment after splenectomy in hepatolenticular degeneration patients associated with hypersplenism. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.972561] [Reference Citation Analysis]
|
| 259 |
Chu J, Yang Y, Liu Y, Pei L, Zhou Y, Lu T, Zhang Y, Hu H, Li Y, Yang F, Lin S. Bacterial Infections Confer a Risk of Progression to Acute-on-Chronic Liver Failure in Patients with HBV-Related Compensated Cirrhosis During Severe Hepatitis Flares. Infect Dis Ther 2022. [PMID: 36151452 DOI: 10.1007/s40121-022-00695-9] [Reference Citation Analysis]
|
| 260 |
Roca TP, Villar LM, Nogueira Lima FS, Vasconcelos MPA, Borzacov LMP, Silva EDCE, Lago BVD, Silva MTLD, Botelho Souza LF, Salcedo JMV, Santos ADOD, Vieira DS. Genomic Variability of Hepatitis B Virus Circulating in Brazilian Western Amazon. Viruses 2022;14:2100. [DOI: 10.3390/v14102100] [Reference Citation Analysis]
|
| 261 |
Lei J, Yan T, Zhang L, Chen B, Cheng J, Gao X, Liu Z, Li Y, Zuo S, Lu Y. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitorsComparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.. [DOI: 10.21203/rs.3.rs-2069277/v1] [Reference Citation Analysis]
|
| 262 |
Luo Q, Zhu Q, Zong X, Li M, Yu H, Jiang C, Liao X, Masaki N. Diagnostic Performance of Transient Elastography Versus Two-Dimensional Shear Wave Elastography for Liver Fibrosis in Chronic Viral Hepatitis: Direct Comparison and a Meta-Analysis. BioMed Research International 2022;2022:1-12. [DOI: 10.1155/2022/1960244] [Reference Citation Analysis]
|
| 263 |
Sterling RK, Wahed AS, Cloherty G, Hoofnagle JH, Lee WM; Hepatitis B Research Network Investigators. Acute Hepatitis B Virus Infection in North American Adults. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00876-X. [PMID: 36116752 DOI: 10.1016/j.cgh.2022.09.004] [Reference Citation Analysis]
|
| 264 |
Tan YW. Risk stratification of primary liver cancer. World J Clin Cases 2022; 10(26): 9545-9549 [DOI: 10.12998/wjcc.v10.i26.9545] [Reference Citation Analysis]
|
| 265 |
Yang JY, Wu YH, Pan MY, Chiou YT, Lee RK, Li TN, Wang LH. Chemical-induced degradation of PreS2 mutant surface antigen via the induction of microautophagy. Antiviral Res 2022;:105417. [PMID: 36122619 DOI: 10.1016/j.antiviral.2022.105417] [Reference Citation Analysis]
|
| 266 |
Begré L, Béguelin C, Boyd A, Peters L, Rockstroh J, Günthard HF, Bernasconi E, Cavassini M, Lacombe K, Mocroft A, Wandeler G, Rauch A. Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection. Front Med 2022;9. [DOI: 10.3389/fmed.2022.988356] [Reference Citation Analysis]
|
| 267 |
Ghany MG, Lok AS. Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA. Journal of Clinical Investigation 2022;132:e163175. [DOI: 10.1172/jci163175] [Reference Citation Analysis]
|
| 268 |
Fasano M, Poliseno MC, Fiore JR, Lo Caputo S, D’arminio Monforte A, Santantonio TA. Management of Chronic Hepatitis B in HIV-Coinfected Patients. Viruses 2022;14:2022. [DOI: 10.3390/v14092022] [Reference Citation Analysis]
|
| 269 |
Tony SM, Shaaban MEA, Mohamed AIM, Abdelrahim MEA. Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis. Beni-Suef Univ J Basic Appl Sci 2022;11. [DOI: 10.1186/s43088-022-00294-0] [Reference Citation Analysis]
|
| 270 |
Yao N, Fu S, Wu Y, Tian Z, Feng Y, Li J, Luo X, Yang Y, Ji F, Chen Y, Liu J, Zhao Y, Chen T. Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2022;101:1197-206. [PMID: 36082797 DOI: 10.1111/aogs.14448] [Reference Citation Analysis]
|
| 271 |
Chu CM, Liaw YF. Management of Older Patients With Immunotolerant Chronic Hepatitis B Infection. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00835-7. [PMID: 36087709 DOI: 10.1016/j.cgh.2022.08.039] [Reference Citation Analysis]
|
| 272 |
Zhu M, Wang H, Lou T, Xiong P, Zhang J, Li L, Sun Y, Wu Y. Current treatment of chronic hepatitis B: Clinical aspects and future directions. Front Microbiol 2022;13:975584. [DOI: 10.3389/fmicb.2022.975584] [Reference Citation Analysis]
|
| 273 |
Hsu YC, Jun DW, Peng CY, Yeh ML, Trinh H, Wong GL, Kim SE, Chen CH, Oh H, Lin CH, Trinh L, Wong VW, Yoon E, Ahn SB, Huang D, Cho YK, Jeong JY, Jeong SW, Kim HS, Xie Q, Liu L, Riveiro-Barciela M, Tsai PC, Accarino EV, Toyoda H, Enomoto M, Preda C, Marciano S, Hoang J, Huang CF, Kozuka R, Yasuda S, Istratescu D, Lee DH, Su JY, Huang YT, Huang JF, Dai CY, Chuang WL, Yuen MF, Gadano A, Cheung R, Lim SG, Buti M, Yu ML, Nguyen MH. Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort. Hepatol Int 2022. [PMID: 36070123 DOI: 10.1007/s12072-022-10411-x] [Reference Citation Analysis]
|
| 274 |
Yang X, Zhang K, Xu Q, Shu X, Mo Z, Xie D, Gao Z, Deng H. Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg. Front Immunol 2022;13:997608. [DOI: 10.3389/fimmu.2022.997608] [Reference Citation Analysis]
|
| 275 |
Yip TC, Lai JC, Liang LY, Hui VW, Wong VW, Wong GL. Risk of HCC in Patients with HBV, Role of Antiviral Treatment. Curr Hepatology Rep 2022. [DOI: 10.1007/s11901-022-00588-y] [Reference Citation Analysis]
|
| 276 |
Bley E, Mohan N, Jackson I, Chaisidhivej N, Jarrett S, Lo KB, Navarro V, Rossi S, Rodgers SK, Kalman RS. Follow Up Imaging in Hepatocellular Cancer Ultrasound Screening Exams with Poor Visualization Scores. J Ultrasound Med 2022. [PMID: 36063062 DOI: 10.1002/jum.16093] [Reference Citation Analysis]
|
| 277 |
Su WC, Chen TT, Yang SS, Shih LN, Liu CK, Wang CC, Wu CH. The effect of a pay-for-performance program on health-related quality of life for patients with hepatitis in Taiwan. Health Qual Life Outcomes 2022;20:130. [PMID: 36064530 DOI: 10.1186/s12955-022-02038-1] [Reference Citation Analysis]
|
| 278 |
Lei B, Song H, Xu F, Wei Q, Wang F, Tan G, Ma H. When does hepatitis B virus meet long-stranded noncoding RNAs? Front Microbiol 2022;13:962186. [DOI: 10.3389/fmicb.2022.962186] [Reference Citation Analysis]
|
| 279 |
Yang H, Bae SH, Nam H, Lee HL, Lee SW, Yoo SH, Song MJ, Kwon JH, Nam SW, Choi JY, Yoon SK, Jang JW. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol 2022;77:632-41. [PMID: 35398462 DOI: 10.1016/j.jhep.2022.03.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 280 |
Chang JI, Sinn DH, Cho H, Kim S, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. Dig Dis Sci 2022;67:4565-73. [PMID: 34800218 DOI: 10.1007/s10620-021-07312-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 281 |
Perrillo R, Lin HS, Schwarz KB, Rosenthal P, Lisker-Melman M, Chung RT, Prokunina-Olsson L, Cloherty G, Feld J; Hepatitis B Research Network (HBRN). Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. Hepatology 2022;76:775-87. [PMID: 35188674 DOI: 10.1002/hep.32400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 282 |
Rathi S, Bhagat N, Singh V. A Road Less Traveled: To a Finite Chronic Hepatitis B Therapy. Gastroenterology 2022;163:778-9. [PMID: 35038449 DOI: 10.1053/j.gastro.2022.01.015] [Reference Citation Analysis]
|
| 283 |
Osman HA, Hetta HF, El-adly AM, Meshaal AK, Mekky MA. Detectability of Hepatitis B Virus in Peripheral Blood Mononuclear Cells Among Naive Chronic Hepatitis B Patients With Negative Viremia: A Multicenter Study. Infect Dis Clin Pract 2022;30. [DOI: 10.1097/ipc.0000000000001153] [Reference Citation Analysis]
|
| 284 |
Hwang JP, Artz AS, Shah P, Symington B, Feld JJ, Hammond SP, Ludwig E, Pai A, Ramsey SD, Schlam I, Suga JM, Wang SH, Somerfield MR. Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer. JCO Oncology Practice 2022;18:636-644. [DOI: 10.1200/op.22.00074] [Reference Citation Analysis]
|
| 285 |
Chevaliez S, Roudot-thoraval F, Brouard C, Gordien E, Zoulim F, Brichler S, Brodard V, Pioche C, Pawlotsky J, Leroy V. Clinical and virological features of chronic hepatitis B in the French National Surveillance Program, 2008-2012. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100593] [Reference Citation Analysis]
|
| 286 |
Lim J, Lee JB, An J, Song GW, Kim KM, Lee HC, Shim JH. Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study. J Viral Hepat 2022;29:756-64. [PMID: 35718999 DOI: 10.1111/jvh.13721] [Reference Citation Analysis]
|
| 287 |
Ogawa E. Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply. Aliment Pharmacol Ther 2022;56:1092-3. [PMID: 35995743 DOI: 10.1111/apt.17173] [Reference Citation Analysis]
|
| 288 |
Wu S, Zhou J, Wu X, Sun Y, Wang B, Kong Y, Zhan S, Jia J, Yang HI, You H. Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints. Am J Gastroenterol 2022;117:1444-53. [PMID: 35973147 DOI: 10.14309/ajg.0000000000001865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 289 |
Ni Y, Gao L, Lu Y, Ye S, Zhou L, Qian W, Liang A, Li P. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy. Front Immunol 2022;13:982346. [DOI: 10.3389/fimmu.2022.982346] [Reference Citation Analysis]
|
| 290 |
Massironi S, Pirola L, Mulinacci G, Ciaccio A, Viganò C, Palermo A, Zilli A, Invernizzi P, Danese S. Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks. Inflamm Bowel Dis 2022:izac189. [PMID: 36040402 DOI: 10.1093/ibd/izac189] [Reference Citation Analysis]
|
| 291 |
Bui HH, Vo VH, Nguyen CD, Phan ST, Quach PT, Nguyen DB. Diagnostic Performance of Acoustic Radiation Force Impulse Imaging in Evaluating Liver Fibrosis in Patients with Chronic Hepatitis B Infection: A Cross-Sectional Study. Indian J Radiol Imaging. [DOI: 10.1055/s-0042-1755251] [Reference Citation Analysis]
|
| 292 |
Chang M, Chien R, Liaw Y. Evidence-Based Management of Oral Nucleos(t)ide Analogue Withdrawal in Virally Suppressed Patients with Chronic HBV Infection. Curr Hepatology Rep 2022. [DOI: 10.1007/s11901-022-00587-z] [Reference Citation Analysis]
|
| 293 |
Brown A, Bartell N. Shedding light on the "gray zone": Hepatic fibrosis in chronic hepatitis B patients with fluctuating HBV DNA levels. Saudi J Gastroenterol 2022;28:397-8. [PMID: 36073571 DOI: 10.4103/sjg.sjg_336_22] [Reference Citation Analysis]
|
| 294 |
Li J, Fan P, Xu Z, Dong Y, Wang F, Hong W, Zhao J, Gao Y, Yan J, Cao L, Zhang C, Zhu S, Zhong Y, Wang F, Zhang M. Early initiation of antiviral therapy improves cure of chronic hepatitis B in immune tolerant children: a real-world study.. [DOI: 10.21203/rs.3.rs-1987955/v1] [Reference Citation Analysis]
|
| 295 |
Shin SH, Park SH. Viral Hepatitis in Patients with Inflammatory Bowel Disease. Korean J Gastroenterol 2022;80:51-59. [DOI: 10.4166/kjg.2022.096] [Reference Citation Analysis]
|
| 296 |
Alshuwaykh O, Daugherty T, Cheung A, Goel A, Dhanasekaran R, Ghaziani TT, Ahmed A, Dronamraju D, Kumari R, Kwong A, Nguyen M, Kim WR, Kwo PY. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy. Hepatol Commun 2022;6:3052-61. [PMID: 36004713 DOI: 10.1002/hep4.2064] [Reference Citation Analysis]
|
| 297 |
Ye B, Shen Y, Chen H, Lin S, Mao W, Dong Y, Li X. Differential proteomic analysis of plasma-derived exosomes as diagnostic biomarkers for chronic HBV-related liver disease. Sci Rep 2022;12:14428. [PMID: 36002595 DOI: 10.1038/s41598-022-13272-4] [Reference Citation Analysis]
|
| 298 |
Hu Y, Wu X, Ye Y, Ye L, Han S, Wang X, Yu H. Liver Histology of Treatment-Naïve Children with Chronic Hepatitis B Virus Infection in Shanghai China. Int J Infect Dis 2022:S1201-9712(22)00487-8. [PMID: 36028208 DOI: 10.1016/j.ijid.2022.08.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 299 |
Nikogosova AD, Umrik DV, Tsirulnikova OM. <i>De novo</i> hepatitis B virus infection after liver transplantation. RJTAO 2022;24:37-41. [DOI: 10.15825/1995-1191-2022-3-37-41] [Reference Citation Analysis]
|
| 300 |
Kim SK, Fujii T, Kim SR, Nakai A, Lim YS, Hagiwara S, Kudo M. Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus. Liver Cancer 2022;11:497-510. [PMID: 36589728 DOI: 10.1159/000525518] [Reference Citation Analysis]
|
| 301 |
Wei S, Hu M, Chen H, Xie Q, Wang P, Li H, Peng J. Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study. BMC Gastroenterol 2022;22:387. [PMID: 35978283 DOI: 10.1186/s12876-022-02471-y] [Reference Citation Analysis]
|
| 302 |
Xiong J, Jiang Y, Zhang J, Chen Y, Hu Y. CK1α upregulates the IFNAR1 expression to prompt the anti-HBV effect of type I IFN in hepatoma carcinoma cells. Virol Sin 2022;37:894-903. [PMID: 35985475 DOI: 10.1016/j.virs.2022.08.004] [Reference Citation Analysis]
|
| 303 |
Lalana Garcés M, Ortiz Pastor O, Solé Enrech G, Guerra-ruiz AR, Casals Mercadal G, Almería Lafuente A, Ballesteros Vizoso MA, Medina PG, Salgüero Fernández S, Zamora Trillo A, Aured de la Serna I, Hurtado JC, Pérez-del-pulgar S, Forns X, Morales Ruiz M. Control of occult hepatitis B virus infection. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2022;0. [DOI: 10.1515/almed-2022-0065] [Reference Citation Analysis]
|
| 304 |
Yin X, Li J, Hao Z, Ding R, Qiao Y. A systematic study of traditional Chinese medicine treating hepatitis B virus-related hepatocellular carcinoma based on target-driven reverse network pharmacology. Front Cell Infect Microbiol 2022;12:964469. [DOI: 10.3389/fcimb.2022.964469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 305 |
Da BL. Clinical trials in hepatitis D virus: Measuring success. Hepatology 2022. [PMID: 35969089 DOI: 10.1002/hep.32732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 306 |
Lalana Garcés M, Pastor OO, Solé Enrech G, Guerra-ruiz AR, Mercadal GC, Almería Lafuente A, Ballesteros Vizoso MA, Medina PG, Salgüero Fernández S, Zamora Trillo A, Aured de la Serna I, Hurtado JC, Pérez-del-pulgar S, Forns X, Morales Ruiz M. Revisión de la infección oculta por el virus de la hepatitis B. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2022;0. [DOI: 10.1515/almed-2021-0084] [Reference Citation Analysis]
|
| 307 |
Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Pria HRFD, Trinh VA, Oliva ICG, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee S, Miller E, Zhang HC, Stephen BA, Naing A. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and viral hepatitis: The MD Anderson Cancer Center experience.. [DOI: 10.21203/rs.3.rs-1902983/v1] [Reference Citation Analysis]
|
| 308 |
Caviglia GP, Ciancio A, Rizzetto M. A Review of HDV Infection. Viruses 2022;14:1749. [DOI: 10.3390/v14081749] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 309 |
Huang X, Yan M, Deng Z, Yao L, Han D, Sun L. Natural history of hepatitis B virus-associated decompensated cirrhosis with low-level viremia: a retrospective study.. [DOI: 10.21203/rs.3.rs-1924955/v1] [Reference Citation Analysis]
|
| 310 |
Tschäpe J, Cobernuss-rahn A, Boyle S, Parkin N, Labrot B, Aslam S, Young S, Gohl P. Multi-site Performance Evaluation of the cobas 5800 System and Comparison to the cobas 6800/8800 Systems for Quantitative Measurement of HBV, HCV, and HIV-1 Viral Load.. [DOI: 10.1101/2022.08.09.503351] [Reference Citation Analysis]
|
| 311 |
Feng B, Zheng JR. Importance of quantitative HBsAg detection in whole course management of patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2022; 30(15): 655-660 [DOI: 10.11569/wcjd.v30.i15.655] [Reference Citation Analysis]
|
| 312 |
Raslan E, Abdallah M, Soliman S. The prevalence and determinants of hepatitis B among Egyptian adults: a further analysis of a country-representative survey. Egypt Liver Journal 2022;12:46. [DOI: 10.1186/s43066-022-00207-x] [Reference Citation Analysis]
|
| 313 |
Lim YS, Ahn SH, Shim JJ, Razavi H, Razavi-Shearer D, Sinn DH. Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis. Aliment Pharmacol Ther 2022;56:519-28. [PMID: 35614532 DOI: 10.1111/apt.17052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 314 |
Martin P, Nguyen MH, Dieterich DT, Lau DT, Janssen HLA, Peters MG, Jacobson IM. Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. Clin Gastroenterol Hepatol 2022;20:1766-75. [PMID: 34329775 DOI: 10.1016/j.cgh.2021.07.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 315 |
Huang DQ, Li X, Le MH, Le AK, Yeo YH, Trinh HN, Zhang J, Li J, Wong C, Wong C, Cheung RC, Yang HI, Nguyen MH. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. Clin Gastroenterol Hepatol 2022;20:1803-1812.e5. [PMID: 33465482 DOI: 10.1016/j.cgh.2021.01.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 316 |
Stinco M, Bartolini E, Veronese P, Rubino C, Moriondo M, Ricci S, Trapani S, Azzari C, Resti M, Indolfi G. Epidemiology and Natural History of Childhood-Acquired Chronic Hepatitis C: A Single-Center Long-Term Prospective Study. J Pediatr Gastroenterol Nutr 2022;75:e2-7. [PMID: 35653496 DOI: 10.1097/MPG.0000000000003481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 317 |
Levy MT, Kashuba A, Gane E. Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection-Authors' reply. Aliment Pharmacol Ther 2022;56:548-9. [PMID: 35804469 DOI: 10.1111/apt.17102] [Reference Citation Analysis]
|
| 318 |
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Aliment Pharmacol Ther 2022;56:713-22. [PMID: 35735794 DOI: 10.1111/apt.17107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 319 |
Wong RJ, Hubbard A, Bagley L, Shiau R, Chitnis AS. Estimating Prevalence of Hepatitis B Virus Coinfection Among Adults With Tuberculosis: A Systematic Review With Meta-analysis. J Clin Gastroenterol 2022;56:601-17. [PMID: 34009841 DOI: 10.1097/MCG.0000000000001533] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 320 |
Russo FP, Viganò M, Stock P, Ferrarese A, Pugliese N, Burra P, Aghemo A. HBV-positive and HIV-positive organs in transplantation: A clinical guide for the hepatologist. J Hepatol 2022;77:503-15. [PMID: 35398460 DOI: 10.1016/j.jhep.2022.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 321 |
Mohareb AM, Larmarange J, Kim AY, Coffie PA, Kouamé MG, Boyd A, Freedberg KA, Hyle EP. Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. The Lancet HIV 2022;9:e585-94. [DOI: 10.1016/s2352-3018(22)00123-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 322 |
Manso T, de Salazar A, Rodríguez-velasco M, García F, Aguilera A. Detección y cuantificación de VHB y VHC en muestras de plasma mediante la utilización de diferentes ensayos moleculares: estudio comparativo. Enfermedades Infecciosas y Microbiología Clínica 2022. [DOI: 10.1016/j.eimc.2022.07.007] [Reference Citation Analysis]
|
| 323 |
Uçar S. Analysis of hepatitis B disease with fractal-fractional Caputo derivative using real data from Turkey. Journal of Computational and Applied Mathematics 2022. [DOI: 10.1016/j.cam.2022.114692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 324 |
Kayes T, Crane H, Symonds A, Dumond J, Cottrell M, Di Girolamo J, Manandhar S, Lim TH, Gane E, Kashuba A, Levy MT. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. Aliment Pharmacol Ther 2022;56:510-8. [PMID: 35599363 DOI: 10.1111/apt.17040] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 325 |
Liu CJ, Chen PJ. Changing epidemiology of liver disease in Asia: Dual infection of HBV and HCV. Liver Int 2022;42:1945-54. [PMID: 34402183 DOI: 10.1111/liv.15040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 326 |
Papatheodoridis GV, Mimidis K, Manolakopoulos S, Gatselis N, Goulis J, Kapatais A, Manesis E, Vasiliadis T, Triantos C, Samonakis D, Sevastianos V, Karatapanis S, Elefsiniotis I, Deutsch M, Mylopoulou T, Papatheodoridi M, Kranidioti H, Agorastou P, Karaoulani T, Kyriazidou A, Zisimopoulos K, Dalekos GN. HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks. Aliment Pharmacol Ther 2022;56:702-12. [PMID: 35736010 DOI: 10.1111/apt.17093] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 327 |
Zappulo E, Giaccone A, Schiano Moriello N, Gentile I. Pharmacological approaches to prevent vertical transmission of HIV and HBV. Expert Rev Clin Pharmacol 2022;:1-14. [PMID: 35876100 DOI: 10.1080/17512433.2022.2105202] [Reference Citation Analysis]
|
| 328 |
Wang W, Jia R, Gao Y, Liu J, Luan J, Qiao F, Liu L, Zhang X, Wang F, Fu J. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients. Front Immunol 2022;13:894410. [DOI: 10.3389/fimmu.2022.894410] [Reference Citation Analysis]
|
| 329 |
Yan Y, Chang L, Ji H, Han Y, Wang L. Evaluation of the Aptima HBV Quant Assay Compared to Abbott RealTime M2000 HBV Quant Assay and Procleix Ultrio Plus dHBV Assay in Plasma Samples. Microbiol Spectr 2022;:e0176122. [PMID: 35880868 DOI: 10.1128/spectrum.01761-22] [Reference Citation Analysis]
|
| 330 |
Zhang Z, Lu W, Huang D, Zhou X, Ding R, Li X, Wang Y, Lin W, Zeng D, Feng Y. Capabilities of hepatitis B surface antigen are divergent from hepatitis B virus DNA in delimiting natural history phases of chronic hepatitis B virus infection. Front Immunol 2022;13:944097. [DOI: 10.3389/fimmu.2022.944097] [Reference Citation Analysis]
|
| 331 |
Xu C, Yi Y, Xie Z, Zhu D, Abuduwaili D, Wang Z, Xi Y. Platelets, mean platelet volume, lymphocytes, leukocytes, and ratios of them altered in patients with hepatitis B virus‐related decompensated cirrhosis. Precision Medical Sciences. [DOI: 10.1002/prm2.12070] [Reference Citation Analysis]
|
| 332 |
Skrlec I, Talapko J. Hepatitis B and circadian rhythm of the liver. World J Gastroenterol 2022; 28(27): 3282-3296 [DOI: 10.3748/wjg.v28.i27.3282] [Reference Citation Analysis]
|
| 333 |
He Y, Zhou Y, Wang H, Peng X, Chang Y, Hu P, Ren H, Xu H. The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B. BMC Pediatr 2022;22:426. [PMID: 35854256 DOI: 10.1186/s12887-022-03482-0] [Reference Citation Analysis]
|
| 334 |
Zheng W, Guo W, Xiong M, Chen X, Gao L, Song Y, Cao D. Clinic-radiological features and radiomics signatures based on Gd-BOPTA-enhanced MRI for predicting advanced liver fibrosis. Eur Radiol. [DOI: 10.1007/s00330-022-08992-0] [Reference Citation Analysis]
|
| 335 |
Schmitz JE, Stratton CW, Persing DH, Tang Y, Mcadam AJ. Forty Years of Molecular Diagnostics for Infectious Diseases. J Clin Microbiol. [DOI: 10.1128/jcm.02446-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 336 |
Feld JJ, King WC, Ghany MG, Chang KM, Terrault N, Perrillo RP, Khalili M, Hinerman AS, Janssen H, Lok AS; Hepatitis B Research Network (HBRN). Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00653-X. [PMID: 35843468 DOI: 10.1016/j.cgh.2022.06.015] [Reference Citation Analysis]
|
| 337 |
Aceituno L, Bañares J, Ruiz-ortega L, Callejo-pérez A, Muñoz-couselo E, Ortiz-velez C, Díaz-mejía N, Barreira-díaz A, Carreras MJ, Farriols A, Buti M, Riveiro-barciela M. The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate. Front Med 2022;9. [DOI: 10.3389/fmed.2022.916213] [Reference Citation Analysis]
|
| 338 |
Sun H, Liu Y, Zhang Y, Jie Y, Wu Y, Li Z, Wei X, Li X, Niu B. Finite versus Indefinite Nucleos(t)ide Analogue Therapy of Patients with Chronic Hepatitis B Exhibiting Negative HBsAg Levels after Treatment. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/6069781] [Reference Citation Analysis]
|
| 339 |
Li Z, Xie B, Yi N, Cai H, Yi W, Gao X. Efficacy and safety of tenofovir disoproxil fumarate or telbivudine used throughout pregnancy for the prevention of mother-to-child transmission of hepatitis B virus: A cohort study. Eur J Obstet Gynecol Reprod Biol 2022;276:102-6. [PMID: 35853269 DOI: 10.1016/j.ejogrb.2022.07.009] [Reference Citation Analysis]
|
| 340 |
Martins TLS, Silva GRDCE, Silva CDA, Gomes DO, Diniz e Silva BV, Carneiro MADS, Pacheco LR, Araujo NMD, Zanchetta MS, Teles SA, Caetano KAA. Hepatitis B and C in Immigrants and Refugees in Central Brazil: Prevalence, Associated Factors, and Immunization. Viruses 2022;14:1534. [DOI: 10.3390/v14071534] [Reference Citation Analysis]
|
| 341 |
Sagnelli C, Sica A, Creta M, Calogero A, Ciccozzi M, Sagnelli E. Epidemiological and clinical aspects of hepatitis B virus infection in Italy over the last 50 years. World J Gastroenterol 2022; 28(26): 3081-3091 [DOI: 10.3748/wjg.v28.i26.3081] [Reference Citation Analysis]
|
| 342 |
Hu Q, Wang Q, Xu W, Huang C, Tao S, Qi X, Zhang Y, Li X, Jiang X, Song J, Li Q, Chen L, Huang Y. Development and Validation of a Non-invasive Model to Predict Liver Histological Lesions in Chronic Hepatitis B Patients With Persistently Normal Alanine Aminotransferase and Detectable Viremia. Front Med 2022;9. [DOI: 10.3389/fmed.2022.944547] [Reference Citation Analysis]
|
| 343 |
Dai Y, Zhao Z, Liu C. Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. Front Pharmacol 2022;13:942841. [DOI: 10.3389/fphar.2022.942841] [Reference Citation Analysis]
|
| 344 |
Quan M, Liu X, Liu C, Li W, Xing H, Pan JS. Antiviral Therapy for Prevention of Perinatal Hepatitis B Virus Transmission Reduces the Incidence of Postpartum Hepatitis Flare. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/7046955] [Reference Citation Analysis]
|
| 345 |
Mu Y, Ren XH, Han D, Guan YY, Liu PL, Cheng SX, Liu H. Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity. Pharmaceutics 2022;14:1439. [PMID: 35890334 DOI: 10.3390/pharmaceutics14071439] [Reference Citation Analysis]
|
| 346 |
Yang G, Zhuang L, Sun T, Yeo YH, Tao L, Zhang W, Ma W, Wu L, Yang Z, Yang Y, Xue D, Zhang J, Feng R, Matthias P E, Dooley S, Seki E, Liu P, Liu C. Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B. Can J Gastroenterol Hepatol 2022;2022:1048104. [PMID: 35855954 DOI: 10.1155/2022/1048104] [Reference Citation Analysis]
|
| 347 |
Toy M, Hutton D, Jia J, So S. Costs and health impact of delayed implementation of a national hepatitis B treatment program in China. J Glob Health 2022;12:04043. [PMID: 35796158 DOI: 10.7189/jogh.12.04043] [Reference Citation Analysis]
|
| 348 |
Won J, Lee AR, Dezhbord M, Lee DR, Kim SH, Kim JC, Park S, Kim N, Jae B, Kim K. Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir. Biomedicines 2022;10:1637. [DOI: 10.3390/biomedicines10071637] [Reference Citation Analysis]
|
| 349 |
Zhu Y, Li H, Wang X, Zheng X, Huang Y, Chen J, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Shi Y, Shang J, Yan H, Zheng Y, Qiao L, Zhang Y, Xiang X, Dan Y, Sun S, Hou Y, Zhang Q, Xiong Y, Li S, Chen J, Huang Z, Li B, Jiang X, Luo S, Chen Y, Gao N, Liu C, Ji L, Yuan W, Li J, Li T, Zheng R, Zhou X, Ren H, Zhou Y, Xu B, Yu R, Tan W, Deng G. Hepatitis B Virus Reactivation Increased the Risk of Developing Hepatic Failure and Mortality in Cirrhosis With Acute Exacerbation. Front Microbiol 2022;13:910549. [DOI: 10.3389/fmicb.2022.910549] [Reference Citation Analysis]
|
| 350 |
Shiue SJ, Cheng CL, Shiue HS, Chen CN, Cheng SW, Wu LW, Jargalsaikhan G, Chan TS, Lin HY, Wu MS. Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile. Nutrients 2022;14:2790. [PMID: 35889747 DOI: 10.3390/nu14142790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 351 |
Wang J, Geng X, Zhang X, Xiao Y, Wang W. Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database. Front Pharmacol 2022;13:921084. [DOI: 10.3389/fphar.2022.921084] [Reference Citation Analysis]
|
| 352 |
Palom A, Rando-segura A, Vico J, Pacín B, Vargas E, Barreira-díaz A, Rodríguez-frías F, Riveiro-barciela M, Esteban R, Buti M. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100547] [Reference Citation Analysis]
|
| 353 |
Lai MW, Chang YL, Cheng PJ, Chueh HY, Chang SC, Yeh CT. Absence of chronicity in infants born to immunized mothers with occult HBV infection in Taiwan. J Hepatol 2022;77:63-70. [PMID: 35176439 DOI: 10.1016/j.jhep.2022.01.030] [Reference Citation Analysis]
|
| 354 |
Fang HW, Yen YH, Hung CH, Wang JH, Hu TH, Lu SN, Chen CH. Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir. Dig Dis Sci 2022;67:3402-11. [PMID: 34241753 DOI: 10.1007/s10620-021-07128-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 355 |
Wang T, Tan W, Wang X, Zheng X, Huang Y, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Yan H, Zheng Y, Zhang W, Yin S, Gu W, Zhang Y, Dong F, Wei J, Deng G, Xiang X, Zhou Y, Hou Y, Zhang Q, Xiong S, Liu J, Long L, Chen R, Chen J, Jiang X, Luo S, Chen Y, Jiang C, Zhao J, Ji L, Mei X, Li J, Li T, Zheng R, Zhou X, Ren H, Shi Y, Li H. Role of precipitants on transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 356 |
Yoon EL, Jun DW. Precision medicine in the era of potent antiviral therapy for chronic hepatitis B. J Gastroenterol Hepatol 2022;37:1191-6. [PMID: 35430754 DOI: 10.1111/jgh.15856] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 357 |
Rozenberg-Ben-Dror K, Maier MM, Beste L, Lowy E, Chartier M, Ross D, Morgan TR. Improving quality of hepatitis B care in the Veteran's Health Administration. Clin Liver Dis (Hoboken) 2022;19:213-8. [PMID: 35795619 DOI: 10.1002/cld.1237] [Reference Citation Analysis]
|
| 358 |
Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: The promising paths forward. Hepatology 2022;76:233-50. [PMID: 34990029 DOI: 10.1002/hep.32314] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 359 |
Zhou H, Wang X, Steer CJ, Song G, Niu J. Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing. Hepatol Commun 2022;6:1652-63. [PMID: 35338607 DOI: 10.1002/hep4.1933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 360 |
Lin C, Huang Y, Luo L, Fang F, Zhang J, Xun Z, Fu Y, Shang H, Liu C, Ou Q. Adenosine Triphosphate in Serum as a Promising Biomarker for Differential Diagnosis of Hepatitis B Disease Progression. Front Immunol 2022;13:927761. [DOI: 10.3389/fimmu.2022.927761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 361 |
Ledoux N. Hepatitis B and Acute Liver Failure. Critical Care Nursing Clinics of North America 2022. [DOI: 10.1016/j.cnc.2022.04.012] [Reference Citation Analysis]
|
| 362 |
Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, Hu J, Wang Y, Tao R, Xiao F, Zhang X, Wang X, Han M, Luo X, Yan W, Ning Q. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol 2022;77:42-54. [PMID: 35149125 DOI: 10.1016/j.jhep.2022.01.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 363 |
Xu Y, Qi W, Wang X, Zhang Y, Han L, Shi J, Wang G, Liu J, Duan H, Cong X, Zhao P, Zhou C, Wang J. Signal transducer and activator of transcription 3 cooperates with androgen receptor/cell cycle-related kinase signalling pathway in the progression of hepatitis B virus infection and gender differences. J Viral Hepat 2022;29:569-78. [PMID: 35567395 DOI: 10.1111/jvh.13699] [Reference Citation Analysis]
|
| 364 |
Broquetas T, Carrión JA. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. HMER 2022;Volume 14:87-100. [DOI: 10.2147/hmer.s291976] [Reference Citation Analysis]
|
| 365 |
Jacobson IM, Brown RS Jr, McMahon BJ, Perrillo RP, Gish R. An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus. J Clin Gastroenterol 2022;56:478-92. [PMID: 35389923 DOI: 10.1097/MCG.0000000000001695] [Reference Citation Analysis]
|
| 366 |
Tserashkou DV, Mitsura VM. Chronic hepatitis B virus infection: clinical characteristics and antiviral therapy. jour 2022;19:82-89. [DOI: 10.51523/2708-6011.2022-19-2-10] [Reference Citation Analysis]
|
| 367 |
Ding ZN, Meng GX, Xue JS, Yan LJ, Liu H, Yan YC, Chen ZQ, Hong JG, Wang DX, Dong ZR, Li T. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis. J Cancer Res Clin Oncol 2022. [PMID: 35767193 DOI: 10.1007/s00432-022-04133-8] [Reference Citation Analysis]
|
| 368 |
Peng J, Yao X, Yuan C, Liu X, Xia R, He J, Li R, Yao Y. The Investigation of Hepatitis B Vaccine Immune Responses in Occult Hepatitis B Virus-Infected Patients. Front Immunol 2022;13:903685. [PMID: 35747142 DOI: 10.3389/fimmu.2022.903685] [Reference Citation Analysis]
|
| 369 |
Ahmed Z, Shetty A, Victor DW, Kodali S. Viral hepatitis: A narrative review of hepatitis A–E. World J Meta-Anal 2022; 10(3): 99-121 [DOI: 10.13105/wjma.v10.i3.99] [Reference Citation Analysis]
|
| 370 |
Chen YC, Hsu CW, Chien RN, Tai DI. One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study. Medicine (Baltimore) 2022;101:e29269. [PMID: 35758355 DOI: 10.1097/MD.0000000000029269] [Reference Citation Analysis]
|
| 371 |
Pan S, Yu Y, Wang S, Tu B, Shen Y, Qiu Q, Liu X, Su N, Zuo Y, Luan J, Zhang JY, Shi M, Meng F, Wang FS. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy. Front Immunol 2022;13:892618. [PMID: 35711409 DOI: 10.3389/fimmu.2022.892618] [Reference Citation Analysis]
|
| 372 |
Pruessmann JN, Langan EA, Rupp J, Marquardt J, Terheyden P, Zillikens D, Ludwig RJ, Boch K. Challenge of hepatitis B testing following intravenous immunoglobulin therapy in patients with autoimmune skin diseases. J Dermatol 2022. [PMID: 35726741 DOI: 10.1111/1346-8138.16500] [Reference Citation Analysis]
|
| 373 |
Zhang WB, Hou SZ, Chen YL, Mao F, Dong Y, Chen JG, Wang WP. Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of α-Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients. Front Oncol 2022;12:862297. [PMID: 35720017 DOI: 10.3389/fonc.2022.862297] [Reference Citation Analysis]
|
| 374 |
Feng M, Lei L, Xu J, Shi Y, Yang W. Platelet-to-Portal Vein Width Ratio and Platelet-to-Spleen Thickness Ratio Can Be Used to Predict Progressive Liver Fibrosis Among Patients With HBV Infection With HBeAg-Negativity and a Normal ALT Level. Front Med 2022;9:837898. [DOI: 10.3389/fmed.2022.837898] [Reference Citation Analysis]
|
| 375 |
Song Z, Ma Y, Jiang D, Zhao R, Dong F. Long-Term Safety of Rituximab in DLBCL Patients With Hepatitis B-Related Cirrhosis: A Retrospective Case Series. Front Med (Lausanne) 2022;9:890339. [PMID: 35712098 DOI: 10.3389/fmed.2022.890339] [Reference Citation Analysis]
|
| 376 |
Yendewa GA, Lakoh S, Jiba DF, Yendewa SA, Barrie U, Deen GF, Samai M, Jacobson JM, Sahr F, Salata RA. Hepatitis B Virus and Tuberculosis Are Associated with Increased Noncommunicable Disease Risk among Treatment-Naïve People with HIV: Opportunities for Prevention, Early Detection and Management of Comorbidities in Sierra Leone. J Clin Med 2022;11. [PMID: 35743539 DOI: 10.3390/jcm11123466] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 377 |
Gherlan GS. Occult hepatitis B — the result of the host immune response interaction with different genomic expressions of the virus. World J Clin Cases 2022; 10(17): 5518-5530 [DOI: 10.12998/wjcc.v10.i17.5518] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 378 |
Lee KC, Cheng JS, Chang ML, Chien RN, Liaw YF. Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study. Hepatol Int 2022. [PMID: 35699864 DOI: 10.1007/s12072-022-10357-0] [Reference Citation Analysis]
|
| 379 |
Shimakawa Y, Ndow G, Kaneko A, Aoyagi K, Lemoine M, Tanaka Y; PROLIFICA/HBcrAg-RDT Study Group. Rapid Point-of-Care Test for Hepatitis B Core-Related Antigen to Diagnose High Viral Load in Resource-Limited Settings. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00554-7. [PMID: 35697265 DOI: 10.1016/j.cgh.2022.05.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 380 |
Lazarus JV, Al-Rifai A, Sanai FM, Alghamdi AS, Sharara AI, Saad MF, van Selm L, Alqahtani SA. Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: A scoping review. Liver Int 2022. [PMID: 35689428 DOI: 10.1111/liv.15338] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 381 |
Shamaa O, Mendiratta V, Trudeau S, Gordon SC. Evolving Screening and Vaccination Recommendations for Hepatitis B in the USA. Curr Hepatology Rep 2022;21:37-43. [DOI: 10.1007/s11901-022-00583-3] [Reference Citation Analysis]
|
| 382 |
Hou L, Zhang Y, Tang S, Tang X. The loss and return of self: An interpretative phenomenological analysis of coping and recovery from chronic hepatitis B in China. Nurs Health Sci 2022. [PMID: 35670524 DOI: 10.1111/nhs.12963] [Reference Citation Analysis]
|
| 383 |
Kolbila L, Adjei CA, Kyei JM, Agyemang-prempeh C, Fosu PK. Perceived Supportive Care Needs of Adolescents With Chronic Hepatitis B in a Resource-limited Setting. Journal of Patient Experience 2022;9:237437352211065. [DOI: 10.1177/23743735221106596] [Reference Citation Analysis]
|
| 384 |
Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, Corral O, Soriano V. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. Hepatol Int 2022. [PMID: 35666390 DOI: 10.1007/s12072-022-10365-0] [Reference Citation Analysis]
|
| 385 |
Azhari H, Frolkis AD, Shaheen AA, Israelson H, Pinto J, Congly SE, Borman MA, Aspinall AA, Stinton LM, Nguyen HH, Swain MG, Burak KW, Lee SS, Sadler MD, Coffin CS. Real-world tertiary referral centre experience stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B. CanLivJ 2022. [DOI: 10.3138/canlivj-2022-0002] [Reference Citation Analysis]
|
| 386 |
Wu S, Yi W, Gao Y, Deng W, Bi X, Lin Y, Yang L, Lu Y, Liu R, Chang M, Shen G, Hu L, Zhang L, Li M, Xie Y. Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection. Front Immunol 2022;13:893512. [PMID: 35634301 DOI: 10.3389/fimmu.2022.893512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 387 |
Delobel D, Furutani Y, Nagoshi S, Tsubota A, Miyasaka A, Watashi K, Wakita T, Matsuura T, Usui K. SEB genotyping: SmartAmp-Eprimer binary code genotyping for complex, highly variable targets applied to HBV. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07458-4] [Reference Citation Analysis]
|
| 388 |
Kalisvaart M, Chadha R, De Martin E, Alconchel F, Goldaracena N, Keskin O, Liu J, Nasralla D, Mazzola A, Rammohan A, Spiro M, Tanaka T, Campos-Varela I, Victor D, Vinaixa C, Yoon U, Yoon YI, Hessheimer A, Kabacam G, Sapisochin G, Shaker T, Bhangui P, Chan A, Kirchner V. Proceedings of the 26th Annual Virtual Congress of the International Liver Transplantation Society. Transplantation 2022. [PMID: 35676871 DOI: 10.1097/TP.0000000000004183] [Reference Citation Analysis]
|
| 389 |
Zhang W, Xu C, Rui Y, Chen J, Chen T, Dai Y, Xu B, Hu Y, Chen J, Zhou Y. Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers. Journal of Virus Eradication 2022. [DOI: 10.1016/j.jve.2022.100076] [Reference Citation Analysis]
|
| 390 |
Jang H, Yoon JS, Park SY, Lee HA, Jang MJ, Kim SU, Sinn DH, Seo YS, Kim HY, Kim SE, Jun DW, Yoon EL, Sohn JH, Ahn SB, Shim JJ, Jeong SW, Cho YK, Kim HS, Nam JY, Lee YB, Kim YJ, Yoon JH, Zoulim F, Lampertico P, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Papatheodoridis GV, Lee JH. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol 2022;20:1343-1353.e16. [PMID: 34500103 DOI: 10.1016/j.cgh.2021.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 391 |
Guo F, Yuan Y, Chen Z, Gao F, Li X, Wang H, Wang X, Bai G. Downregulation of the long non-coding RNA MALAT1 in tenofovir-treated pregnant women with hepatitis B virus infection promotes immune recovery of natural killer cells via the has-miR-155-5p/HIF-1α axis. International Immunopharmacology 2022;107:108701. [DOI: 10.1016/j.intimp.2022.108701] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 392 |
Gane E, Yuen MF, Kakuda TN, Ogawa T, Takahashi Y, Goeyvaerts N, Lonjon-Domanec I, Vaughan T, Schluep T, Hamilton J, Njumbe Ediage E, Hillewaert V, Snoeys J, Lenz O, Talloen W, Biermer M. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B. Antivir Ther 2022;27:13596535221093856. [PMID: 35695169 DOI: 10.1177/13596535221093856] [Reference Citation Analysis]
|
| 393 |
Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 394 |
Yu L, Guan Y, Li L, Lu N, Zhang C. The transcription factor Eomes promotes expression of inhibitory receptors on hepatic CD8 + T cells during HBV persistence. The FEBS Journal 2022;289:3241-3261. [DOI: 10.1111/febs.16342] [Reference Citation Analysis]
|
| 395 |
Mao D, Lau ESH, Wu H, Yang A, Fan B, Shi M, Tam CHT, Chow E, Kong APS, Ma RCW, Luk A, Chan JCN. Risk Associations of Glycemic Burden and Obesity With Liver Cancer-A 10-Year Analysis of 15,280 Patients With Type 2 Diabetes. Hepatol Commun 2022;6:1350-60. [PMID: 35044101 DOI: 10.1002/hep4.1891] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 396 |
Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, Tang ASP, Lim KE, Lim GEH, Tamaki N, Kim BK, Teng MLP, Fung J, Loomba R, Nguyen MH, Huang DQ. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis. JAMA Netw Open 2022;5:e2219407. [PMID: 35767258 DOI: 10.1001/jamanetworkopen.2022.19407] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 397 |
Liu R, Li M, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hao H, Hu L, Gao Y, Xu M, Xie Y. Hepatitis B core-related antigen serum levels are associated with significant liver fibrosis in treatment-naive chronic HBV infection patients. J Viral Hepat 2022;29:438-46. [PMID: 35357759 DOI: 10.1111/jvh.13674] [Reference Citation Analysis]
|
| 398 |
Hsu YC, Wu JL, Tseng CH, Nguyen MH, Lin CW, Hung CL. Severe Acute Exacerbation After Cessation of Nucleos(t)ide Analog for Chronic Hepatitis B: A Real-World Study of Routine Practice. Clin Gastroenterol Hepatol 2022;20:1413-1415.e3. [PMID: 34464721 DOI: 10.1016/j.cgh.2021.08.037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 399 |
Watermeyer G, Awuku Y, Fredericks E, Epstein D, Setshedi M, Devani S, Mudombi W, Kassianides C, Katsidzira L. Challenges in the management of inflammatory bowel disease in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00048-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 400 |
Lee J, Lee JG, Hwang S, Lee KW, Kim JM, Ryu JH, Kim BW, Choi DL, You YK, Kim DS, Nah YW, Kang KJ, Cho JY, Yu HC, Hong G, Choi D, Moon JI, Kim MS. Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study. Hepatol Int 2022;16:537-44. [PMID: 35467324 DOI: 10.1007/s12072-022-10320-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 401 |
Wang J, Zhang X, Geng X, Shi J, Jia X, Dang S, Wang W. Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases. EClinicalMedicine 2022;48:101425. [PMID: 35706497 DOI: 10.1016/j.eclinm.2022.101425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 402 |
Hu CY, Tsou Y, Chung M, Lin N, Chen C, Lee P, Liu C. Hepatitis B Virus Infection Flare Induced Acute-on-chronic Liver Failure After COVID-19 Vaccination: A Case Report. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon-126460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 403 |
Vélez Aguirre JD, Lepesqueur Guillén LH, Yepes Barreto IDJ. La esteatohepatitis no alcohólica: una causa emergente de cirrosis en Colombia. Rev colomb Gastroenterol 2022;37:136-144. [DOI: 10.22516/25007440.783] [Reference Citation Analysis]
|
| 404 |
Arnouk S, Whitsett M, Papadopoulos J, Stewart Lewis Z, Dagher NN, Feldman DM, Park JS. Successful Treatment of Tenofovir Alafenamide-Induced Lactic Acidosis: A Case Report. Journal of Pharmacy Practice. [DOI: 10.1177/08971900221105042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 405 |
Hakami T. Acute liver failure due to hepatitis B virus reactivation induced by doxorubicin and cyclophosphamide chemotherapy for adjuvant treatment of breast cancer: A case report. Clin Case Rep 2022;10:e05894. [PMID: 35620259 DOI: 10.1002/ccr3.5894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 406 |
Chen Y, Gao WK, Shu YY, Ye J. Clinical treatment of chronic hepatitis B virus infection in indeterminate phase: Current status and future prospects. Shijie Huaren Xiaohua Zazhi 2022; 30(10): 436-443 [DOI: 10.11569/wcjd.v30.i10.436] [Reference Citation Analysis]
|
| 407 |
Oh H, Lee HY, Kim J, Kim YJ. Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail. Cancers (Basel) 2022;14:2617. [PMID: 35681596 DOI: 10.3390/cancers14112617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 408 |
Huang Y, Qin A, Tsai C, Chen P. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. Viruses 2022;14:1128. [DOI: 10.3390/v14061128] [Reference Citation Analysis]
|
| 409 |
Zhang L, Yang S, Yu Y, Wang S, Yu Y, Jin Y, Zhao A, Mao Y, Lu L. Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus. Hepatol Commun 2022. [PMID: 35593183 DOI: 10.1002/hep4.1994] [Reference Citation Analysis]
|
| 410 |
Sagnelli C, Sica A, Creta M, Borsetti A, Ciccozzi M, Sagnelli E. Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. Pathogens 2022;11:567. [DOI: 10.3390/pathogens11050567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 411 |
Fujita M, Kusumoto S, Ishii I, Iwata T, Fujisawa T, Sugiyama M, Hata A, Mizokami M. Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma. Sci Rep 2022;12:7365. [PMID: 35513395 DOI: 10.1038/s41598-022-10665-3] [Reference Citation Analysis]
|
| 412 |
Hui RW, Mak LY, Seto WK, Yuen MF. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: A spotlight on drugs at phase II clinical trials. Expert Opin Emerg Drugs 2022. [PMID: 35511483 DOI: 10.1080/14728214.2022.2074977] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 413 |
Tapper EB, Ufere NN, Huang DQ, Loomba R. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther 2022;55:1099-115. [PMID: 35235219 DOI: 10.1111/apt.16831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 414 |
Sandmann L, Cornberg M. HCC and HBV reactivation-A preventable condition not to be missed. Hepatology 2022;75:1075-7. [PMID: 35007342 DOI: 10.1002/hep.32333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 415 |
Wang Z, Zhou Y, Yu P, Liu Y, Mei M, Bian Z, Shao W, Lv J, Li X, Lu W, Xu L. Retrospective Evaluation of Non-Invasive Assessment Based on Routine Laboratory Markers for Assessing Advanced Liver Fibrosis in Chronic Hepatitis B Patients. IJGM 2022;Volume 15:5159-71. [DOI: 10.2147/ijgm.s364216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 416 |
Zhao D, Zhang X, Tang Y, Guo P, Ai R, Hou M, Wang Y, Yuan X, Cui L, Zhang Y, Zhao S, Li W, Wang Y, Sun X, Liu L, Dong S, Li L, Zhao W, Nan Y. Identification and Validation of Novel Biomarkers for Hepatocellular Carcinoma, Liver Fibrosis/Cirrhosis and Chronic Hepatitis B via Transcriptome Sequencing Technology. JHC 2022;Volume 9:389-403. [DOI: 10.2147/jhc.s357380] [Reference Citation Analysis]
|
| 417 |
Choi HSJ, Tonthat A, Janssen HLA, Terrault NA. Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B. Hepatol Commun 2022;6:935-49. [PMID: 34894108 DOI: 10.1002/hep4.1875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 418 |
Kolli H, Ali MJ, Campoverde Reyes KJ, Lau DT. Case of cryoglobulinaemia associated with chronic hepatitis B. BMJ Case Rep 2022;15:e249630. [DOI: 10.1136/bcr-2022-249630] [Reference Citation Analysis]
|
| 419 |
Tseng TC, Hosaka T, Liu CJ, Suzuki F, Hong CM, Kumada H, Yang WT, Hsu CY, Su TH, Yang HC, Liu CH, Chen PJ, Chen HH, Kao JH. Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase. Am J Gastroenterol 2022;117:748-57. [PMID: 35191399 DOI: 10.14309/ajg.0000000000001691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 420 |
Xun Z, Yao X, Zhu C, Ye Y, Wu S, Chen T, Zeng Y, Lin C, Yang B, Ou Q, Liu C. Proteomic characterization of the natural history of chronic HBV infection revealed by tandem mass tag-based quantitative proteomics approach. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 421 |
Yuan BH, Li RH, Huo RR, Li MJ, Papatheodoridis G, Zhong JH. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J Gastroenterol Hepatol 2022;37:782-94. [PMID: 35080052 DOI: 10.1111/jgh.15783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 422 |
Ortonne V, Lucas Q, Garrigou O, Soulier A, Challine D, Pawlotsky JM, Leroy V, Chevaliez S. Alinity m, a Random-Access System, for Hepatitis B Virus DNA Quantification in Plasma and Whole Blood Collected on Dried Blood Spots. mSphere 2022;:e0008222. [PMID: 35477312 DOI: 10.1128/msphere.00082-22] [Reference Citation Analysis]
|
| 423 |
Keles Onal A, Sarikaya S, Özdolap Çoban Ş, Baki AE, Köktürk F. Biyolojik DMARD Kullanan Hastalarda Kronik Hepatit B Enfeksiyonu ve Okkült Hepatit B Sıklığı ve Tedavi Yönetimi. Medical Journal of Western Black Sea 2022;6:72-77. [DOI: 10.29058/mjwbs.941637] [Reference Citation Analysis]
|
| 424 |
Koffas A, Mak LY, Gill US, Kennedy PTF. Early Treatment Consideration in Patients with Hepatitis B 'e' Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift? Viruses 2022;14. [PMID: 35632642 DOI: 10.3390/v14050900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 425 |
Hong YM, Yoon KT. [Definition and Management of the Immune Tolerance Phase in Chronic Hepatitis B]. Korean J Gastroenterol 2022;79:156-60. [PMID: 35473773 DOI: 10.4166/kjg.2022.049] [Reference Citation Analysis]
|
| 426 |
Chi X, Jiang L, Yuan Y, Huang X, Yang X, Hochwald S, Liu J, Huang H. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02279-w] [Reference Citation Analysis]
|
| 427 |
Chen W, Fu M, Zhang C, Xing Q, Zhou F, Lin M, Dong X, Huang J, Lin S, Hong M, Zheng Q, Pan J. Deep Learning-Based Universal Expert-Level Recognizing Pathological Images of Hepatocellular Carcinoma and Beyond. Front Med 2022;9:853261. [DOI: 10.3389/fmed.2022.853261] [Reference Citation Analysis]
|
| 428 |
Zhu Z, Qin Y, Liang Q, Xia W, Zhang T, Wang W, Zhang M, Jiang T, Wu H, Tian Y. Increased HBV Coinfection and Decreased IFN-γ-Producing HBV-Specific CD8+ T Cell Numbers During HIV Disease Progression. Front Immunol 2022;13:861804. [PMID: 35432386 DOI: 10.3389/fimmu.2022.861804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 429 |
Wong GL, Lok AS. Chronic hepatitis B and D. Yamada's Textbook of Gastroenterology 2022. [DOI: 10.1002/9781119600206.ch87] [Reference Citation Analysis]
|
| 430 |
Akyüz F, Çavuş B, Nizam N, Göktürk S, Baran B, Yazıcı H, Evirgen S, Akyüz Ü, Öbekli T, Karaca Ç, Demir K, Beşışık F, Kaymakoğlu S. Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data. Clin Exp Hepatol 2022;8:7-13. [PMID: 35415260 DOI: 10.5114/ceh.2022.114153] [Reference Citation Analysis]
|
| 431 |
Odenwald MA, Paul S. Viral hepatitis: Past, present, and future. World J Gastroenterol 2022; 28(14): 1405-1429 [DOI: 10.3748/wjg.v28.i14.1405] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 432 |
Song A, Liu Y, Cao Z, Lu J, Ren S, Zheng S, Ma L, Hu Z, Lin X, Li H, Zheng Y, Chen X. Clinical Features and T Cell Immune Characteristics of Postpartum Hepatitis Flare in Pregnant Women With HBeAg-Positive Chronic HBV Infection. Front Immunol 2022;13:881321. [DOI: 10.3389/fimmu.2022.881321] [Reference Citation Analysis]
|
| 433 |
Calabrese C. Vaccinations in Patients with Rheumatic Disease: Consider Disease and Therapy. Rheum Dis Clin North Am 2022;48:397-409. [PMID: 35400367 DOI: 10.1016/j.rdc.2022.02.001] [Reference Citation Analysis]
|
| 434 |
Ma GX, Zhu L, Lu W, Tan Y, Truehart J, Johnson C, Handorf E, Nguyen MT, Yeh MC, Wang MQ. Examining the Influencing Factors of Chronic Hepatitis B Monitoring Behaviors among Asian Americans: Application of the Information-Motivation-Behavioral Model. Int J Environ Res Public Health 2022;19. [PMID: 35457509 DOI: 10.3390/ijerph19084642] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 435 |
Liu T, Huang C, Tsai P, Yeh M, Jang T, Huang J, Dai C, Yu M, Chuang W. The compound annual growth rate of the fibrosis‐4 index in chronic hepatitis B patients. The Kaohsiung J of Med Scie. [DOI: 10.1002/kjm2.12543] [Reference Citation Analysis]
|
| 436 |
Chu JN, Nguyen TT, Rivadeneira NA, Hiatt RA, Sarkar U. Exploring factors associated with hepatitis B screening in a multilingual and diverse population. BMC Health Serv Res 2022;22:479. [PMID: 35410249 DOI: 10.1186/s12913-022-07813-w] [Reference Citation Analysis]
|
| 437 |
Diao Y, Hu D, Hu X, Wang P, Wang X, Luo X, Wang H, Ning Q. The Role of Metabolic Factors and Steatosis in Treatment-Naïve Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase. Infect Dis Ther. [DOI: 10.1007/s40121-022-00629-5] [Reference Citation Analysis]
|
| 438 |
Bae J, Kim JE, Perumalsamy H, Park S, Kim Y, Jun DW, Yoon TH. Mass Cytometry Study on Hepatic Fibrosis and Its Drug-Induced Recovery Using Mouse Peripheral Blood Mononuclear Cells. Front Immunol 2022;13:814030. [PMID: 35222390 DOI: 10.3389/fimmu.2022.814030] [Reference Citation Analysis]
|
| 439 |
Hammond SP, Ho VT, Marty FM. Hepatitis B virus vaccination after allogeneic hematopoietic cell transplantation prevents post-transplant HBV reactivation. Transplant Cell Ther 2022:S2666-6367(22)01197-6. [PMID: 35413458 DOI: 10.1016/j.jtct.2022.04.004] [Reference Citation Analysis]
|
| 440 |
Tseng C, Liu W, Chen C, Chang T, Tseng K. Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07326-1] [Reference Citation Analysis]
|
| 441 |
Wang J, Zhang Q, Ai J, Liu D, Liu C, Xiang H, Gu Y, Guo Y, Lv J, Huang Y, Liu Y, Xu D, Chen S, Li J, Li Q, Liang J, Bian L, Zhang Z, Guo X, Feng Y, Liu L, Zhang X, Zhang Y, Xie F, Jiang S, Qin W, Wang X, Rao W, Zhang Q, Tian Q, Zhu Y, Cong Q, Xu J, Hou Z, Zhang N, Zhang A, Zu H, Wang Y, Yan Z, Du X, Hou A, Yan Y, Qiu Y, Wu H, Hu S, Deng Y, Ji J, Yang J, Huang J, Zhao Z, Zou S, Ji H, Ge G, Zhong L, He S, Yan X, Yangzhen BB, Qu C, Zhang L, Yang S, Gao X, Lv M, Zhu Q, Xu X, Zeng Q, Qi X, Zhang W. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int. [DOI: 10.1007/s12072-022-10332-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 442 |
Scavone D, Lauzi S, Stranieri A, Tramontano G, Ratti G, Paltrinieri S. Evaluating the presence of domestic cat hepadnavirus viraemia in cats with biochemical alterations suggestive of liver disease. Vet Rec 2022;:e1626. [PMID: 35393638 DOI: 10.1002/vetr.1626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 443 |
Luo Y, Xiang K, Liu J, Song J, Feng J, Chen J, Dai Y, Hu Y, Zhuang H, Zhou Y. Inhibition of In Vitro Infection of Hepatitis B Virus by Human Breastmilk. Nutrients 2022;14:1561. [DOI: 10.3390/nu14081561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 444 |
Xiao HM, Shi MJ, Jiang JM, Cai GS, Xie YB, Tian GJ, Xue JD, Mao DW, Li Q, Yang HZ, Guo H, Lei CL, Lu W, Chen L, Liu HB, Wang J, Gao YQ, Chen JZ, Wu SD, Chen HJ, Zhao PT, Zhang CZ, Ou-Yang WW, Wen ZH, Chi XL. Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: A randomized controlled trial. J Ethnopharmacol 2022;293:115210. [PMID: 35398501 DOI: 10.1016/j.jep.2022.115210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 445 |
Zhang JH, Zhang X, Zhou ZH, Zhu XJ, Zheng C, Li M, Jin SG, Mao DW, Xue JD, Shi WB, Chi XL, Wang XB, Li XD, Li Y, Wang H, Li Q, Zhou DQ, Wang CB, Shi CH, Li CZ, Wu JH, Kong XN, Sun XH, Gao YQ. Bushen Jianpi Formula Combined with Entecavir for the Treatment of HBeAg-Negative Chronic Hepatitis B: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med 2022;2022:6097221. [PMID: 35368769 DOI: 10.1155/2022/6097221] [Reference Citation Analysis]
|
| 446 |
Yardeni D, Heller T, Koh C. Chronic hepatitis D-What is changing? J Viral Hepat 2022;29:240-51. [PMID: 35122369 DOI: 10.1111/jvh.13651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 447 |
Chon YE, Park SY, Kim SU, Hong HP, Lee JS, Lee HW, Kim MN, Park JY, Kim DY, Ahn SH, Kim BK. Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study. J Viral Hepat 2022;29:289-96. [PMID: 35152517 DOI: 10.1111/jvh.13656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 448 |
Feng M, Liu K, Zhao G, Lou S, An B, Lin L, Ding Y, Bao S, Wang H. A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105315] [Reference Citation Analysis]
|
| 449 |
Lim YS, Seto WK, Kurosaki M, Fung S, Kao JH, Hou J, Gordon SC, Flaherty JF, Yee LJ, Zhao Y, Agarwal K, Lampertico P. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther 2022;55:921-43. [PMID: 35178711 DOI: 10.1111/apt.16788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 450 |
Li G, Wang Y, De Clercq E. Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharm Sin B 2022;12:1567-90. [PMID: 35847492 DOI: 10.1016/j.apsb.2021.11.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 451 |
Yuen MF, Wong DK, Schluep T, Lai CL, Ferrari C, Locarnini S, Lo RC, Gish RG, Hamilton J, Wooddell CI, Mak LY, Given BD. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut 2022;71:789-97. [PMID: 33712437 DOI: 10.1136/gutjnl-2020-323445] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 452 |
Schwarzenberg SJ, Ling SC, Rosenthal P, Murray KF, Teckman J, Mogul D, Rodriguez-Baez N, Schwarz K. Lessons Learned From Children Enrolled Into the Hepatitis B Virus Research Network Multi-Center Prospective Study. J Pediatr Gastroenterol Nutr 2022;74:431-3. [PMID: 35045562 DOI: 10.1097/MPG.0000000000003381] [Reference Citation Analysis]
|
| 453 |
Steckstor M, Katsounas A, Canbay A. Chronische Hepatitis B: Stiller Begleiter mit gravierenden Folgeschäden. MMW - Fortschritte der Medizin 2022;164:42-50. [DOI: 10.1007/s15006-022-0831-1] [Reference Citation Analysis]
|
| 454 |
Zhao X, Bai X, Xi Y. Intrauterine Infection and Mother-to-Child Transmission of Hepatitis B Virus: Route and Molecular Mechanism. IDR 2022;Volume 15:1743-51. [DOI: 10.2147/idr.s359113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 455 |
Chen Y, Peng L, He J, Wu J, Tian R, Xu J, Fan X, Dai J, An R, Song J, Chen Z, Liu Y, Chen X, Zou Z. Impact of hepatitis B virus infection on maternal and infant outcomes of women with gestational diabetes mellitus: A three-year retrospective study. Journal of Diabetes and its Complications 2022. [DOI: 10.1016/j.jdiacomp.2022.108201] [Reference Citation Analysis]
|
| 456 |
Yoo S, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Yoo C, Ryoo BY, Choi J. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment. Clin Gastroenterol Hepatol 2022;20:898-907. [PMID: 34182151 DOI: 10.1016/j.cgh.2021.06.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 457 |
Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Tak WY, Park JY, Kweon YO, Kim DY, Ahn SH, Jang SY, Park SY, Kim SU. Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. Clin Gastroenterol Hepatol 2022;20:e794-807. [PMID: 34091048 DOI: 10.1016/j.cgh.2021.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 458 |
An J, Kim D, Oh B, Oh YJ, Song J, Park N, Kim HI, Kang HJ, Oh JH, Kim W, Lee E, Sung CO, Song GW, Kim DG, Yu E, Letouzé E, Zucman-Rossi J, Lee HC, Shim JH. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas. Hepatology 2022;75:997-1011. [PMID: 34478159 DOI: 10.1002/hep.32135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 459 |
Gómez Camarero J, Badia Aranda E, Quiñones Castro R, Saiz Chumillas RM, Alcoba Vega L, Díez Ruiz S, Gómez Manero N, Vinuesa Campo R, Jorquera Plaza F. Hepatitis B and C screening in hospitalized patients with SARS-CoV-2 infection. Gastroenterología y Hepatología (English Edition) 2022;45:256-264. [DOI: 10.1016/j.gastre.2022.04.003] [Reference Citation Analysis]
|
| 460 |
Emiroğlu HH, Emiroğlu M. Efficacy of Entecavir Treatment in a 8-Year-Old Child with Chronic Hepatitis B. vhd 2022;28:38-40. [DOI: 10.4274/vhd.galenos.2022.2021-7-2] [Reference Citation Analysis]
|
| 461 |
Wong RJ, Jain MK, Therapondos G, Niu B, Kshirsagar O, Thamer M. Low Rates of Hepatitis B Virus Treatment Among Treatment-Eligible Patients in Safety-Net Health Systems. J Clin Gastroenterol 2022;56:360-8. [PMID: 33780210 DOI: 10.1097/MCG.0000000000001530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 462 |
Nagra N, Kozarek RA, Burman BE. Therapeutic Advances in Viral Hepatitis A-E. Adv Ther 2022;39:1524-52. [PMID: 35220557 DOI: 10.1007/s12325-022-02070-z] [Reference Citation Analysis]
|
| 463 |
Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B; CREATE Study Group. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). Clin Gastroenterol Hepatol 2022;20:e784-93. [PMID: 33309804 DOI: 10.1016/j.cgh.2020.12.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 28.0] [Reference Citation Analysis]
|
| 464 |
Yardeni D, Ghany MG. Review article: hepatitis B-current and emerging therapies. Aliment Pharmacol Ther 2022;55:805-19. [PMID: 35224760 DOI: 10.1111/apt.16828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 465 |
Lebray P, Delignat S, Frelicot A, Carrette M, Gautier A, Jamet N, Lecefel C, Houot M, Bourguignon S, Thabut D, Conti F, Liou A. Hepatitis B or Delta liver transplant patients at risk of recurrence: Long-term effectiveness and budget impact of low-dose subcutaneous anti-hepatitis B immunoglobulin plus patient education program. Journal of Liver Transplantation 2022. [DOI: 10.1016/j.liver.2022.100088] [Reference Citation Analysis]
|
| 466 |
Usai C, Gill US, Riddell AC, Asselah T, Kennedy PT. Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus. Aliment Pharmacol Ther 2022;55:978-93. [PMID: 35292991 DOI: 10.1111/apt.16807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 467 |
Luo M, Zhou B, Hou J, Jiang D. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients. Hepatol Res 2022;52:337-51. [PMID: 35089634 DOI: 10.1111/hepr.13749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 468 |
Winckelmann A, Fahnøe U, Bajpai P, Dalegaard MI, Lundh A, Ryom L, Bukh J, Weis N. Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment. Journal of Clinical Virology 2022. [DOI: 10.1016/j.jcv.2022.105159] [Reference Citation Analysis]
|
| 469 |
Zhou L, He Q, Liu X, Yang X, Ou X, Situ B, Li Y, Pan X, Xu Q. Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse. Med Sci Monit 2022;28:e934785. [PMID: 35351845 DOI: 10.12659/MSM.934785] [Reference Citation Analysis]
|
| 470 |
Long V, Mok ZR, Lee GH, Chandran NS. Change in hepatitis B virus DNA status in patients receiving chronic immunosuppressive therapy for moderate-to-severe skin disease. Ann Acad Med Singap 2022;51:192-195. [DOI: 10.47102/annals-acadmedsg.2021312] [Reference Citation Analysis]
|
| 471 |
Lee TH, Hunt CM, Maier MM, Lowy E, Beste LA. Hepatitis B Virus-Related Care Quality In Patients With Hepatitis B/Hiv Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study. Clin Infect Dis 2022:ciac227. [PMID: 35349635 DOI: 10.1093/cid/ciac227] [Reference Citation Analysis]
|
| 472 |
Colombatto P, Coco B, Bonino F, Brunetto MR. Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine. Viruses 2022;14:701. [DOI: 10.3390/v14040701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 473 |
Ersöz Acar B. İmmünsüpresif ilaçlar ve HBV reaktivasyonu. Bolu Abant Izzet Baysal Universitesi Tip Fakultesi Abant Tip Dergisi 2022. [DOI: 10.47493/abantmedj.1051982] [Reference Citation Analysis]
|
| 474 |
Proulx J, Ghaly M, Park I, Borgmann K. HIV-1-Mediated Acceleration of Oncovirus-Related Non-AIDS-Defining Cancers. Biomedicines 2022;10:768. [DOI: 10.3390/biomedicines10040768] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 475 |
Lan W, Wang Y, Zhou Z, Sun X, Zhang Y, Zhang F. Metabolic Regulation of Hepatitis B Virus Infection in HBV-Transgenic Mice. Metabolites 2022;12:287. [DOI: 10.3390/metabo12040287] [Reference Citation Analysis]
|
| 476 |
Lee H, Jang S, Ahn SH, Kim BK. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU/mL. Hepatol Int 2022. [PMID: 35322374 DOI: 10.1007/s12072-022-10310-1] [Reference Citation Analysis]
|
| 477 |
Tao X, Chen L, Zhao Y, Liu Y, Shi R, Jiang B, Mi Y, Xu L. A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease. Front Med 2022;9:862879. [DOI: 10.3389/fmed.2022.862879] [Reference Citation Analysis]
|
| 478 |
Cardoso AC, Figueiredo-Mendes C, Villela-Nogueira CA, Marcellin P. Staging Fibrosis in Chronic Viral Hepatitis. Viruses 2022;14:660. [PMID: 35458391 DOI: 10.3390/v14040660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 479 |
Moini M, Fung S. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. Viruses 2022;14. [PMID: 35458387 DOI: 10.3390/v14040657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 480 |
Hu Z, Zeng H, Hou J, Wang J, Xu L, Zhang Y, Chen M, Zhou Z. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. Viruses 2022;14. [PMID: 35458386 DOI: 10.3390/v14040656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 481 |
Sagnelli C, Macera M, Camaioni C, Salvati A, Coppola N, Sagnelli E. SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis. Infection 2022. [PMID: 35316530 DOI: 10.1007/s15010-022-01804-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 482 |
Huang X, Zhuang J, Yang Y, Jian J, Ai W, Liu C, Tang W, Jiang C, He Y, Huang L, Peng S, Pan JS. Diagnostic Value of Serum Chitinase-3-Like Protein 1 for Liver Fibrosis: A Meta-analysis. BioMed Research International 2022;2022:1-13. [DOI: 10.1155/2022/3227957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 483 |
Malik GF, Zakaria N, Majeed MI, Ismail FW. Viral Hepatitis - The Road Traveled and the Journey Remaining. Hepat Med 2022;14:13-26. [PMID: 35300491 DOI: 10.2147/HMER.S352568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 484 |
Johannessen A, Stockdale AJ, Henrion MY, Okeke E, Seydi M, Wandeler G, Sonderup M, Spearman CW, Vinikoor M, Sinkala E, Desalegn H, Fall F, Riches N, Davwar P, Duguru M, Maponga T, Taljaard J, Matthews PC, Andersson M, Sombie R, Shimakawa Y, Lemoine M. Diagnostic performance of non-invasive fibrosis markers for chronic hepatitis B in sub-Saharan Africa: a Bayesian individual patient data meta-analysis.. [DOI: 10.1101/2022.03.18.22272415] [Reference Citation Analysis]
|
| 485 |
Htet NH, Naing C, Vongpunsawad S, Win TT, Poovorawan Y; Cochrane Hepato-Biliary Group. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd014610] [Reference Citation Analysis]
|
| 486 |
Zhou Q, Zhang Q, Wang K, Huang T, Deng S, Wang Y, Cheng C. Anti-rheumatic Drug-induced Hepatitis B Virus Reactivation and Preventive Strategies for Hepatocellular Carcinoma. Pharmacol Res 2022;:106181. [PMID: 35301112 DOI: 10.1016/j.phrs.2022.106181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 487 |
Danis N, Salih Akarca U, Turan I, Karasu Z, Ersoz G, Yilmaz F, Nart D, Zeytinoglu A, Selda Erensoy M, Gunsar F. Predictive value of FibroScan in detecting liver fibrosis in HBeAg negative patients with chronic hepatitis B whose HBV DNA 2000-20000 IU/ml with ALT 1-2 times the upper limit of normal and those with HBV DNA >20000 IU/ml and normal ALT. North Clin Istanb 2021;8:568-74. [PMID: 35284786 DOI: 10.14744/nci.2021.35545] [Reference Citation Analysis]
|
| 488 |
Choi YH, Lee HW, Purdy MA. Natural antibody IgG levels are associated with HBeAg-positivity and seroconversion in chronic hepatitis B patients treated with entecavir. Sci Rep 2022;12:4382. [PMID: 35288624 DOI: 10.1038/s41598-022-08457-w] [Reference Citation Analysis]
|
| 489 |
Yang J, Wang J, Li H, Gao S, Fan Y, Wang K. IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Front Oncol 2022;12:746643. [DOI: 10.3389/fonc.2022.746643] [Reference Citation Analysis]
|
| 490 |
Yuan C, Peng J, Xia R, He J, Qiu T, Yao Y. Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy. Front Microbiol 2022;13:865124. [DOI: 10.3389/fmicb.2022.865124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 491 |
Liaw YF, Chien RN. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation". Kaohsiung J Med Sci 2022. [PMID: 35262284 DOI: 10.1002/kjm2.12518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 492 |
Rosenbohm JM, Klapperich CM, Cabodi M. Tunable Duplex Semiquantitative Detection of Nucleic Acids with a Visual Lateral Flow Immunoassay Readout. Anal Chem 2022;94:3956-62. [PMID: 35199994 DOI: 10.1021/acs.analchem.1c05039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 493 |
Mayran C, Foulongne V, Van de Perre P, Fournier-Wirth C, Molès JP, Cantaloube JF. Rapid Diagnostic Test for Hepatitis B Virus Viral Load Based on Recombinase Polymerase Amplification Combined with a Lateral Flow Read-Out. Diagnostics (Basel) 2022;12. [PMID: 35328174 DOI: 10.3390/diagnostics12030621] [Reference Citation Analysis]
|
| 494 |
Yip TC, Gill M, Wong GL, Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol Int 2022. [PMID: 35235148 DOI: 10.1007/s12072-022-10306-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 495 |
Wang XH, Hu ZL, Fu YZ, Hou JY, Li WX, Zhang YJ, Xu L, Zhou QF, Chen MS, Zhou ZG. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. J Gastroenterol 2022;57:185-98. [PMID: 35152312 DOI: 10.1007/s00535-022-01855-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 496 |
Liu YC, Jeng WJ, Peng CW, Chien RN, Liaw YF. Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies. Liver Int 2022;42:551-60. [PMID: 34936719 DOI: 10.1111/liv.15140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 497 |
Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong G, Brakenhoff SM, Chien RN, Feld J, Sonneveld MJ, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng WJ, Janssen HLA; RETRACT-B Study Group. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology 2022;162:757-771.e4. [PMID: 34762906 DOI: 10.1053/j.gastro.2021.11.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 498 |
Zhou Y, Li J, Gordon SC, Trudeau S, Rupp LB, Boscarino JA, Daida YG, Schmidt MA, Lu M. Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States. J Viral Hepat 2022;29:189-95. [PMID: 34905259 DOI: 10.1111/jvh.13639] [Reference Citation Analysis]
|
| 499 |
Barone M, Venerito V, Paolillo R, Emmi G, Fornaro M, Cacciapaglia F, Cantarini L, Di Leo A, Iannone F, Lopalco G. Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. Intern Emerg Med 2022;17:475-80. [PMID: 34476737 DOI: 10.1007/s11739-021-02836-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 500 |
Mustafayev K, Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.02.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 501 |
Dong B, Chen Y, Lyu G, Qin R. Liver stiffness measurement as a quantitative method for liver fibrosis in children with non-alcoholic fatty liver disease: A meta-analysis. J Paediatr Child Health 2022;58:481-90. [PMID: 34554611 DOI: 10.1111/jpc.15751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 502 |
Lu M, Li J, Zhou Y, Rupp LB, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Daida YG, Schmidt MA, Trudeau S, Gordon SC; CHeCS Investigators. Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006-2016). J Clin Gastroenterol 2022;56:273-9. [PMID: 33780209 DOI: 10.1097/MCG.0000000000001522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 503 |
Pol S. Withdrawal of Nucleos(t)ide Analogues in the Treatment of Chronic Hepatitis B: A Cornelian Choice. Gastroenterology 2022;162:698-9. [PMID: 34914942 DOI: 10.1053/j.gastro.2021.12.240] [Reference Citation Analysis]
|
| 504 |
. Preferred Therapy for Specific Viral Pathogens. 2022 Nelson’s Pediatric Antimicrobial Therapy 2022. [DOI: 10.1542/9781610025652-7] [Reference Citation Analysis]
|
| 505 |
Li C, Li H, Gong M, Wei J. Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate. Clin Case Rep 2022;10:e05641. [PMID: 35356169 DOI: 10.1002/ccr3.5641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 506 |
Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou Α, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, Dalekos G, Kao JH, Hadziyannis S, Papatheodoridis GV. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver Int 2022;42:541-50. [PMID: 34890120 DOI: 10.1111/liv.15128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 507 |
Li M, Sun F, Bi X, Lin Y, Yang L, Lu Y, Zhang L, Wan G, Yi W, Zhao L, Xie Y. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virologica Sinica 2022. [DOI: 10.1016/j.virs.2022.03.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 508 |
Lin C, Lin Y, Liang K, Chen L, Chien C, Hu C, Huang T, Shyu Y, Yeh C, Chien R. Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan. Clinical Therapeutics 2022;44:403-417.e6. [DOI: 10.1016/j.clinthera.2022.01.010] [Reference Citation Analysis]
|
| 509 |
Dionne-Odom J, Cozzi GD, Franco RA, Njei B, Tita ATN. Treatment and prevention of viral hepatitis in pregnancy. Am J Obstet Gynecol 2022;226:335-46. [PMID: 34516961 DOI: 10.1016/j.ajog.2021.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 510 |
Masetti C, Pugliese N, Aghemo A, Viganò M. Safety of current antiviral drugs for chronic hepatitis B. Expert Opin Drug Saf 2022. [PMID: 35209776 DOI: 10.1080/14740338.2022.2045271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 511 |
Chien RN, Liaw YF. Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses 2022;14:434. [PMID: 35216027 DOI: 10.3390/v14020434] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 512 |
Kaur SP, Talat A, Karimi-Sari H, Grees A, Chen HW, Lau DTY, Catana AM. Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg). J Clin Med 2022;11:1126. [PMID: 35207397 DOI: 10.3390/jcm11041126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 513 |
Suzuki K, Suda G, Yamamoto Y, Abiko S, Kinoshita K, Miyamoto S, Sugiura R, Kimura M, Maehara O, Yamada R, Kitagataya T, Shigesawa T, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS One 2022;17:e0261760. [PMID: 35051189 DOI: 10.1371/journal.pone.0261760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 514 |
Cerva C, Salpini R, Alkhatib M, Malagnino V, Piermatteo L, Battisti A, Bertoli A, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Ferrari L, Laura C, Teti E, Cantonetti M, Arcese W, Ceccherini-silberstein F, Perno C, Andreoni M, Svicher V, Sarmati L. Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines 2022;10:443. [DOI: 10.3390/biomedicines10020443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 515 |
Riccardo BA, Giulio V, Massimiliano C, Giovanna L, Valentina T, Paola C, Teresa MG, Diana F, Viviana N, Marta R, Chiara BM, Damiano P, Alberto G, Pietro A, Federica P, Massimiliano DF, Cinzia C, Emanuela Z, Riccardo S, Ivan G, Antonio S, Martina P, Marcello A, Vincenzo BM, Claudio S, Claudio G, Eleonora C, Marcello M, Roberta L; Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. J Neurol 2022. [PMID: 35165767 DOI: 10.1007/s00415-022-11009-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 516 |
Ghazzawi M, James PB, Massaquoi SP, Yendewa SA, Salata RA, Yendewa GA. Factors Associated with HBsAg Seropositivity among Pregnant Women Receiving Antenatal Care at 10 Community Health Centers in Freetown, Sierra Leone: A Cross-Sectional Study. Pathogens 2022;11:243. [DOI: 10.3390/pathogens11020243] [Reference Citation Analysis]
|
| 517 |
Campbell C, Wang T, Smith DA, Freeman O, Noble T, Várnai KA, Harris S, Salih H, Roadknight G, Little S, Glampson B, Mercuri L, Papadimitriou D, Jones CR, Taylor V, Chaudhry A, Phan H, Borca F, Olza J, Warricker F, Romão L, Ramlakhan D, English L, Klenerman P, Andersson MI, Collier J, Nastouli E, Khakoo SI, Gelson W, Cooke GS, Woods K, Davies J, Barnes E, Matthews PC. Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. Wellcome Open Res 2022;7:51. [DOI: 10.12688/wellcomeopenres.17522.1] [Reference Citation Analysis]
|
| 518 |
Jachs M, Hartl L, Bauer D, Simbrunner B, Stättermayer AF, Strassl R, Trauner M, Mandorfer M, Reiberger T. Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression. JPM 2022;12:239. [DOI: 10.3390/jpm12020239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 519 |
Kamiya N, Sugimoto T, Abe-Chayama H, Akiyama R, Tsuboi Y, Mogami A, Imamura M, Hayes CN, Chayama K. Untying relaxed circular DNA of hepatitis B virus by polymerase reaction provides a new option for accurate quantification and visualization of covalently closed circular DNA. J Gen Virol 2022;103. [PMID: 35130138 DOI: 10.1099/jgv.0.001591] [Reference Citation Analysis]
|
| 520 |
Peliganga LB, Horta MAP, Lewis-ximenez LL. Enduring Challenges despite Progress in Preventing Mother-to-Child Transmission of Hepatitis B Virus in Angola. Pathogens 2022;11:225. [DOI: 10.3390/pathogens11020225] [Reference Citation Analysis]
|
| 521 |
Krishnan A, Prichett L, Tao X, Alqahtani SA, Hamilton JP, Mezey E, Strauss AT, Kim A, Potter JJ, Chen PH, Woreta TA. Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. World J Gastroenterol 2022; 28(5): 570-587 [DOI: 10.3748/wjg.v28.i5.570] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 522 |
Kumar M, Abbas Z, Azami M, Belopolskaya M, Dokmeci AK, Ghazinyan H, Jia J, Jindal A, Lee HC, Lei W, Lim SG, Liu CJ, Li Q, Al Mahtab M, Muljono DH, Niriella MA, Omata M, Payawal DA, Sarin SK, Ségéral O, Tanwandee T, Trehanpati N, Visvanathan K, Yang JM, Yuen MF, Zheng Y, Zhou YH. Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy. Hepatol Int 2022. [PMID: 35113359 DOI: 10.1007/s12072-021-10285-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 523 |
Yim HJ, Kim W, Ahn SH, Jung YK, Um SH, Sohn JH, Jang JY, Kim DJ, Park ES, Jin SY, Kim KH. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. J Gastroenterol Hepatol 2022;37:378-86. [PMID: 34653281 DOI: 10.1111/jgh.15710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 524 |
Chang HL, Wen WH, Lee CN, Chiu YE, Liu CJ, Chang MH, Lin LH, Chen HL. Kinetics of hepatitis B surface antigen in pregnant women with and without tenofovir disoproxil fumarate. J Viral Hepat 2022;29:107-14. [PMID: 34724288 DOI: 10.1111/jvh.13628] [Reference Citation Analysis]
|
| 525 |
Osuga T, Miyanishi K, Hamaguchi K, Tanaka S, Ohnuma H, Murase K, Takada K, Kato J. A case of acute exacerbation of chronic hepatitis C during the course of adrenal Cushing's syndrome. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5337] [Reference Citation Analysis]
|
| 526 |
Yang D, Hu H, Li R, Tang CL, Ma KS, Guo DY. The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B. Abdom Radiol (NY) 2022;47:630-9. [PMID: 34910237 DOI: 10.1007/s00261-021-03345-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 527 |
Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res 2022;52:153-64. [PMID: 34687121 DOI: 10.1111/hepr.13726] [Reference Citation Analysis]
|
| 528 |
Lu J, Zhang C, He P, Ou M, Xia J, Huang M. Risk factors for very low-level viremia in patients with chronic hepatitis B virus infection: A single-center retrospective study. Liver Research 2022. [DOI: 10.1016/j.livres.2022.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 529 |
Jo AJ, Choi WM, Kim HJ, Choi SH, Han S, Ko MJ, Lim YS. A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study. J Viral Hepat 2022;29:115-23. [PMID: 34762757 DOI: 10.1111/jvh.13631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 530 |
Ramrakhiani NS, Chen VL, Le M, Yeo YH, Barnett SD, Waljee AK, Zhu J, Nguyen MH. Optimizing hepatitis B virus screening in the United States using a simple demographics-based model. Hepatology 2022;75:430-7. [PMID: 34496066 DOI: 10.1002/hep.32142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 531 |
Chang Y, Jeong SW, Jang JY. Hepatitis B Virus Reactivation Associated With Therapeutic Interventions. Front Med (Lausanne) 2021;8:770124. [PMID: 35096867 DOI: 10.3389/fmed.2021.770124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 532 |
Siddique SM, May FP. Race-Based Clinical Recommendations in Gastroenterology. Gastroenterology 2022;162:408-414.e2. [PMID: 34890599 DOI: 10.1053/j.gastro.2021.12.234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 533 |
Giadans CG, Ríos DA, Ameigeiras B, Haddad L, De Matteo EN, Valva P, Preciado MV. Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same. J Viral Hepat 2022;29:124-34. [PMID: 34820942 DOI: 10.1111/jvh.13635] [Reference Citation Analysis]
|
| 534 |
Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen HLA, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol 2022;76:311-8. [PMID: 34606915 DOI: 10.1016/j.jhep.2021.09.025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 535 |
Dai CY, Yeh ML, Yu ML. An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously. J Hepatol 2022;76:478-80. [PMID: 34492252 DOI: 10.1016/j.jhep.2021.08.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 536 |
Chen B, Huang H, Pan CQ. The role of gut microbiota in hepatitis B disease progression and treatment. J Viral Hepat 2022;29:94-106. [PMID: 34415656 DOI: 10.1111/jvh.13595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 537 |
Lee HW, Park SY, Lee YR, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. Am J Gastroenterol 2022;117:288-94. [PMID: 34506308 DOI: 10.14309/ajg.0000000000001497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 538 |
Cacoub P, Asselah T. Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease. Am J Gastroenterol 2022;117:253-63. [PMID: 34913875 DOI: 10.14309/ajg.0000000000001575] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 539 |
Su S, Wong WC, Zou Z, Cheng DD, Ong JJ, Chan P, Ji F, Yuen M, Zhuang G, Seto W, Zhang L. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. The Lancet Global Health 2022;10:e278-87. [DOI: 10.1016/s2214-109x(21)00517-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 540 |
Laras A, Papatheodoridi M, Panopoulou E, Papatheodoridis GV, Hadziyannis SJ, Hadziyannis E. Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B. Virol J 2022;19. [DOI: 10.1186/s12985-022-01749-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 541 |
Jiang K, Zhang L, Li J, Hu H, Huang Q, Qiu T, Mo X, Ren J, Guo W, Tao Y, Cui H, Zuo Y, Chen X, Xie Y, Li Y, Liang H, Liu Z, Xie L, Mao R, Jiang Q, Huang K. Diagnostic efficacy of FibroScan for liver inflammation in patients with chronic hepatitis B: a single-center study with 1185 liver biopsies as controls. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02108-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 542 |
Chang ML, Liaw YF. Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses. Int J Mol Sci 2022;23:1552. [PMID: 35163476 DOI: 10.3390/ijms23031552] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 543 |
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study. Hepatol Int. [DOI: 10.1007/s12072-021-10295-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 544 |
Yang JY, Wu Y, Pan MY, Chiou Y, Lee RK, Li T, Wang LH. Chemical-induced degradation of PreS2 mutant surface antigen reverses HBV-mediated hepatocarcinogenesis.. [DOI: 10.1101/2022.01.24.477454] [Reference Citation Analysis]
|
| 545 |
Kim TH, Kim M, Yim HJ, Suh SJ, Jung YK, Seo YS, Um SH, Lee JI, Lee SH, Kim SG, Kim IH, Kim HS, Cho EY, Kim TY, Hwang SG. Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.121627] [Reference Citation Analysis]
|
| 546 |
Yang R, Yin N, Zhao Y, Li D, Zhang X, Li X, Zhang Y, Faiola F. Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System. Front Pharmacol 2021;12:772768. [PMID: 35046808 DOI: 10.3389/fphar.2021.772768] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 547 |
Gane EJ, Schwabe C, Berliba E, Tangkijvanich P, Jucov A, Ghicavii N, Verbinnen T, Lenz O, Talloen W, Kakuda TN, Westland C, Patel M, Yogaratnam JZ, Dragone L, Van Remoortere P. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. J Antimicrob Chemother 2022:dkab491. [PMID: 35040959 DOI: 10.1093/jac/dkab491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 548 |
Chen R, Zou J, Long L, Huang H, Zhang M, Fan X, Huang Y. Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B. Front Med 2022;8:796901. [DOI: 10.3389/fmed.2021.796901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 549 |
Song MJ. Postpartum Hepatic Flares in Immune-Tolerant Pregnant Patients with Chronic Hepatitis B Virus Infection. Gut Liver 2022;16:5-7. [PMID: 35027508 DOI: 10.5009/gnl210472] [Reference Citation Analysis]
|
| 550 |
Zhao Z, Tang H, Li F. Measles-Associated Severe Pneumonia in a Patient with HBeAg-Negative Chronic Hepatitis B: A Case Report. Zoonoses 2022;2. [DOI: 10.15212/zoonoses-2021-0013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 551 |
Sundaram S, Giri S. Liver Diseases in the Parturient. Indian Journal of Critical Care Medicine 2021;25:S248-54. [DOI: 10.5005/jp-journals-10071-24027] [Reference Citation Analysis]
|
| 552 |
Akdemir Kalkan I, Karasahin O, Sarigul F, Altunisik Toplu S, Aladag M, Akgul F, Mete AO, Golbol A, Nazik S, Kömür S, Merve Oren M, Yildiz Y, Demir Y, Ayhan M, Tasova Y, Bayındır Y, Dal T, Celen MK. Comparison of Tenofovir Alafenamide and Entecavir Therapy in Patients with Chronic Hepatitis B Initially Treated with Tenofovir Disoproxil: A Retrospective Observational Survey. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.118721] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 553 |
Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 554 |
Lee JJ, Chang JM, Yang LJ, Hsu CC, Lin MH, Lin MY. Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: A nationwide survey in 2010-2018. J Formos Med Assoc 2022:S0929-6646(21)00584-2. [PMID: 34996670 DOI: 10.1016/j.jfma.2021.12.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 555 |
Wu Y, Chen Y, Zhu P, Ye B, Lu Y, Shi J, Tan Y, Zhao Y, Yu J, Lai X, Lan J, Si T, Ni L, Huang H, Luo Y. Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantatio:a multi-institutional experience from an HBV endemic area. Ann Hematol. [DOI: 10.1007/s00277-021-04730-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 556 |
Russo FP, Zanetto A, Pinto E, Battistella S, Penzo B, Burra P, Farinati F. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Int J Mol Sci 2022;23:500. [PMID: 35008926 DOI: 10.3390/ijms23010500] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 557 |
Man X, Wei R. Advancements in the prevention of hepatitis B recurrence by nucleos(t)ide analogue monotherapies after liver transplantation. Eur J Inflamm 2022;20:1721727X2211392. [DOI: 10.1177/1721727x221139254] [Reference Citation Analysis]
|
| 558 |
Gyura AN, Harrison ER. Care of the Child with an Infectious Disease or Immunological Defect. Pediatric Diagnostic Labs for Primary Care: An Evidence-based Approach 2022. [DOI: 10.1007/978-3-030-90642-9_6] [Reference Citation Analysis]
|
| 559 |
Pereira SL, Duro R, Sarmento A. Late Hepatitis B reactivation after treatment with rituximab. IDCases 2022;27:e01393. [DOI: 10.1016/j.idcr.2022.e01393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 560 |
Robbins M, Doucette K. Hepatitis Viruses. Infectious Complications in Biologic and Targeted Therapies 2022. [DOI: 10.1007/978-3-031-11363-5_23] [Reference Citation Analysis]
|
| 561 |
Kaewdech A, Assawasuwannakit S, Sripongpun P, Chamroonkul N, Tangkijvanich P, Piratvisuth T. Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up. Front Med (Lausanne) 2022;9:859430. [PMID: 35402452 DOI: 10.3389/fmed.2022.859430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 562 |
Cacciola I, Pitrone C, Franzè MS, Mazzeo C, Muscianisi M, Porcari S, Pintabona G, Morace C, Basile G, Cucinotta E, Pollicino T, Raimondo G. Prevalence of hepatitis B and C viral infections in hospitalized patients with increased liver enzyme levels and with no known history of hepatic disease. Ann Hepatol 2022;27 Suppl 1:100578. [PMID: 34752948 DOI: 10.1016/j.aohep.2021.100578] [Reference Citation Analysis]
|
| 563 |
Choi WM, Yip TC, Lim YS, Wong GL, Kim WR. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J Hepatol 2022;76:186-94. [PMID: 34592365 DOI: 10.1016/j.jhep.2021.09.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 564 |
Hansi N, Mak LL, Gill U, Kennedy P. Chronic Hepatitis B. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-10012-3_8] [Reference Citation Analysis]
|
| 565 |
Cohen C, Evans AA, Block TM. Hepatitis Viruses: Hepatitis B and Hepatitis D. Viral Infections of Humans 2022. [DOI: 10.1007/978-1-4939-9544-8_32-1] [Reference Citation Analysis]
|
| 566 |
Zhang HC, Wang LS, Miller E. Hepatology (Liver and Bile Duct). Managing Immunotherapy Related Organ Toxicities 2022. [DOI: 10.1007/978-3-031-00241-0_7] [Reference Citation Analysis]
|
| 567 |
Kasatkin D, Korobko D, Matson M, Lendoeva D, Ivanova S. Approaches to vaccine prevention in multiple sclerosis. Z nevrol psikhiatr im S S Korsakova 2022;122:29. [DOI: 10.17116/jnevro202212209129] [Reference Citation Analysis]
|
| 568 |
Poynard T, Lacombe JM, Deckmyn O, Peta V, Akhavan S, Zoulim F, de Ledinghen V, Samuel D, Mathurin P, Ratziu V, Thabut D, Housset C, Fontaine H, Pol S, Carrat F. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. Gastro Hep Advances 2022;1:604-17. [DOI: 10.1016/j.gastha.2022.02.008] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 569 |
Huang R, Liu J, Wang J, Li J, Wu C. Letter to the Editor: Is HBV genotype strongly associated with HCC risk in patients with chronic hepatitis B? Hepatology 2022;75:233-4. [PMID: 34519071 DOI: 10.1002/hep.32155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 570 |
O’connell KA, Mari A, Van Voorhees AS. Laboratory Monitoring: HIV, TB and Hepatitis. Updates in Clinical Dermatology 2022. [DOI: 10.1007/978-3-030-92938-1_2] [Reference Citation Analysis]
|
| 571 |
Gish RG, Asselah T, Squires K, Mayers D. Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens. Antivir Chem Chemother 2022;30:204020662211387. [DOI: 10.1177/20402066221138705] [Reference Citation Analysis]
|
| 572 |
Squires JE, Alonso EM, Ibrahim SH, Kasper V, Kehar M, Martinez M, Squires RH. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Diagnosis and Management of Pediatric Acute Liver Failure. J Pediatr Gastroenterol Nutr 2022;74:138-58. [PMID: 34347674 DOI: 10.1097/MPG.0000000000003268] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 573 |
Toy M, Hutton D, McCulloch K, Romero N, Revill PA, Penicaud MC, So S, Cowie BC. The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia. Liver Int 2022;42:16-25. [PMID: 34328697 DOI: 10.1111/liv.15027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 574 |
Ren Y, Zhao J, Xu M, Wang Y, Bai L, Jiang Y, Liu S, Chen Y, Duan Z, Zheng S. Association between serum sphingolipids and necroinflammation of liver tissue pathology in chronic hepatitis B. Int J Med Sci 2022;19:2080-6. [PMID: 36483591 DOI: 10.7150/ijms.75820] [Reference Citation Analysis]
|
| 575 |
Lee Y, Singal A, Luu M, Nissen N, Gores G, Yang J. Increasing Incidence of Intrahepatic Cholangiocarcinoma Relative to Hepatocellular Carcinoma in the United States. Gastro Hep Advances 2022;1:121-4. [DOI: 10.1016/j.gastha.2021.10.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 576 |
Mao QG, Liang HQ, Yin YL, Tang JM, Yang JE, Wu CC, Chen Y, Zhang MY, Liu YY, Zheng XT, Zhuang LY, Chen SD. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B. Clin Res Hepatol Gastroenterol 2022;46:101758. [PMID: 34303003 DOI: 10.1016/j.clinre.2021.101758] [Reference Citation Analysis]
|
| 577 |
Kim S, Yoo S, Lee JI, Kim S, Chang HY, Kim D, Jeong SH, Lee KS, Lee HW. Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance. Dig Dis Sci 2022;67:321-8. [PMID: 33517556 DOI: 10.1007/s10620-021-06845-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 578 |
Abdelbary MS, Samir R, El-Nahaas SM, Shahin RMH, El-Sayed M, Gaber Y, Tantawi O, Zayed NA, Yosry A. Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt. J Clin Exp Hepatol 2022;12:1276-84. [PMID: 36157140 DOI: 10.1016/j.jceh.2022.04.020] [Reference Citation Analysis]
|
| 579 |
Miller HM, Westbrook RH. Pregnancy and Liver Disease. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-10012-3_13] [Reference Citation Analysis]
|
| 580 |
Jha A, Pathak Y. Polymeric nanomaterials for infectious diseases. Nanotheranostics for Treatment and Diagnosis of Infectious Diseases 2022. [DOI: 10.1016/b978-0-323-91201-3.00007-4] [Reference Citation Analysis]
|
| 581 |
Taneja S, Roy A, Singh V. Clinical Approach to Hepatitis B. Clinical Rounds in Hepatology 2022. [DOI: 10.1007/978-981-16-8448-7_3] [Reference Citation Analysis]
|
| 582 |
Vittal A, Sharma D, Hu A, Majeed NA, Terry N, Auh S, Ghany MG. Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. Aliment Pharmacol Ther 2022;55:8-25. [PMID: 34850415 DOI: 10.1111/apt.16659] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 583 |
Kumar N, Satyapriya S, Tahaseen S, Singh K, Kumar A. Severe progression of autoimmune hepatitis in a young COVID-19 adult patient: A case report. J Acute Dis 2022;11:161. [DOI: 10.4103/2221-6189.355327] [Reference Citation Analysis]
|
| 584 |
Erken R, Loukachov VV, de Niet A, Jansen L, Stelma F, Helder JT, Peters MW, Zaaijer HL, Kootstra NA, Willemse SB, Reesink HW. A Prospective Five-Year Follow-up After peg-Interferon Plus Nucleotide Analogue Treatment or no Treatment in HBeAg Negative Chronic Hepatitis B Patients. J Clin Exp Hepatol 2022;12:735-44. [PMID: 35677522 DOI: 10.1016/j.jceh.2021.12.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 585 |
Bergasa NV. Chronic Hepatitis B. Clinical Cases in Hepatology 2022. [DOI: 10.1007/978-1-4471-4715-2_7] [Reference Citation Analysis]
|
| 586 |
Cocci A, Romano A. Sexually Transmitted Diseases (STDs). Management of Urology 2022. [DOI: 10.1007/978-3-031-12049-7_17] [Reference Citation Analysis]
|
| 587 |
Mazur-melewska K. Antimicrobial Prophylaxis: Rules of Conduct in Typical Infections. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00138-5] [Reference Citation Analysis]
|
| 588 |
Ramírez Mena A, Tine JM, Fortes L, Ndiaye O, Ka D, Ngom NF, Ramette A, Bittel P, Seydi M, Wandeler G; for SEN-B. Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal. J Viral Hepat 2022;29:60-8. [PMID: 34610183 DOI: 10.1111/jvh.13615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 589 |
Xu H, Locarnini S, Wong D, Hammond R, Colledge D, Soppe S, Huynh T, Shaw T, Thompson AJ, Revill PA, Hogarth PM, Wines BD, Walsh R, Warner N. Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. J Hepatol 2022;76:34-45. [PMID: 34371070 DOI: 10.1016/j.jhep.2021.07.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 590 |
Koc ÖM, Verbeek J, Koek GH, Bielen R, Busschots D, Gamil M, Robaeys G, Nevens F. A long-term study of liver-related events in Caucasian hepatitis B patients with normal ALT values and high viremia. Acta Gastroenterol Belg 2022;85:56-61. [PMID: 35304994 DOI: 10.51821/85.1.9160] [Reference Citation Analysis]
|
| 591 |
O’gurek DT. Diseases of the Liver. Family Medicine 2022. [DOI: 10.1007/978-3-030-54441-6_97] [Reference Citation Analysis]
|
| 592 |
Sripongpun P, Kim WR, Mannalithara A, Kwong A, Daugherty T, Goel A, Kwo PY. Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol 2022;20:230-2. [PMID: 33285291 DOI: 10.1016/j.cgh.2020.11.047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 593 |
Goh MJ, Kang W, Kim KM, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. Scand J Gastroenterol 2022;57:70-7. [PMID: 34731072 DOI: 10.1080/00365521.2021.1988700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 594 |
Zeng Q. Anti-HBV Drugs in Liver Cirrhosis. Pharmacotherapy for Liver Cirrhosis and Its Complications 2022. [DOI: 10.1007/978-981-19-2615-0_1] [Reference Citation Analysis]
|
| 595 |
Ye Q, Kam LY, Yeo YH, Dang N, Huang DQ, Cheung R, Nguyen MH. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J Hepatol 2022;76:63-74. [PMID: 34474097 DOI: 10.1016/j.jhep.2021.08.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 596 |
Sato K, Inoue J, Akahane T, Kobayashi T, Takai S, Nakamura T, Sato T, Kimura O, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Onuki M, Sawahashi S, Niitsuma H, Masamune A. Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir. Tohoku J Exp Med 2022;258:277-285. [DOI: 10.1620/tjem.2022.j084] [Reference Citation Analysis]
|
| 597 |
Kar P, Goswami B, Mahanta J, Bhimo T, Das AK, Deka M, Lynrah KG, Kotwal MR, Bhaumik P, Jini M, Karna R, Karra VK, Kaur H. Epidemiology, Genotyping, Mutational and Phylogenetic Analysis of Hepatitis B Virus Infection in North-east India. J Clin Exp Hepatol 2022;12:43-51. [PMID: 35068784 DOI: 10.1016/j.jceh.2021.04.002] [Reference Citation Analysis]
|
| 598 |
Chua JV, Baddley JW. Anti-tumor Necrosis Factor-Alpha Agents. Infectious Complications in Biologic and Targeted Therapies 2022. [DOI: 10.1007/978-3-031-11363-5_5] [Reference Citation Analysis]
|
| 599 |
Seong G, Sinn DH, Kang W, Gwak GY, Choi MS, Lee JH, Koh KC, Woon Paik S, Paik YH. Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. Eur J Gastroenterol Hepatol 2022;34:69-75. [PMID: 32925504 DOI: 10.1097/MEG.0000000000001915] [Reference Citation Analysis]
|
| 600 |
Sharma P. Value of Liver Function Tests in Cirrhosis. J Clin Exp Hepatol 2022;12:948-64. [PMID: 35677506 DOI: 10.1016/j.jceh.2021.11.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 601 |
Akgöllü E. Effect of FOXP3 gene variants on the immune-active HBV and inactive HBV phases. Cukurova Medical Journal 2021;46:1485-1492. [DOI: 10.17826/cumj.978353] [Reference Citation Analysis]
|
| 602 |
Jacob R, Danta M. Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection. Expert Opin Pharmacother 2021;:1-8. [PMID: 34937470 DOI: 10.1080/14656566.2021.2019708] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 603 |
Şen H, Uysal A, Kaya MN, Kirik A. Balıkesir Üniversitesi Tıp Fakültesi Araştırma ve Uygulama Hastanesinde Sağlık Çalışanlarında Hepatit B Serolojik Testlerinin Uygunsuz Kullanımı. Harran Üniversitesi Tıp Fakültesi Dergisi 2021. [DOI: 10.35440/hutfd.834094] [Reference Citation Analysis]
|
| 604 |
Suzuki T, Matsuura K, Nagura Y, Iio E, Ogawa S, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y. Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection. PLoS One 2021;16:e0261878. [PMID: 34962955 DOI: 10.1371/journal.pone.0261878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 605 |
Xie Y, Ma H, Feng B, Song G. Combining the HBcrAg decline and HBV mutations predicts spontaneous HBeAg seroconversion in chronic hepatitis B patients during the immune clearance phase. J Med Virol 2021. [PMID: 34951036 DOI: 10.1002/jmv.27545] [Reference Citation Analysis]
|
| 606 |
González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 607 |
Zhong Z, Liao W, Dai L, Feng X, Su G, Gao Y, Wu Q, Yang P. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection. Ann Rheum Dis 2021:annrheumdis-2021-221650. [PMID: 34933869 DOI: 10.1136/annrheumdis-2021-221650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 608 |
Zhong S, Zhang T, Tang L, Li Y. Cytokines and Chemokines in HBV Infection. Front Mol Biosci 2021;8:805625. [PMID: 34926586 DOI: 10.3389/fmolb.2021.805625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 609 |
Tan N, Luo H, Kang Q, Pan J, Cheng R, Xi H, Chen H, Han Y, Yang Y, Xu X. High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment. Virus Res 2021;309:198660. [PMID: 34929214 DOI: 10.1016/j.virusres.2021.198660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 610 |
Kłujszo EH, Zarębska-Michaluk D, Kręcisz B, Witkowska A. Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection. Dermatol Ther 2021;:e15274. [PMID: 34921578 DOI: 10.1111/dth.15274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 611 |
Liu Z, Zhang Y, Xu M, Li X, Zhang Z. Distribution of hepatitis B virus genotypes and subgenotypes: A meta-analysis. Medicine (Baltimore) 2021;100:e27941. [PMID: 34918643 DOI: 10.1097/MD.0000000000027941] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 612 |
Wu LL, Li XY, Deng H, Xie DY, Gu YR, Bi YH, Huang YH, Gao ZL. Transforming growth factor-β: An early predictor of a functional cure in chronic hepatitis B treated with interferon. Virus Res 2021;309:198657. [PMID: 34919970 DOI: 10.1016/j.virusres.2021.198657] [Reference Citation Analysis]
|
| 613 |
Wang Y, Xiao X, Chen S, Huang C, Zhou J, Dai E, Li Y, Liu L, Huang X, Gao Z, Wu C, Fang M, Gao C. The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing. Front Immunol 2021;12:775461. [PMID: 34899733 DOI: 10.3389/fimmu.2021.775461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 614 |
Huang CC, Wu KL, Liu JS, Chang YY. Autonomic impairment in treatment-naive patients with chronic hepatitis B and C infections. Auton Neurosci 2021;238:102928. [PMID: 35021146 DOI: 10.1016/j.autneu.2021.102928] [Reference Citation Analysis]
|
| 615 |
Goriacheva LG, Ventslovayte ND, Greshnyakova VA. Viral hepatitis in children: state and prospects for solving the problem. Det infekc 2021;20:35-41. [DOI: 10.22627/2072-8107-2021-20-4-35-41] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 616 |
Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Erratum to: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2021:ciab801. [PMID: 34878522 DOI: 10.1093/cid/ciab801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 617 |
Duan Y, Chen Z, Li H, Shen W, Zeng Y, Peng M, Hu P. Potential Molecular Targets of Tenofovir Disoproxil Fumarate for Alleviating Chronic Liver Diseases via a Non-Antiviral Effect in a Normal Mouse Model. Front Mol Biosci 2021;8:763150. [PMID: 34869594 DOI: 10.3389/fmolb.2021.763150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 618 |
Wang C, Ma C, Gong L, Dai S, Li Y. Preventive and therapeutic role of betaine in liver disease: A review on molecular mechanisms. Eur J Pharmacol 2021;912:174604. [PMID: 34743980 DOI: 10.1016/j.ejphar.2021.174604] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 619 |
Zhang X, Jie Y, Wan Z, Lin S, Li Y, Lin M, Wu S, Wu X, Shi M, Xiao H, Cao M, Gong J, Chi X. Prognostic Value of Inflammatory Indicators in Chronic Hepatitis B Patients With Significant Liver Fibrosis: A Multicenter Study in China. Front Pharmacol 2021;12:653751. [PMID: 34858162 DOI: 10.3389/fphar.2021.653751] [Reference Citation Analysis]
|
| 620 |
Cliff ERS, Sasadeusz J, Visvanathan K, Grigg A. Very late-onset hepatitis B reactivation following chemoimmunotherapy. Leuk Lymphoma 2021;:1-5. [PMID: 34852722 DOI: 10.1080/10428194.2021.2010066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 621 |
Li J, Chen H, Chen J, Zhou B, Hou J, Jiang DK. A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B. Pharmgenomics Pers Med 2021;14:1505-15. [PMID: 34848996 DOI: 10.2147/PGPM.S337962] [Reference Citation Analysis]
|
| 622 |
Liu CJ, Sheen IS, Chen CY, Chuang WL, Wang HY, Tseng KC, Chang TT, Yang J, Massetto B, Suri V, Camus G, Jiang D, Zhang F, Gaggar A, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment. Clin Infect Dis 2022;75:453-9. [PMID: 34864948 DOI: 10.1093/cid/ciab971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 623 |
Kikuchi M, Sawabe M, Aoyagi H, Wakae K, Watashi K, Hattori S, Kawabe N, Yoshioka K, Tanaka J, Muramatsu M, Wakita T, Aizaki H. Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers. Hepatol Int 2021. [PMID: 34855104 DOI: 10.1007/s12072-021-10269-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 624 |
Dokmak A, Trivedi HD, Bonder A, Wolf J. Pregnancy in Chronic Liver Disease: Before and After Transplantation. Ann Hepatol 2021;26:100557. [PMID: 34656772 DOI: 10.1016/j.aohep.2021.100557] [Reference Citation Analysis]
|
| 625 |
Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, Wang B, Zhan S, Kong Y, Jia J, You H, Yang HI. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clin Gastroenterol Hepatol 2021;19:2499-513. [PMID: 33667678 DOI: 10.1016/j.cgh.2021.02.040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 626 |
McMahon BJ, Nolen LD, Snowball M, Homan C, Negus S, Roik E, Spradling PR, Bruden D. HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study. Hepatology 2021;74:2965-73. [PMID: 34292609 DOI: 10.1002/hep.32065] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 627 |
Zhang M, Zhang Z, Imamura M, Osawa M, Teraoka Y, Piotrowski J, Ishida Y, Sozzi V, Revill PA, Saito T, Chayama K, Liang TJ. Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models. J Hepatol 2021;75:1335-45. [PMID: 34363922 DOI: 10.1016/j.jhep.2021.07.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 628 |
Cheung KW, Seto MTY, Tsui PM, So PL, Wong D, Kong CW, Wang W, Ng EHY. Knowledge, perception and expectation of management of hepatitis B infection among pregnant hepatitis B carriers in Hong Kong. J Viral Hepat 2021;28:1699-709. [PMID: 34467599 DOI: 10.1111/jvh.13609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 629 |
Dezanet LNC, Miailhes P, Lascoux-Combe C, Chas J, Maylin S, Gabassi A, Rougier H, Delaugerre C, Lacombe K, Boyd A. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B. Liver Int 2021;41:2874-84. [PMID: 34297463 DOI: 10.1111/liv.15019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 630 |
Tsuge M. The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection. Liver Int 2021;41:2836-48. [PMID: 34559952 DOI: 10.1111/liv.15065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 631 |
Myers L, Mitra A, Ahn J. Addressing Hepatitis B in the Context of Hepatitis C. Curr Hepatology Rep 2021;20:175-182. [DOI: 10.1007/s11901-021-00578-6] [Reference Citation Analysis]
|
| 632 |
Huang S, Kao J. Management of Hepatitis B in Persons Who Inject Drugs (PWID). Curr Hepatology Rep 2021;20:158-165. [DOI: 10.1007/s11901-021-00574-w] [Reference Citation Analysis]
|
| 633 |
Wong RJ, Cheung RC. Real-World Safety and Effectiveness of Oral Nucleos(t)ide Analogs in the Treatment of Chronic Hepatitis B Virus Infection. Curr Hepatology Rep 2021;20:144-150. [DOI: 10.1007/s11901-021-00571-z] [Reference Citation Analysis]
|
| 634 |
Erken R, Zaaijer HL, Willemse SB, Bakker E, Takkenberg BB, Reesink HW, Kootstra NA. Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy. Ann Hepatol 2021;26:100540. [PMID: 34583061 DOI: 10.1016/j.aohep.2021.100540] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 635 |
Lee CK, Jonas MM. Viral Hepatitis B—Management in Children. Curr Hepatology Rep 2021;20:137-143. [DOI: 10.1007/s11901-021-00570-0] [Reference Citation Analysis]
|
| 636 |
Hubbard A, Hirode G, Chitnis A, Wong R. Prevalence of hepatitis B surface antigen and hepatitis B core antibody among adults with latent tuberculosis infection. Eur J Gastroenterol Hepatol 2021;33:e610-4. [PMID: 35048652 DOI: 10.1097/MEG.0000000000002180] [Reference Citation Analysis]
|
| 637 |
van Bömmel F, Berg T. Hepatitis B: Wann ist eine Beendigung der Therapie mit Nukleos(t)idanaloga gerechtfertigt? Gastroenterologe 2021;16:417-432. [DOI: 10.1007/s11377-021-00572-w] [Reference Citation Analysis]
|
| 638 |
Kong H, Ju E, Yi K, Xu W, Lao YH, Cheng D, Zhang Q, Tao Y, Li M, Ding J. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. Adv Sci (Weinh) 2021;8:e2102051. [PMID: 34665528 DOI: 10.1002/advs.202102051] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 639 |
Han H, Yang J, Jin WK, Li X, Zhang F, Zhuge YZ, Wu M, Yang B. Diagnostic value of conventional ultrasound and shear wave elastography in detecting transjugular intrahepatic portosystemic shunt dysfunction. Acta Radiol 2021;62:1575-82. [PMID: 33251812 DOI: 10.1177/0284185120975183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 640 |
Satapathy SK, Kuntzen C, Qiu H, Jiang Y, Bodenheimer HC, Roth NC, Lee TP, Hirsch JS, Trindade AJ, Bernstein DE; Northwell Health COVID-19 Research Consortium. Severity of liver test abnormalities in coronavirus disease 2019 depends on comorbidities and predicts early in-hospital mortality. Eur J Gastroenterol Hepatol 2021;33:e320-8. [PMID: 33560687 DOI: 10.1097/MEG.0000000000002055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 641 |
Furquim d'Almeida A, Ho E, Van Hees S, Vanwolleghem T. Clinical management of chronic hepatitis B: A concise overview. United European Gastroenterol J 2021. [PMID: 34846093 DOI: 10.1002/ueg2.12176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 642 |
Zhang Z, Lu W, Zeng D, Huang D, Lin W, Yan L, Feng Y. Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection. J Clin Med 2021;10:5617. [PMID: 34884319 DOI: 10.3390/jcm10235617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 643 |
Hur MH, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6009. [PMID: 34885118 DOI: 10.3390/cancers13236009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 644 |
Sharma SR, Devi P, Mishra A, Farooq U, Singh S, Sharma V, Ahamad I. Study of occurrence of HBeAg among Hepatitis- B surface antigen positive cases. IJMMTD 2021;7:269-273. [DOI: 10.18231/j.ijmmtd.2021.055] [Reference Citation Analysis]
|
| 645 |
Huang D, Yan W, Han M, Yuan W, Wang P, Chen Y, Wan X, Luo X, Wu D, Ning Q. Insufficient immunity led to virologic breakthrough in NAs-treated chronic hepatitis B patients switching to Peg-IFN-ɑ. Antiviral Res 2021;197:105220. [PMID: 34848218 DOI: 10.1016/j.antiviral.2021.105220] [Reference Citation Analysis]
|
| 646 |
Khanam A, Kottilil S. Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management. Front Med (Lausanne) 2021;8:752875. [PMID: 34820395 DOI: 10.3389/fmed.2021.752875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 647 |
Su PY, Su WW, Hsu YC, Huang SP, Yen HH. Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study. PeerJ 2021;9:e12527. [PMID: 34820208 DOI: 10.7717/peerj.12527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 648 |
Mak LY, Hoang J, Jun DW, Chen CH, Peng CY, Yeh ML, Kim SE, Huang DQ, Jeong JY, Yoon E, Oh H, Tsai PC, Huang CF, Ahn SB, Trinh H, Xie Q, Wong GLH, Enomoto M, Shim JJ, Lee DH, Liu L, Kozuka R, Cho YK, Jeong SW, Kim HS, Trinh L, Dao A, Huang R, Hui RW, Tsui V, Quek S, Khine HHTW, Ogawa E, Dai CY, Huang JF, Cheung R, Wu C, Chuang WL, Lim SG, Yu ML, Yuen MF, Nguyen MH. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Hepatol Int 2021. [PMID: 34822056 DOI: 10.1007/s12072-021-10271-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 649 |
Birkness-Gartman JE, Oshima K. Liver pathology in pregnancy. Pathol Int 2021. [PMID: 34818440 DOI: 10.1111/pin.13186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 650 |
Hecker C, Welponer T, Herold M, Trinka E, Broussalis E, Killer-Oberpfalzer M. Update on treatment strategies for vasculitis affecting the central nervous system. Drug Discov Today 2021:S1359-6446(21)00501-8. [PMID: 34838730 DOI: 10.1016/j.drudis.2021.11.020] [Reference Citation Analysis]
|
| 651 |
Thompson KA, Blank G, Toy J, Moore DM, Lachowsky N, Bacani N, Zhang W, Sereda P, Lima VD, Barrios R, Montaner JSG, Hull MW. Chronic Hepatitis B Infection Among Preexposure Prophylaxis Users Enrolled in a Population-Based Program in British Columbia, Canada. Open Forum Infect Dis 2021;8:ofab492. [PMID: 34805433 DOI: 10.1093/ofid/ofab492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 652 |
Papatheodoridi A, Karakousis N, Lembessis P, Chatzigeorgiou A, Papatheodoridis GV. The Significance of Circulating Cell-Free DNA Markers in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. Pathogens 2021;10:1524. [PMID: 34832679 DOI: 10.3390/pathogens10111524] [Reference Citation Analysis]
|
| 653 |
Esmaeilzadeh A, Bahmaie N, Nouri E, Hajkazemi MJ, Zareh Rafie M. Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study. Int J Mol Sci 2021;22:12552. [PMID: 34830435 DOI: 10.3390/ijms222212552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 654 |
Kawanaka M, Nishino K, Kawamoto H, Haruma K. Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. World J Gastroenterol 2021; 27(43): 7497-7508 [PMID: 34887645 DOI: 10.3748/wjg.v27.i43.7497] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 655 |
Niño-Sandoval TC, Rocha NS, Sarinho FW, Vasconcelos CFM, Vasconcelos AFM, Vasconcelos BC. Effect of autohemotherapy in the treatment of viral infections - a systematic review. Public Health 2021;201:78-88. [PMID: 34798327 DOI: 10.1016/j.puhe.2021.09.024] [Reference Citation Analysis]
|
| 656 |
Sedano R, Castro L, Venegas M, Miranda J, Hurtado C, Poniachik J, Brahm J. Liver transplantation in acute liver failure due to Hepatitis B. Two clinical cases. Ann Hepatol 2021;21:100107. [PMID: 31623992 DOI: 10.1016/j.aohep.2019.06.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 657 |
Fang Y, Xu X, Hou F, Jia W. A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients. Antiviral Therapy 2021;26:126-33. [DOI: 10.1177/13596535211059895] [Reference Citation Analysis]
|
| 658 |
Sirilert S, Tongsong T, Kumfu S, Chattipakorn SC, Chattipakorn N. Effects of intrauterine exposure to hepatitis B virus in foetuses. J Med Microbiol 2021;70. [PMID: 34779762 DOI: 10.1099/jmm.0.001455] [Reference Citation Analysis]
|
| 659 |
Chen Q, Liu J, He Y, Yang L, Luo H, Wang Y, Zhang X, Li N. Prevalence of HBsAg among reproductive age couples in Chongqing: A population-based, cross-sectional study. PLoS One 2021;16:e0260028. [PMID: 34780552 DOI: 10.1371/journal.pone.0260028] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 660 |
Ge FL, Si LL, Yang Y, Li YH, Lv ZL, Liu WH, Liao H, Wang J, Zou J, Li L, Li H, Zhang ZL, Wang JB, Lu XC, Xu DP, Bai ZF, Liu Y, Xiao XH. Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model. Front Pharmacol 2021;12:756975. [PMID: 34776974 DOI: 10.3389/fphar.2021.756975] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 661 |
Liu J, Wang J, Yan X, Xue R, Zhan J, Jiang S, Geng Y, Liu Y, Mao M, Xia J, Yin S, Tong X, Chen Y, Ding W, Huang R, Wu C. Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis. Hepatol Commun 2021. [PMID: 34783181 DOI: 10.1002/hep4.1859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 662 |
Lu J, Wang X, Zhu Y, Ma L, Zheng S, Hu Z, Chen X. Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. Gut Liver 2021;15:887-94. [PMID: 34446613 DOI: 10.5009/gnl21001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 663 |
Zhou X, Li TM, Luo JZ, Lan CL, Wei ZL, Fu TH, Liao XW, Zhu GZ, Ye XP, Peng T. CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis. J Hepatocell Carcinoma 2021;8:1323-38. [PMID: 34765572 DOI: 10.2147/JHC.S335425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 664 |
Simionescu AA, Streinu-Cercel A, Popescu FD, Stanescu AMA, Vieru M, Danciu BM, Miron VD, Săndulescu O. Comprehensive Overview of Vaccination during Pregnancy in Europe. J Pers Med 2021;11:1196. [PMID: 34834548 DOI: 10.3390/jpm11111196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 665 |
Harputluoglu M, Carr BI. Hepatitis B Before and After Hepatocellular Carcinoma. J Gastrointest Cancer 2021. [PMID: 34762265 DOI: 10.1007/s12029-021-00745-4] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 666 |
Campbell C, Wang T, Smith DA, Freeman O, Noble T, Várnai KA, Harris S, Salih H, Roadknight G, Little S, Glampson B, Mercuri L, Papadimitriou D, Jones CR, Taylor V, Chaudhry A, Phan H, Borca F, Olza J, Warricker F, Romão L, Ramlakhan D, English L, Klenerman P, Andersson MI, Collier J, Nastouli E, Khakoo SI, Gelson W, Cooke GS, Woods K, Davies J, Barnes E, Matthews PC. Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK.. [DOI: 10.1101/2021.11.10.21265651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 667 |
Wang YW, Tsai XC, Hou HA, Tien FM, Liu JH, Chou WC, Ko BS, Chen YW, Lin CC, Cheng CL, Lo MY, Lin YC, Lu LC, Wu SJ, Kuo SH, Hong RL, Huang TC, Yao M. Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. Ann Hematol 2021. [PMID: 34766217 DOI: 10.1007/s00277-021-04711-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 668 |
Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C, Kendrick S. Health-related quality of life for adults living with hepatitis B in the United States: a qualitative assessment. J Patient Rep Outcomes 2021;5:121. [PMID: 34757456 DOI: 10.1186/s41687-021-00398-8] [Reference Citation Analysis]
|
| 669 |
Alqahtani SA, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. Cells 2021;10:3091. [PMID: 34831314 DOI: 10.3390/cells10113091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 670 |
Lim J, Chon YE, Kim MN, Lee JH, Hwang SG, Lee HC, Ha Y. Cirrhosis, Age, and Liver Stiffness-Based Models Predict Hepatocellular Carcinoma in Asian Patients with Chronic Hepatitis B. Cancers (Basel) 2021;13:5609. [PMID: 34830764 DOI: 10.3390/cancers13225609] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 671 |
Wang K, Xia Y, Zhu Y, Yu W, Guo Y, Liu L. Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. J Immunother Cancer 2021;9:e003195. [DOI: 10.1136/jitc-2021-003195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 672 |
Li R, Lin X, Wang JY, Wang X, Lu J, Liu Y, Cao Z, Ren S, Ma L, Jin Y, Zheng S, Hu Z, Wang L, Chen X. Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. Ann Transl Med 2021;9:1365. [PMID: 34733917 DOI: 10.21037/atm-21-1666] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 673 |
Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical Updates on Chronic Hepatitis B Virus Infection in 2021. Cureus 2021;13:e19152. [PMID: 34733599 DOI: 10.7759/cureus.19152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 674 |
Garbuzenko DV. [The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection]. Vopr Virusol 2021;66:331-9. [PMID: 34738448 DOI: 10.36233/0507-4088-70] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 675 |
Aguirre A, Yazdany J. Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement. J Rheumatol 2022;49:1-4. [PMID: 34725177 DOI: 10.3899/jrheum.211000] [Reference Citation Analysis]
|
| 676 |
Jo HS, Khan JF, Han JH, Yu YD, Kim DS. Efficacy and Safety of Hepatitis B Virus Vaccination Following Hepatitis B Immunoglobulin Withdrawal After Liver Transplantation. Transplant Proc 2021:S0041-1345(21)00736-3. [PMID: 34740450 DOI: 10.1016/j.transproceed.2021.09.038] [Reference Citation Analysis]
|
| 677 |
Tout I, Loureiro D, Asselah T. The Changing Demographics of Hepatitis B Virus Infection. Clin Liver Dis 2021;25:673-87. [PMID: 34593147 DOI: 10.1016/j.cld.2021.06.001] [Reference Citation Analysis]
|
| 678 |
Sandmann L, Wedemeyer H. New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. Clin Liver Dis 2021;25:831-9. [PMID: 34593156 DOI: 10.1016/j.cld.2021.06.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 679 |
Ghany MG, King WC, Lisker-Melman M, Lok ASF, Terrault N, Janssen HLA, Khalili M, Chung RT, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. Hepatology 2021;74:2395-409. [PMID: 34133774 DOI: 10.1002/hep.32018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 680 |
Charatcharoenwitthaya P, Kaewdech A, Piratvisuth T. Controversies in Treating Chronic HBV: The Role of PEG-interferon-alfa. Clin Liver Dis 2021;25:741-62. [PMID: 34593151 DOI: 10.1016/j.cld.2021.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 681 |
Dekker SE, Green EW, Ahn J. Treatment and Prevention of Acute Hepatitis B Virus. Clin Liver Dis 2021;25:711-24. [PMID: 34593149 DOI: 10.1016/j.cld.2021.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 682 |
Airewele NE, Shiffman ML. Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus. Clin Liver Dis 2021;25:817-29. [PMID: 34593155 DOI: 10.1016/j.cld.2021.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 683 |
Yeh ML, Liang PC, Huang CI, Hsieh MH, Lin YH, Jang TY, Wei YJ, Hsu PY, Hsu CT, Wang CW, Hsieh MY, Lin ZY, Chen SC, Huang CF, Huang JF, Dai CY, Chuang WL, Yu ML. Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. J Gastroenterol Hepatol 2021;36:3239-46. [PMID: 34318943 DOI: 10.1111/jgh.15640] [Reference Citation Analysis]
|
| 684 |
Kim HL, Kim GA, Park JA, Kang HR, Lee EK, Lim YS. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. Gut 2021;70:2172-82. [PMID: 33239344 DOI: 10.1136/gutjnl-2020-321309] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 685 |
Buti M, Riveiro-Barciela M, Esteban R. Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. Clin Liver Dis 2021;25:725-40. [PMID: 34593150 DOI: 10.1016/j.cld.2021.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 686 |
Wang X, Chen Y, Xu M, Cheng K, Duan X, Liao W, Wang Y, Lu Y, Duan Z, Wang L. Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir. Expert Rev Gastroenterol Hepatol 2021;15:1337-44. [PMID: 34511012 DOI: 10.1080/17474124.2021.1980385] [Reference Citation Analysis]
|
| 687 |
Chi Z, Zhao W, Li JW, Liu H, Shao C, Zhao H, Gui-Qiang W. Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy. Clin Res Hepatol Gastroenterol 2021;45:101563. [PMID: 33272888 DOI: 10.1016/j.clinre.2020.10.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 688 |
Huang DQ, Kew GS, Lim SG. Controversies in Treating Chronic Hepatitis B virus: The Role of Hepatitis B Virus DNA and Surface Antigen Titer. Clin Liver Dis 2021;25:763-84. [PMID: 34593152 DOI: 10.1016/j.cld.2021.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 689 |
Lee WM, King WC, Janssen HLA, Ghany MG, Fontana RJ, Fried M, Sterling RK, Feld JJ, Wang J, Mogul DB, Cooper SL, Bisceglie AMD; Hepatitis B Research Network (HBRN). Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. J Viral Hepat 2021;28:1526-38. [PMID: 34355475 DOI: 10.1111/jvh.13591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 690 |
Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. J Viral Hepat 2021;28:1570-8. [PMID: 34435412 DOI: 10.1111/jvh.13601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 691 |
Wang L, Zhao J, Liu J, Zhen C, Zhang M, Dong Y, Gan Y, Xu Z, Li Y, Zhu S, Wang FS. Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B. J Viral Hepat 2021;28:1554-62. [PMID: 34448324 DOI: 10.1111/jvh.13598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 692 |
Rivera CG, Otto AO, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs. Curr Opin HIV AIDS 2021;16:279-85. [PMID: 34545037 DOI: 10.1097/COH.0000000000000706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 693 |
Khemichian S, Kahn J, Terrault NA. Use of Hepatitis B Virus-Positive Organs in Organ Transplantation. Clin Liver Dis 2021;25:841-57. [PMID: 34593157 DOI: 10.1016/j.cld.2021.06.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 694 |
Yamashige D, Hosaka T, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs. J Gastroenterol 2021;56:1008-21. [PMID: 34596753 DOI: 10.1007/s00535-021-01826-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 695 |
Sarowar A, Hirode G, Janssen HLA, Feld JJ. Controversies in Treating Chronic Hepatitis B Virus Infection: Discordant Serologic Results. Clin Liver Dis 2021;25:805-16. [PMID: 34593154 DOI: 10.1016/j.cld.2021.06.007] [Reference Citation Analysis]
|
| 696 |
Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Xiao L, Li C, Wu Q, Sun C, Niu J, Hou J; TMF Study Group. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther 2021;54:1134-49. [PMID: 34587302 DOI: 10.1111/apt.16611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 697 |
Zamor PJ, Lane AM. Interpretation of HBV Serologies. Clin Liver Dis 2021;25:689-709. [PMID: 34593148 DOI: 10.1016/j.cld.2021.06.012] [Reference Citation Analysis]
|
| 698 |
Pappas SC. Hepatitis B and Health Care Workers. Clin Liver Dis 2021;25:859-74. [PMID: 34593158 DOI: 10.1016/j.cld.2021.06.010] [Reference Citation Analysis]
|
| 699 |
Dooghaie Moghadam A, Eslami P, Dowlati Beirami A, Iravani S, Farokhi E, Mansour-Ghanaei A, Hashemi MR, Aghajanpoor Pasha M, Mehrvar A, Nassiri-Toosi M. An Overview of the Current Hepatitis B Treatment Strategies after Liver Transplantation. Middle East J Dig Dis 2021;13:5-14. [PMID: 34712432 DOI: 10.34172/mejdd.2021.197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 700 |
Zhang YR, Wang H, Zhou N, Zhang YD, Lin Y, Wu LY, Wei SF, Ma YY, Wang CX. A Multidisciplinary Team Approach to the Treatment of Liver Cirrhosis. J Inflamm Res 2021;14:5443-50. [PMID: 34712056 DOI: 10.2147/JIR.S328334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 701 |
Wang Z, Wen P, Hu B, Cao S, Shi X, Guo W, Zhang S. Dopamine and dopamine receptor D1 as a novel favourable biomarker for hepatocellular carcinoma. Cancer Cell Int 2021;21:586. [PMID: 34717619 DOI: 10.1186/s12935-021-02298-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 702 |
Zhang C, Li JW, Wu Z, Zhao H, Wang GQ. Significant Histologic Changes Are Not Rare in Treatment-naive Hepatitis B Patients with Normal Alanine Aminotransferase Level: A Meta-analysis. J Clin Transl Hepatol 2021;9:615-25. [PMID: 34722176 DOI: 10.14218/JCTH.2020.00136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 703 |
Liu YC, Hsu CM, Hsiao SY, Hsiao HH. Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. J Pers Med 2021;11:1108. [PMID: 34834460 DOI: 10.3390/jpm11111108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 704 |
Chi XM, Wang XM, Wang ZF, Wu RH, Gao XZ, Xu HQ, Ding YH, Niu JQ. Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B. World J Gastroenterol 2021; 27(40): 6927-6938 [PMID: 34790015 DOI: 10.3748/wjg.v27.i40.6927] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 705 |
Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 706 |
Gane E, Pastagia M, Schwertschlag U, De Creus A, Schwabe C, Vandenbossche J, Slaets L, Fevery B, Smyej I, Wu LS, Li R, Siddiqui S, Oey A, Musto C, Van Remoortere P. Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults. Antiviral Therapy 2021;26:58-68. [DOI: 10.1177/13596535211056581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 707 |
Garg K, Kramer J, Eswaran S. Common Gastrointestinal Medications Implicated in Drug-Induced Liver Injury. Clin Liver Dis (Hoboken) 2021;18:184-8. [PMID: 34745575 DOI: 10.1002/cld.1110] [Reference Citation Analysis]
|
| 708 |
Ma Y, Yang L, Bao Y, Yang Y, Chen L, Zheng M. Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy. Front Immunol 2021;12:751754. [PMID: 34691067 DOI: 10.3389/fimmu.2021.751754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 709 |
Zhu S, Wu L, Mei Y, Liu Z, Lin L, Yuan J, Li J, Li X, Peng L. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol. BMJ Open 2021;11:e049104. [PMID: 34697111 DOI: 10.1136/bmjopen-2021-049104] [Reference Citation Analysis]
|
| 710 |
Lai CY, Yang SS, Lee SW, Tsai HJ, Lee TY. Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation. J Clin Med 2021;10:4883. [PMID: 34768403 DOI: 10.3390/jcm10214883] [Reference Citation Analysis]
|
| 711 |
Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 712 |
Zhang Y, Hu X, Chang J, Chen J, Han X, Zhang T, Shen J, Shang N, Han J, Wang H, Kang W, Meng F. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol 2021;21:395. [PMID: 34686147 DOI: 10.1186/s12876-021-01974-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 713 |
Hayashi T, Takeshita Y, Hutin YJ, Harmanci H, Easterbrook P, Hess S, van Holten J, Oru EO, Kaneko S, Yurdaydin C, Bulterys M. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response? Arch Public Health 2021;79:180. [PMID: 34663473 DOI: 10.1186/s13690-021-00693-2] [Reference Citation Analysis]
|
| 714 |
Miao J, Gao P, Li Q, He K, Zhang L, Wang J, Huang L. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int J Mol Sci 2021;22:11227. [PMID: 34681886 DOI: 10.3390/ijms222011227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 715 |
Sun F, Liu Z, Wang B. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study. BMC Cancer 2021;21:1103. [PMID: 34649509 DOI: 10.1186/s12885-021-08483-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 716 |
Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Yao ZA, Qiang R, Chen ST, Zhao X, Liu S, Cao ZM, Xu L, Li GH, Chen J, Wang L. YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial. Trials 2021;22:701. [PMID: 34649610 DOI: 10.1186/s13063-021-05650-6] [Reference Citation Analysis]
|
| 717 |
Lin Z, Zhang X, Zhou Y, Chen C, He LN, Li H, Wang Y, Chen T, Hong S, Zhang L. Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus. Cancer Immunol Immunother 2021. [PMID: 34647153 DOI: 10.1007/s00262-021-03082-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 718 |
Qi W, Shen J, Dai J, Wu Y, Zhang Y, Leng S, Gao F, Ran S, Peng W, Zhang X, Wen T, Li C. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study. Cancer Med 2021. [PMID: 34643050 DOI: 10.1002/cam4.4348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 719 |
Xu H, Li X, Wu Z, Zhao L, Shen J, Liu J, Qin J, Shen Y, Ke J, Wei Y, Li J, Gao Y. LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB. Front Mol Biosci 2021;8:749648. [PMID: 34631799 DOI: 10.3389/fmolb.2021.749648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 720 |
Chen P, Wei W, Jin L, Kuai W, Li F, Liu H, Jiang B, Zhu Y. Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naïve patients with chronic hepatitis B. Exp Ther Med 2021;22:1325. [PMID: 34630679 DOI: 10.3892/etm.2021.10760] [Reference Citation Analysis]
|
| 721 |
Sun T, Li R, Qiu Y, Shen S, Wang W. New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram. Int J Gen Med 2021;14:6149-65. [PMID: 34611429 DOI: 10.2147/IJGM.S335400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 722 |
Yeh ML, Liang PC, Trinh S, Huang CI, Huang CF, Hsieh MY, Huang JF, Dai CY, Chuang WL, Nguyen MH, Yu ML. Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide☆. J Formos Med Assoc 2021:S0929-6646(21)00431-9. [PMID: 34625346 DOI: 10.1016/j.jfma.2021.09.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 723 |
Kamal H, Fornes R, Simin J, Stål P, Duberg AS, Brusselaers N, Aleman S. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. J Viral Hepat 2021;28:1431-42. [PMID: 34291520 DOI: 10.1111/jvh.13577] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 724 |
Calvet X, Carpio D, Rodríguez-lago I, García-vicuña R, Barreiro-de-acosta M, Juanola X, Aguas M, Castillo C, Gratacós J. Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. Gastroenterología y Hepatología (English Edition) 2021;44:587-598. [DOI: 10.1016/j.gastre.2021.01.003] [Reference Citation Analysis]
|
| 725 |
Kaneko S, Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2021;36:2943-51. [PMID: 34057248 DOI: 10.1111/jgh.15563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 726 |
Yip TC, Wong VW, Lui GC, Chow VC, Tse YK, Hui VW, Liang LY, Chan HL, Hui DS, Wong GL. Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. Hepatology 2021;74:1750-65. [PMID: 33961298 DOI: 10.1002/hep.31890] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 727 |
Li J, Le MH, Barakat MT, Cheung RC, Nguyen MH. The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. Am J Gastroenterol 2021;116:2068-78. [PMID: 34328446 DOI: 10.14309/ajg.0000000000001386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 728 |
Li M, Zhao L, Zhou J, Sun Y, Wu X, Ou X, You H, Kong Y, Jia J. Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. Lancet Reg Health West Pac 2021;16:100249. [PMID: 34590058 DOI: 10.1016/j.lanwpc.2021.100249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 729 |
Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
|
| 730 |
Lee H, Lee YH, Kim SU, Kim HC. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol 2021;19:2138-2147.e10. [PMID: 33348045 DOI: 10.1016/j.cgh.2020.12.022] [Cited by in Crossref: 127] [Cited by in F6Publishing: 130] [Article Influence: 63.5] [Reference Citation Analysis]
|
| 731 |
van Bömmel F, Berg T. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatol Commun 2021;5:1632-48. [PMID: 34558833 DOI: 10.1002/hep4.1708] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 732 |
Li J, Qu L, Sun X, Liu Y, Gong Q, Yu D, Zhang D, Jiang J, Chen J, Wei D, Han Y, Gao Y, Zhang Q, She W, Chen L, Zhang J, Zhang X. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients. J Viral Hepat 2021;28:1381-91. [PMID: 34228855 DOI: 10.1111/jvh.13571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 733 |
Yoo SH, Lim TS, Lee HW, Kim JK, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Lee JI, Lee KS, Kim SU. Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. J Viral Hepat 2021;28:1362-72. [PMID: 34185929 DOI: 10.1111/jvh.13560] [Reference Citation Analysis]
|
| 734 |
Anteby R, Klang E, Horesh N, Nachmany I, Shimon O, Barash Y, Kopylov U, Soffer S. Deep learning for noninvasive liver fibrosis classification: A systematic review. Liver Int 2021;41:2269-78. [PMID: 34008300 DOI: 10.1111/liv.14966] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 735 |
Jeng WJ, Lok AS. Should Treatment Indications for Chronic Hepatitis B Be Expanded? Clin Gastroenterol Hepatol 2021;19:2006-14. [PMID: 32434068 DOI: 10.1016/j.cgh.2020.04.091] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 736 |
Ling SC, Lin HS, Murray KF, Rosenthal P, Mogul D, Rodriguez-Baez N, Schwarzenberg SJ, Teckman J, Schwarz KB; Hepatitis B Research Network (HBRN). Chronic Hepatitis Is Common and Often Untreated Among Children with Hepatitis B Infection in the United States and Canada. J Pediatr 2021;237:24-33.e12. [PMID: 34022250 DOI: 10.1016/j.jpeds.2021.05.035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 737 |
Jeong S, Cho Y, Park SM, Kim W. Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:e77-86. [PMID: 33883516 DOI: 10.1097/MCG.0000000000001548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 738 |
Asif B, Koh C. Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials. Expert Opin Investig Drugs 2021;:1-16. [PMID: 34482769 DOI: 10.1080/13543784.2021.1977795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 739 |
Muhammad H, Zaffar D, Tehreem A, Ting P, Simsek C, Gokcan H, Gurakar A, Idilman R. HBV/HDV management after liver transplantation: Review. Journal of Liver Transplantation 2021;4:100046. [DOI: 10.1016/j.liver.2021.100046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 740 |
Lou T, Li B, Xiong P, Jin C, Chen Y. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China. J Viral Hepat 2021;28:1373-80. [PMID: 34218498 DOI: 10.1111/jvh.13569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 741 |
Asín-Prieto E, Parra-Guillen ZP, Gómez Mantilla JD, Vandenbossche J, Stuyckens K, de Trixhe XW, Perez-Ruixo JJ, Troconiz IF. A quantitative systems pharmacology model for acute viral hepatitis B. Comput Struct Biotechnol J 2021;19:4997-5007. [PMID: 34589180 DOI: 10.1016/j.csbj.2021.08.052] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 742 |
Yu X, Xin L, Rongyong M, Aibing W, Jianzhong C. Clinical efficacy and safety of TCM prescriptions combined with nucleoside (acid) analogues in treating chronic hepatitis B: a meta-analysis. Digital Chinese Medicine 2021;4:170-9. [DOI: 10.1016/j.dcmed.2021.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 743 |
Inada K, Kaneko S, Kurosaki M, Yamashita K, Kirino S, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. JGH Open 2021;5:1085-91. [PMID: 34584979 DOI: 10.1002/jgh3.12636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 744 |
Park JM, Choe WH, Kim JH, Kwon SY, Yoo BC. The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma. J Liver Cancer 2021;21:155-162. [DOI: 10.17998/jlc.2021.09.22] [Reference Citation Analysis]
|
| 745 |
Garteiser P, Pagé G, d'Assignies G, Leitao HS, Vilgrain V, Sinkus R, Van Beers BE. Necro-inflammatory activity grading in chronic viral hepatitis with three-dimensional multifrequency MR elastography. Sci Rep 2021;11:19386. [PMID: 34588519 DOI: 10.1038/s41598-021-98726-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 746 |
Akbar SMF, Al Mahtab M, Cesar Aguilar J, Uddin MH, Khan MSI, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical. Exploration of Medicine. [DOI: 10.37349/emed.2021.00058] [Reference Citation Analysis]
|
| 747 |
Wang M, Qian M, Fu R, Zhang Y, Shen X, Yue D, Wang N, Yang L. The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Front Public Health 2021;9:709220. [PMID: 34568257 DOI: 10.3389/fpubh.2021.709220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 748 |
Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 749 |
Stinco M, Rubino C, Trapani S, Indolfi G. Treatment of hepatitis B virus infection in children and adolescents. World J Gastroenterol 2021; 27(36): 6053-6063 [PMID: 34629819 DOI: 10.3748/wjg.v27.i36.6053] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 750 |
Xu WX, Li YM, Li JG, Mei YY, Chen YM, Li XJ, Lin CS, Deng H, Zhao ZX, Xie DY, Gao ZL, Peng L. The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients. Gastroenterol Rep (Oxf) 2021;9:313-22. [PMID: 34567563 DOI: 10.1093/gastro/goab013] [Reference Citation Analysis]
|
| 751 |
Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021;13:1042-57. [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 752 |
Zhang H, Chen F, Giang E, Bao F, Lauer GM, Marsh C, Law M, Pockros PJ. Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy. Antiviral Therapy 2021;26:3-8. [DOI: 10.1177/13596535211042205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 753 |
Liu Y, He S, Yin S, Zhong Q, Zhong J, Zhang X, Fan R, Hou J. Prevalence of Dual-Positivity for Both Hepatitis B e Antigen and Hepatitis B e Antibody Among Hospitalized Patients with Chronic Hepatitis B Virus Infection. Int J Gen Med 2021;14:5759-70. [PMID: 34557028 DOI: 10.2147/IJGM.S328714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 754 |
Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol 2021;12:733364. [PMID: 34557195 DOI: 10.3389/fimmu.2021.733364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 755 |
Quan Z, Zeng H, Yi X, Li C, Fang Z, Yang X. Psoas Major and Iliopsoas Hematomas without Anticoagulant Therapy as a Complication of Carbon Monoxide Poisoning: A Case Report. Am J Case Rep 2021;22:e933322. [PMID: 34556624 DOI: 10.12659/AJCR.933322] [Reference Citation Analysis]
|
| 756 |
Chen TY, Mai JY, Zhang P, Xue JH, He SL, Xi J, Chen JJ, Cheng Y. Efficacy of erzhu jiedu recipe on hepatitis B cirrhosis with hyperalphafetoproteinemia: A randomized, double-blind, placebo-controlled clinical trial. Medicine (Baltimore) 2021;100:e27231. [PMID: 34559118 DOI: 10.1097/MD.0000000000027231] [Reference Citation Analysis]
|
| 757 |
Hammami MB, Kohli R, Woreta T, Sulkowski MS, Hamilton JP, Toman L, Saberi B, Laurin J, Wang JG, Philosophe B, Cameron AM, Gurakar A. Hepatitis B Virus/Hepatitis D Virus-Coinfected Liver Transplant Candidate Receiving Hepatitis B Virus-Deoxyribonucleic Acid-Positive Allograft and Treated With High-Dose Hepatitis B Immune Globulin. ACG Case Rep J 2021;8:e00582. [PMID: 34549060 DOI: 10.14309/crj.0000000000000582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 758 |
Kakuda TN, Yogaratnam JZ, Westland C, Gane EJ, Schwabe C, Vuong J, Patel M, Snoeys J, Talloen W, Lenz O, Fry J, Chanda S, van Remoortere P. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers. Antiviral Therapy 2021;26:13-24. [DOI: 10.1177/13596535211044331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 759 |
Lee AU, Lee C. Hepatitis D Review: Challenges for the Resource-Poor Setting. Viruses 2021;13:1912. [PMID: 34696341 DOI: 10.3390/v13101912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 760 |
Yuan Q, Haque O, Hong S, Ortiz A, Bethea ED, Sise ME, Markmann JF, Elias N. Influence of donor and recipient hepatitis B virus infection on long-term outcomes after kidney transplantation. Clin Transplant 2021;:e14466. [PMID: 34545965 DOI: 10.1111/ctr.14466] [Reference Citation Analysis]
|
| 761 |
Zhou J, Wang FD, Wang ML, Tao YC, Wu DB, Sheng YJ, Xiao GB, Chen XB, Chen X, Chen EQ. Antiviral Therapy for Chronic HBV Infection With Persistently Normal Alanine Aminotransferase: Controversy and Consensus. Front Med (Lausanne) 2021;8:717125. [PMID: 34527683 DOI: 10.3389/fmed.2021.717125] [Reference Citation Analysis]
|
| 762 |
Shah AS, Civelli VF, Bali V, Johnson RH, Heidari A. A Case of S-Variant Hepatitis B Virus: An Immune System Escape Artist. J Investig Med High Impact Case Rep 2021;9:23247096211045450. [PMID: 34521227 DOI: 10.1177/23247096211045450] [Reference Citation Analysis]
|
| 763 |
Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, Huang YH. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020;8:e001072. [PMID: 32863270 DOI: 10.1136/jitc-2020-001072] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 764 |
Tang X, Huang W, Kang J, Ding K. Early dynamic changes of quasispecies in the reverse transcriptase region of hepatitis B virus in telbivudine treatment. Antiviral Res 2021;195:105178. [PMID: 34509461 DOI: 10.1016/j.antiviral.2021.105178] [Reference Citation Analysis]
|
| 765 |
Fulcher IR, Shpitser I, Didelez V, Zhou K, Scharfstein DO. Discussion on "Causal mediation of semicompeting risks" by Yen-Tsung Huang. Biometrics 2021. [PMID: 34510405 DOI: 10.1111/biom.13519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 766 |
Wang ST, Tseng CW, Hsu CW, Tung CH, Huang KY, Lu MC, Lai NS. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib. Int J Rheum Dis 2021;24:1362-9. [PMID: 34506078 DOI: 10.1111/1756-185X.14217] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 767 |
Huang YS, Cheng CY, Liou BH, Lu PL, Cheng SH, Lee YT, Liu CE, Sun HY, Yang CJ, Tang HJ, Lin SP, Ho MW, Huang SH, Tsai HC, Lee CH, Hung CC; Taiwan HIV Study Group. Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. J Acquir Immune Defic Syndr 2021;86:473-81. [PMID: 33273214 DOI: 10.1097/QAI.0000000000002589] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 768 |
Yao K, Wang J, Wang L, Xia J, Yan X, Wu W, Liu J, Wang L, Yin S, Tong X, Ding W, Huang R, Wu C. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA. J Med Virol 2021. [PMID: 34499353 DOI: 10.1002/jmv.27327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 769 |
Gómez Camarero J, Badia Aranda E, Quiñones Castro R, Saiz Chumillas RM, Alcoba Vega L, Díez Ruiz S, Gómez Manero N, Vinuesa Campo R, Jorquera Plaza F. Hepatitis B and C screening in hospitalized patients with SARS-CoV-2 infection. Gastroenterol Hepatol 2021:S0210-5705(21)00250-8. [PMID: 34508809 DOI: 10.1016/j.gastrohep.2021.09.002] [Reference Citation Analysis]
|
| 770 |
Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021;80:1255-65. [PMID: 34493491 DOI: 10.1136/annrheumdis-2021-221244] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 771 |
Zang C, Zhao Y, Qin L, Liu G, Sun J, Li K, Zhao Y, Sheng S, Zhang H, He N, Zhao P, Wang Q, Li X, Peng Y, Dong T, Zhang Y. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages. BMC Cancer 2021;21:1007. [PMID: 34496797 DOI: 10.1186/s12885-021-08720-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 772 |
Xu X, Wu C, Jiang L, Peng C, Pan L, Zhang X, Shen W, Chen L, Lou Z, Xu K, Li L, Dong Y, Ruan B. Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049. Int J Health Policy Manag 2021;11:2115-23. [PMID: 34664496 DOI: 10.34172/ijhpm.2021.126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 773 |
Yang N, Zhou G, Cheng X, He J, Chen Y, Chen C, Li M, Ge J, Wang M, Zhang T, Ge W, Zhu H, Han G. Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method. Front Pharmacol 2021;12:734760. [PMID: 34483946 DOI: 10.3389/fphar.2021.734760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 774 |
Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 775 |
Okello CD, Niyonzima N, Ferraresso M, Kadhumbula S, Ddungu H, Tarlock K, Balagadde-Kambugu J, Omoding A, Ngendahayo L, Karagu A, Mwaiselage J, Harlan JM, Uldrick TS, Turner SD, Orem J. Haematological malignancies in sub-Saharan Africa: east Africa as an example for improving care. Lancet Haematol 2021;8:e756-69. [PMID: 34481552 DOI: 10.1016/S2352-3026(21)00198-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 776 |
Atteya A, Ahmad A, Daghstani D, Mushtaq K, Yassin MA. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 2020;27:1073274820976594. [PMID: 33297765 DOI: 10.1177/1073274820976594] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 777 |
Lee JH, Kim HS. Current laboratory tests for diagnosis of hepatitis B virus infection. Int J Clin Pract 2021;:e14812. [PMID: 34487586 DOI: 10.1111/ijcp.14812] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 778 |
Chen W, Zhang Q, Li S, Liang R, Liang H, Yu Y, Qiu C, Lv J, Zhang W. Acute-on-Chronic Liver Failure Precipitated by Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a Patient with Hepatitis B Virus-Related Cirrhosis: A Case Report. Infectious Diseases & Immunity 2021;1:169-73. [DOI: 10.1097/id9.0000000000000023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 779 |
Kardani K, Bolhassani A, Kardani M, Agi E; Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran, Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran. Correlation of SARS-CoV-2 Infection with Hepatitis and Liver Disorders. JoMMID 2021;9:122-32. [DOI: 10.52547/jommid.9.3.122] [Reference Citation Analysis]
|
| 780 |
Lee YT, Wang JJ, Luu M, Tseng HR, Rich NE, Lu SC, Nissen NN, Noureddin M, Singal AG, Yang JD. State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States. Hepatology 2021;74:1384-94. [PMID: 33728665 DOI: 10.1002/hep.31811] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 781 |
Giráldez-Gallego Á, Rodríguez-Seguel E, Manuel Pascasio-Acevedo J. Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question. J Viral Hepat 2021;28:1329-30. [PMID: 34185939 DOI: 10.1111/jvh.13563] [Reference Citation Analysis]
|
| 782 |
Jaroenlapnopparat A, Chayanupatkul M, Tangkijvanich P. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review. J Gastroenterol Hepatol 2021;36:2349-62. [PMID: 33811375 DOI: 10.1111/jgh.15516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 783 |
Leprieur EG. Infections virales chroniques (hépatites, VIH) et impact sur le choix thérapeutique. Revue des Maladies Respiratoires Actualités 2021;13:2S272-2S279. [DOI: 10.1016/s1877-1203(21)00120-8] [Reference Citation Analysis]
|
| 784 |
Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut 2021;70:1782-94. [PMID: 34103404 DOI: 10.1136/gutjnl-2020-323888] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 33.5] [Reference Citation Analysis]
|
| 785 |
Xia M, Chi H, Wu Y, Hansen BE, Li Z, Liu S, Liao G, Zhang X, Zhou B, Hou J, Sun J, Janssen HLA, Peng J. Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment. Aliment Pharmacol Ther 2021;54:709-14. [PMID: 34275138 DOI: 10.1111/apt.16538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 786 |
Tran S, Jeong D, Henry L, Cheung RC, Nguyen MH. Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. Am J Gastroenterol 2021;116:1885-95. [PMID: 33927125 DOI: 10.14309/ajg.0000000000001271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 787 |
Schaefer EAK. A Deep Ravine Rather Than a Shallow Gap: Many More Bridges Needed to Improve Care of Chronic Hepatitis B in the United States. Am J Gastroenterol 2021;116:1842-3. [PMID: 34187982 DOI: 10.14309/ajg.0000000000001364] [Reference Citation Analysis]
|
| 788 |
Lemmer P, Selbach N, Baars T, Porsch-Özcürümez M, Heider D, Canbay A, Sowa JP. Transaminase Concentrations Cannot Separate Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Irrespective of Histological Algorithm. Dig Dis 2022;40:644-53. [PMID: 34469884 DOI: 10.1159/000519317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 789 |
Rodríguez-Tajes S, Lens S, Forns X. Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question. J Viral Hepat 2021;28:1331-2. [PMID: 34048102 DOI: 10.1111/jvh.13555] [Reference Citation Analysis]
|
| 790 |
Shan S, Jia J. Prevention of Mother-to-Child Transmission of Hepatitis B Virus in the Western Pacific Region. Clin Liver Dis (Hoboken) 2021;18:18-21. [PMID: 34484699 DOI: 10.1002/cld.1096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 791 |
De Pooter D, Van Gulck E, Chen A, Evans CF, Neefs JM, Horton H, Boden D. A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates. Vaccines (Basel) 2021;9:969. [PMID: 34579206 DOI: 10.3390/vaccines9090969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 792 |
Chi CT, Lee IC, Lee RC, Hung YW, Su CW, Hou MC, Chao Y, Huang YH. Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. Cancers (Basel) 2021;13:4325. [PMID: 34503135 DOI: 10.3390/cancers13174325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 793 |
Srisuwarn P, Sumethkul V. Kidney transplant from donors with hepatitis B: A challenging treatment option. World J Hepatol 2021;13:853-67. [PMID: 34552692 DOI: 10.4254/wjh.v13.i8.853] [Reference Citation Analysis]
|
| 794 |
Medas R, Liberal R, Macedo G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J Clin Cases 2021; 9(24): 6979-6986 [PMID: 34540953 DOI: 10.12998/wjcc.v9.i24.6979] [Reference Citation Analysis]
|
| 795 |
Ohsaki E, Suwanmanee Y, Ueda K. Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy. Viruses 2021;13:1691. [PMID: 34578273 DOI: 10.3390/v13091691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 796 |
Zhang X, Tian D, Chen Y, Chen C, He LN, Zhou Y, Li H, Lin Z, Chen T, Wang Y, Russo A, Nadal E, Passiglia F, Soo RA, Watanabe S, Moran T, Oh IJ, Fu S, Hong S, Zhang L. Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. Transl Lung Cancer Res 2021;10:3191-202. [PMID: 34430357 DOI: 10.21037/tlcr-21-455] [Reference Citation Analysis]
|
| 797 |
Li Z, Li S, Tao H, Zhan Y, Ni K, Gong J, Li G. Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer. World J Surg Oncol 2021;19:251. [PMID: 34446030 DOI: 10.1186/s12957-021-02369-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 798 |
Fukutomi K, Hikita H, Murai K, Nakabori T, Shimoda A, Fukuoka M, Yamai T, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T. Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus-Infected Hepatocytes During Interferon Administration. Hepatol Commun 2021. [PMID: 34558845 DOI: 10.1002/hep4.1804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 799 |
Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tawesak T, Sarin SK, Omata M. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 2021;15:1031-48. [PMID: 34427860 DOI: 10.1007/s12072-021-10239-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 800 |
Chen MH, Wu CS, Chen MH, Tsai CY, Lee FY, Huang YH. High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus. Int J Mol Sci 2021;22:9116. [PMID: 34502025 DOI: 10.3390/ijms22179116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 801 |
Evon DM, Lin HS, Fontana RJ, Khalili M, Yim C, Wahed AS, Hoofnagle JH. Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. GastroHep 2021;3:196-208. [PMID: 34421369 DOI: 10.1002/ygh2.458] [Reference Citation Analysis]
|
| 802 |
Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. Hepatol Int 2021;15:1083-92. [PMID: 34402025 DOI: 10.1007/s12072-021-10234-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 803 |
Dinani A, Sussman N, Noureddin M, Fuchs M, Therapondos G, Girgrah N, Diaz VF, Mantry P, Rinella M, Asgharpour A, Dieterich D. An algorithm for the management of non-alcoholic fatty liver disease in primary care. GHOA 2021;12:114-122. [DOI: 10.15406/ghoa.2021.12.00469] [Reference Citation Analysis]
|
| 804 |
Song DS, Jang JW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B. Clin Infect Dis 2021;73:e892-903. [PMID: 33417679 DOI: 10.1093/cid/ciab007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 805 |
Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099 [PMID: 34497437 DOI: 10.3748/wjg.v27.i30.5088] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 806 |
Zhang M, Fu S, Ren D, Wu Y, Yao N, Ni T, Feng Y, Chen Y, Chen T, Zhao Y, Liu J. Maternal and Fetal Outcomes After Interferon Exposure During Pregnancy: A Systematic Review With Meta-Analysis. Front Reprod Health 2021;3:702929. [DOI: 10.3389/frph.2021.702929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 807 |
Li EM, Xiao LX, Xu Z, Mo ZS, Li JQ, Mei YY, Lin CS. Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy. BMC Pregnancy Childbirth 2021;21:551. [PMID: 34384374 DOI: 10.1186/s12884-021-04020-z] [Reference Citation Analysis]
|
| 808 |
Su WY, Chu NS, Huang JC, Wu PY, Lee WH, Liu YH, Chen SC, Su HM. Low Albumin, Low Bilirubin, and High Alfa-Fetoprotein Are Associated with a Rapid Renal Function Decline in a Large Population Follow-Up Study. J Pers Med 2021;11:781. [PMID: 34442425 DOI: 10.3390/jpm11080781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 809 |
Takayama H, Komura T, Kagaya T, Sugimoto S, Orita N, Asahina Y, Nishikawa M, Ohta H, Kaneko S, Unoura M. Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B. Can J Gastroenterol Hepatol 2021;2021:3259833. [PMID: 34422709 DOI: 10.1155/2021/3259833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 810 |
Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
|
| 811 |
Yang L, Wang Q, Cui T, Huang J, Jin H. Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis. Can J Gastroenterol Hepatol 2021;2021:9996358. [PMID: 34513751 DOI: 10.1155/2021/9996358] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 812 |
Honda T, Yamada N, Murayama A, Shiina M, Aly HH, Kato A, Ito T, Ishizu Y, Kuzuya T, Ishigami M, Murakami Y, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Ishikawa T, Fujishiro M, Muramatsu M, Wakita T, Kato T. Amino Acid Polymorphism in Hepatitis B Virus Associated With Functional Cure. Cell Mol Gastroenterol Hepatol 2021;12:1583-98. [PMID: 34352407 DOI: 10.1016/j.jcmgh.2021.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 813 |
Terrault NA, Ghany MG. Enhanced Screening for Hepatitis D in the USA: Overcoming the Delta Blues. Dig Dis Sci 2021;66:2483-5. [PMID: 32889599 DOI: 10.1007/s10620-020-06584-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 814 |
Hsu YC, Tseng CH, Huang YT, Yang HI. Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective. Semin Liver Dis 2021;41:285-97. [PMID: 34161993 DOI: 10.1055/s-0041-1730924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 815 |
Berg T, Lampertico P. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol 2021;75:474-80. [PMID: 33957187 DOI: 10.1016/j.jhep.2021.04.040] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 816 |
Fong TL, Lee BT, Chang M, Nasanbayar K, Tsogtoo E, Boldbaatar D, Dashdorj ED, Clifford NE, Dashdorj AN, Bang BR, Chida T, Lim C, Sugiyama M, Mizokami M, Dashdorj NJ, Liu P, Glenn JS, Dashdorj ND, Saito T. High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California. Dig Dis Sci 2021;66:2833-9. [PMID: 32770488 DOI: 10.1007/s10620-020-06499-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 817 |
Lee J, Kim GA, Kim HJ, Cho S, Ko MJ, Lim YS. Tenofovir disoproxil fumarate on the risk of hepatocellular carcinoma in chronic hepatitis B patients with failure to preceding treatments: A nationwide cohort study. J Viral Hepat 2021;28:1150-9. [PMID: 33934466 DOI: 10.1111/jvh.13530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 818 |
Navarroza AMC, Wong SN. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease. Indian J Gastroenterol 2021;40:380-8. [PMID: 34213749 DOI: 10.1007/s12664-021-01184-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 819 |
Li Y, Wu S. Liver stiffness measured with two-dimensional shear wave elastography comparable to histopathology falls dominantly on the severe liver fibrosis. Clin Hemorheol Microcirc 2021. [PMID: 34334386 DOI: 10.3233/CH-211223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 820 |
Han Z, Zhang Y, Zhou J, Wang Q, Huang Y, Hou H. Risk of mother-to-child transmission of hepatitis B virus after fetal blood sampling: a report of six cases. BMC Infect Dis 2021;21:716. [PMID: 34330230 DOI: 10.1186/s12879-021-06423-x] [Reference Citation Analysis]
|
| 821 |
Pei SN, Liu YF, Kuo CY, Wang MC, Ma MC, Liao CK, Ng HY, Chen CH. Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab. Leuk Lymphoma 2021;:1-8. [PMID: 34323157 DOI: 10.1080/10428194.2021.1948034] [Reference Citation Analysis]
|
| 822 |
Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 823 |
Xu XL, Jiang LS, Wu CS, Pan LY, Lou ZQ, Peng CT, Dong Y, Ruan B. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool? J Formos Med Assoc 2021:S0929-6646(21)00344-2. [PMID: 34325952 DOI: 10.1016/j.jfma.2021.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 824 |
Ghenea AE, Pădureanu V, Cioboată R, Udriștoiu AL, Drocaş AI, Țieranu E, Carsote M, Vasile CM, Moroşanu A, Biciușcă V, Salan AI, Turculeanu A, Ungureanu A. The Study of Clinical and Biochemical Parameters in Assessing the Response to the Antiviral Therapy in the Chronic Viral Hepatitis B. Medicina (Kaunas) 2021;57:757. [PMID: 34440963 DOI: 10.3390/medicina57080757] [Reference Citation Analysis]
|
| 825 |
Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases 2021; 9(21): 5769-5781 [PMID: 34368296 DOI: 10.12998/wjcc.v9.i21.5769] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 826 |
Tan N, Luo H, Kang Q, Pan JL, Cheng R, Xi HL, Chen HY, Han YF, yang YP, Xu XY. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases 2021; 9(21): 5812-5821 [PMID: 34368300 DOI: 10.12998/wjcc.v9.i21.5812] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 827 |
Lin YC, Chen YJ, Lee SW, Lee TY, Chen YH, Huang WN, Yang SS, Chen YM. Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy. J Clin Med 2021;10:3296. [PMID: 34362079 DOI: 10.3390/jcm10153296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 828 |
Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70:1-187. [PMID: 34292926 DOI: 10.15585/mmwr.rr7004a1] [Cited by in Crossref: 231] [Cited by in F6Publishing: 239] [Article Influence: 115.5] [Reference Citation Analysis]
|
| 829 |
Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 830 |
Varley CD, Winthrop KL. Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections). Curr Rheumatol Rep 2021;23:74. [PMID: 34269903 DOI: 10.1007/s11926-021-01037-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 831 |
Dunn D, Price H, Vudriko T, Kityo C, Musoro G, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R; DART Virology Group. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings. J Acquir Immune Defic Syndr 2021;86:98-103. [PMID: 33306565 DOI: 10.1097/QAI.0000000000002517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 832 |
Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 833 |
Veronese P, Dodi I, Esposito S, Indolfi G. Prevention of vertical transmission of hepatitis B virus infection. World J Gastroenterol 2021; 27(26): 4182-4193 [PMID: 34326618 DOI: 10.3748/wjg.v27.i26.4182] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 834 |
Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 835 |
Sandmann L, Petersen J, Cornberg M. Die wichtigsten Änderungen der S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion im Überblick. Z Gastroenterol 2021;59:641-3. [PMID: 34255314 DOI: 10.1055/a-1498-2680] [Reference Citation Analysis]
|
| 836 |
Spradling PR, Xing J, Harris AM, Ly KN. Estimated prevalence and number of persons with isolated antibody to hepatitis B core antigen and associated occult hepatitis B, United States, 2001-2018. J Infect Dis 2021:jiab366. [PMID: 34252183 DOI: 10.1093/infdis/jiab366] [Reference Citation Analysis]
|
| 837 |
Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 838 |
Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
|
| 839 |
Borojevic B, Chauhan A, Patterson S. Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphoma. BMJ Case Rep 2021;14:e243526. [PMID: 34244190 DOI: 10.1136/bcr-2021-243526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 840 |
Chen R, Pei S, Chen Y, Tan L, Xue Y, Liu S, Huang Y, Fan X. Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report. Front Med (Lausanne) 2021;8:701061. [PMID: 34307428 DOI: 10.3389/fmed.2021.701061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 841 |
Yeo YH, Tseng TC, Hosaka T, Cunningham C, Fung JYY, Ho HJ, Kwak MS, Trinh HN, Ungtrakul T, Yu ML, Kobayashi M, Le AK, Henry L, Li J, Zhang J, Sriprayoon T, Jeong D, Tanwandee T, Gane E, Cheung RC, Wu CY, Lok AS, Lee HS, Suzuki F, Yuen MF, Kao JH, Yang HI, Nguyen MH. Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. Clin Transl Gastroenterol 2020;11:e00196. [PMID: 33094953 DOI: 10.14309/ctg.0000000000000196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 842 |
Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 843 |
Yuen MF, Zhou X, Gane E, Schwabe C, Tanwandee T, Feng S, Jin Y, Triyatni M, Lemenuel-Diot A, Cosson V, Xue Z, Kazma R, Bo Q. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol 2021;6:723-32. [PMID: 34237271 DOI: 10.1016/S2468-1253(21)00176-X] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 844 |
Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. WJGPT 2021;12:56-78. [DOI: 10.4292/wjg.v12.i4.56] [Reference Citation Analysis]
|
| 845 |
Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. World J Gastrointest Pharmacol Ther 2021; 12(4): 56-78 [PMID: 34316384 DOI: 10.4292/wjgpt.v12.i4.56] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 846 |
Xiong S, Zhu D, Liang B, Li M, Pan W, He J, Wang H, Sutter K, Dittmer U, Lu M, Liu D, Yang D, Liu J, Zheng X. Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss. EBioMedicine 2021;69:103464. [PMID: 34233260 DOI: 10.1016/j.ebiom.2021.103464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 847 |
Yang MY, Wu F, Fang F, Yang H, Zhang JF, Chen GD, Yang LY. Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma. BMC Cancer 2021;21:772. [PMID: 34217251 DOI: 10.1186/s12885-021-08491-3] [Reference Citation Analysis]
|
| 848 |
Rodríguez-Tajes S, Pocurull A, Lens S, Mariño Z, Olivas I, Soy G, Alonso A, Vilella A, Forns X. Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis. J Viral Hepat 2021;28:1019-24. [PMID: 33763966 DOI: 10.1111/jvh.13509] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 849 |
Kim MP, Yang JK, Jun BG, Kim YD, Cheon GJ, Jung HJ, Yoo JJ, Kim SG, Kim YS, Jeong SW, Jang JY, Kim HS, Lee SH. Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma. J Viral Hepat 2021;28:1011-8. [PMID: 33759295 DOI: 10.1111/jvh.13508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 850 |
Wong RJ, Jain MK, Therapondos G, Niu B, Kshirsagar O, Thamer M. Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems. Am J Gastroenterol 2021;116:1465-75. [PMID: 33661148 DOI: 10.14309/ajg.0000000000001195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 851 |
Liang LY, Wong VW, Hui VW, Yip TC, Tse Y, Lui GC, Chan HL, Wong GL. Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. GastroHep 2021;3:261-269. [DOI: 10.1002/ygh2.471] [Reference Citation Analysis]
|
| 852 |
Kang C. Bulevirtide in chronic hepatitis D: a profile of its use. Drugs Ther Perspect 2021;37:294-299. [DOI: 10.1007/s40267-021-00843-0] [Reference Citation Analysis]
|
| 853 |
Wellhöner F, Döscher N, Woelfl F, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Pieper DH, Cornberg M, Wedemeyer H, Heidrich B. Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. Hepatology 2021;74:72-82. [PMID: 33411981 DOI: 10.1002/hep.31700] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 854 |
Huang H, Xu C, Hu Y, Zhou YH. Reply to Pan. Clin Infect Dis 2021;73:166-7. [PMID: 32818227 DOI: 10.1093/cid/ciaa1227] [Reference Citation Analysis]
|
| 855 |
Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2021;73:924-39. [PMID: 34101387 DOI: 10.1002/acr.24596] [Cited by in Crossref: 137] [Cited by in F6Publishing: 125] [Article Influence: 68.5] [Reference Citation Analysis]
|
| 856 |
Cheng Y, Ji Y, Duan H, Li Y, Lau G, Wang F. What Should Be Done to Re-evaluate Cessation of Nucleos(t)ide Analog Therapy for Chronic Hepatitis B Infection? Infectious Diseases & Immunity 2021;1:93-102. [DOI: 10.1097/id9.0000000000000014] [Reference Citation Analysis]
|
| 857 |
Zhang ZQ, Shi BS, Lu W, Huang D, Wang YB, Feng YL. Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection. J Virol Methods 2021;296:114226. [PMID: 34217779 DOI: 10.1016/j.jviromet.2021.114226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 858 |
Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, Wu W, Liu Y, Chen Y, Zhang Z, Li J, Huang R, Wu C. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat 2021;28:1025-33. [PMID: 33797145 DOI: 10.1111/jvh.13511] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 859 |
Ohta T, Ito K, Sugiura T, Koyama N, Saitoh S, Murakami S, Tanaka Y. Breakthrough HBV infection in a vaccinated child due to vaccine escape mutant. Acta hepatologica Japonica 2021;62:403-412. [DOI: 10.2957/kanzo.62.403] [Reference Citation Analysis]
|
| 860 |
Ninomiya M, Inoue J, Krueger EW, Chen J, Cao H, Masamune A, McNiven MA. The Exosome-Associated Tetraspanin CD63 Contributes to the Efficient Assembly and Infectivity of the Hepatitis B Virus. Hepatol Commun 2021;5:1238-51. [PMID: 34278172 DOI: 10.1002/hep4.1709] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 861 |
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 26.0] [Reference Citation Analysis]
|
| 862 |
Luo W, Wu S, Chen H, Wu Y, Peng J. Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with α-interferon. J Int Med Res 2021;49:3000605211025139. [PMID: 34182813 DOI: 10.1177/03000605211025139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 863 |
Yonezawa H, Tanaka S, Furuya M, Yamada K, Asanuma K, Fujiya Y, Miyanishi K, Takahashi S, Kato J. Determination of reactivation rate and risk factors for Hepatitis B virus reactivation in low-positive cases: A retrospective cohort study. J Infect Chemother 2021;27:1454-8. [PMID: 34176717 DOI: 10.1016/j.jiac.2021.06.009] [Reference Citation Analysis]
|
| 864 |
Ma Z, Li S, He D, Wang Y, Jiang H, Zhou H, Jin J, Lin N. Rapid quantification of tenofovir in umbilical cord plasma and amniotic fluid in hepatitis B mono-infected pregnant women during labor by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2020;34:e8728. [PMID: 31960519 DOI: 10.1002/rcm.8728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 865 |
Adesina OA, Akanbi OA, Opaleye OO, Japhet MO, Wang B, Oluyege AO, Klink P, Bock CT. Detection of Q129H Immune Escape Mutation in Apparently Healthy Hepatitis B Virus Carriers in Southwestern Nigeria. Viruses 2021;13:1273. [PMID: 34210073 DOI: 10.3390/v13071273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 866 |
Feng J, Tang YN, Zhou LX, Pan JS. Standardized Nursing Procedures for Fecal Microbiota Transplantation via Upper Endoscopy. Gastroenterol Nurs 2021;44:227-32. [PMID: 34176888 DOI: 10.1097/SGA.0000000000000577] [Reference Citation Analysis]
|
| 867 |
Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: Immunological Response, Natural Course and Pregnancy Outcomes. J Clin Med 2021;10:2926. [PMID: 34210105 DOI: 10.3390/jcm10132926] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 868 |
Chen MH, Lee IC, Chen MH, Hou MC, Tsai CY, Huang YH. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Ann Rheum Dis 2021:annrheumdis-2021-220774. [PMID: 34187776 DOI: 10.1136/annrheumdis-2021-220774] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 869 |
Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: An Update on Evidence-Based Management. Obstet Gynecol Surv. 2020;75:557-565. [PMID: 32997148 DOI: 10.1097/ogx.0000000000000831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 870 |
Spence AB, Levy ME, Monroe A, Castel A, Timpone J, Horberg M, Adams-Campbell L, Kumar P. Cancer Incidence and Cancer Screening Practices Among a Cohort of Persons Receiving HIV Care in Washington, DC. J Community Health 2021;46:75-85. [PMID: 32424501 DOI: 10.1007/s10900-020-00844-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 871 |
Dai Z, Wong IOL, Xie C, Xu W, Xiang Y, Peng L, Lau EHY. Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China. Clin Microbiol Infect 2021:S1198-743X(21)00344-X. [PMID: 34197929 DOI: 10.1016/j.cmi.2021.06.024] [Reference Citation Analysis]
|
| 872 |
Wang T, Smith DA, Campbell C, Mokaya J, Freeman O, Salih H, McNaughton AL, Cripps S, Várnai KA, Noble T, Woods K, Collier J, Jeffery K, Davies J, Barnes E, Matthews PC. Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study. BMC Infect Dis 2021;21:610. [PMID: 34174833 DOI: 10.1186/s12879-021-06226-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 873 |
Chitnis AS, Cheung R, Gish RG, Wong RJ. Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States. J Immigr Minor Health 2021. [PMID: 34160726 DOI: 10.1007/s10903-021-01231-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 874 |
Lee SW, Choi J, Kim SU, Lim YS. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:402-12. [PMID: 34157830 DOI: 10.3350/cmh.2021.0179] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 875 |
Ma JL, He LL, Jiang Y, Yang JR, Li P, Zang Y, Wei HS. New model predicting gastroesophageal varices and variceal hemorrhage in patients with chronic liver disease. Ann Hepatol 2020;19:287-94. [PMID: 32197976 DOI: 10.1016/j.aohep.2019.12.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 876 |
Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 877 |
Gu Y, Huang Z, Li X, Chen Y, Liao C, Bi Y, Huang Y. Serum HBV pregenomic RNA exhibited opposite associations with NKdim and NKbright cell immunity in treatment-naïve chronic hepatitis B patients. Biosci Rep 2021;41:BSR20210600. [PMID: 34151357 DOI: 10.1042/BSR20210600] [Reference Citation Analysis]
|
| 878 |
Belopolskaya M, Avrutin V, Kalinina O, Dmitriev A, Gusev D. Chronic hepatitis B in pregnant women: Current trends and approaches. World J Gastroenterol 2021; 27(23): 3279-3289 [PMID: 34163111 DOI: 10.3748/wjg.v27.i23.3279] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 879 |
Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [ |
